Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Authors

Adarsh Bhimraj,1 Rebecca L. Morgan,2 Amy Hirsch Shumaker,3 Valery Lavergne,4 Lindsey Baden,5 Vincent Chi-Chung Cheng,6 Kathryn M. Edwards,7 Rajesh Gandhi,8 Jason Gallagher,9 William J. Muller,10 John C. O’Horo,11 Shmuel Shoham,12 M. Hassan Murad,13 Reem A. Mustafa,14 Shahnaz Sultan,15 Yngve Falck-Ytter3

Affiliations

1Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio
2Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario
3VA Northeast Ohio Healthcare System, Case Western Reserve University School of Medicine, Cleveland, Ohio
4Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada
5Brigham and Women’s Hospital, Boston, Massachusetts
6Queen Mary Hospital, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
7Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
8Infectious Diseases Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
9Department of Pharmacy Practice, Temple University, Philadelphia, Pennsylvania

10Division of Pediatric Infectious Diseases, Northwestern University, Chicago, Illinois

11Division of Infectious Diseases, Joint Appointment Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota

12Johns Hopkins University School of Medicine, Baltimore, Maryland

13Division of Preventive Medicine, Mayo Clinic, Rochester, Minnesota

14Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas

15Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis VA Healthcare System, Minneapolis, Minnesota

**Corresponding Author:** Adarsh Bhimraj

**Panel Members:** Adarsh Bhimraj (lead), Lindsey Baden, Vincent Chi-Chung Cheng, Kathryn M. Edwards, Rajesh Gandhi, Jason Gallagher, William J. Muller, John C. O’Horo, Shmuel Shoham, Amy Hirsch Shumaker

**Methodologists:** Yngve Falck-Ytter (lead), Rebecca L. Morgan, Valery Lavergne, M. Hassan Murad, Reem A. Mustafa, Shahnaz Sultan
Abstract

Background: There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature.

Objective: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature.

Methods: In March 2020, the Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. The process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations.

Results: On April 11, 2020, IDSA released online initial treatment recommendations and narrative summaries of other treatments under evaluation. Since that time, the guideline panel and methodologists have continued to monitor the literature and issue updates and addendums to these guidelines in response to evolving research.

Conclusions: Since the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.
IDSA Disclaimer

It is important to realize that guidelines cannot always account for individual variation among patients. They are assessments of current scientific and clinical information provided as an educational service; are not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); should not be considered inclusive of all proper treatments methods of care, or as a statement of the standard of care; do not mandate any particular course of medical care; and are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Whether and the extent to which to follow guidelines is voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient’s individual circumstances. While IDSA makes every effort to present accurate, complete, and reliable information, these guidelines are presented “as is” without any warranty, either express or implied. IDSA (and its officers, directors, members, employees, and agents) assume no responsibility for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with these guidelines or reliance on the information presented.

The guidelines represent the proprietary and copyrighted property of IDSA. Copyright 2021 Infectious Diseases Society of America. All rights reserved. No part of these guidelines may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of IDSA. Permission is granted to physicians and health care providers solely to copy and use the guidelines in their professional practices and clinical decision-making. No license or permission is granted to any person or entity, and prior written authorization by IDSA is required, to sell, distribute, or modify the guidelines, or to make derivative works of or incorporate the guidelines into any product, including but not limited to clinical decision support software or any other software product. Except for the permission granted above, any person or entity desiring to use the guidelines in any way must contact IDSA for approval in
accordance with the terms and conditions of third-party use, in particular any use of the guidelines in any software product.
Executive Summary

Coronavirus disease 2019 (COVID-19) is a pandemic with a rapidly increasing incidence of infections and deaths. Many pharmacologic therapies are being used or considered for treatment. Given the rapidity of emerging literature, the Infectious Diseases Society of America (IDSA) identified the need to develop living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19.

Summarized below are the recommendations with comments related to the clinical practice guideline for the treatment and management of COVID-19. A detailed description of background, methods, evidence summary and rationale that support each recommendation, and research needs can be found online in the full text. In brief, per Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, recommendations are labeled as “strong” or “conditional”. The word “recommend” indicates strong recommendations and “suggest” indicates conditional recommendations. In situations where promising interventions were judged to have insufficient evidence of benefit to support their use and with potential appreciable harms or costs, the expert panel recommended their use in the context of a clinical trial. These recommendations acknowledge the current “knowledge gap” and aim at avoiding premature favorable recommendations for potentially ineffective or harmful interventions.
Recommendation 1: Among patients with COVID-19, the IDSA guideline panel recommends against hydroxychloroquine. (Strong recommendation, Moderate certainty of evidence)

- **Remark:** Chloroquine is considered to be class equivalent to hydroxychloroquine.

Recommendation 2: Among hospitalized patients with COVID-19, the IDSA guideline panel recommends against hydroxychloroquine plus azithromycin. (Strong recommendation, Low certainty of evidence)

- **Remark:** Chloroquine is considered to be class equivalent to hydroxychloroquine.

Recommendation 3: In persons exposed to COVID-19, the IDSA guideline panel recommends against hydroxychloroquine. (Strong recommendation, Moderate certainty of evidence)

Recommendation (NEW: lopinavir/ritonavir for persons exposed to SARS-CoV-2)

*SPECIAL UPDATE ALERT:* New recommendations have been developed based on newly available literature and approvals. This update will be fully integrated into this document and the IDSA website soon; it is provided here for immediate use.

A new recommendation on the use of lopinavir/ritonavir as post-exposure prophylaxis for persons exposed to SARS-CoV-2 has been developed. The full updated section featuring the new recommendation can be viewed on the [IDSA website](https://www.idsociety.org/).

Recommendation (NEW: lopinavir/ritonavir for ambulatory patients with mild-to-moderate COVID-19)

*SPECIAL UPDATE ALERT:* This recommendation has been updated based on newly available literature and approvals. This update will be fully integrated into this document and the IDSA website soon; it is provided here for immediate use.

A new recommendation on the use of lopinavir/ritonavir for ambulatory patients with mild-to-moderate COVID-19 has been developed. The full updated section featuring the new recommendation can be viewed on the [IDSA website](https://www.idsociety.org/).
Recommendation 4c: Among hospitalized patients with COVID-19, the IDSA guideline panel recommends against the use of the combination lopinavir/ritonavir. (Strong recommendation, Moderate certainty of evidence)

Recommendation 5: Among hospitalized critically ill patients* with COVID-19, the IDSA guideline panel recommends dexamethasone rather than no dexamethasone. (Strong recommendation, Moderate certainty of evidence)

- Remark: If dexamethasone is unavailable, equivalent total daily doses of alternative glucocorticoids may be used. Dexamethasone 6 mg IV or PO for 10 days (or until discharge) or equivalent glucocorticoid dose may be substituted if dexamethasone unavailable. Equivalent total daily doses of alternative glucocorticoids to dexamethasone 6 mg daily are methylprednisolone 32 mg and prednisone 40 mg.

- Severity definition: *Critical illness is defined as patients on mechanical ventilation and extracorporeal mechanical oxygenation (ECMO). Critical illness includes end organ dysfunction as is seen in sepsis/septic shock. In COVID-19, the most commonly reported form of end organ dysfunction is ARDS.

Recommendation 6: Among hospitalized patients with severe*, but non-critical, COVID-19, the IDSA guideline panel suggests dexamethasone rather than no dexamethasone. (Conditional recommendation, Moderate certainty of evidence)

- Remark: Dexamethasone 6 mg IV or PO for 10 days (or until discharge) or equivalent glucocorticoid dose may be substituted if dexamethasone unavailable. Equivalent total daily doses of alternative glucocorticoids to dexamethasone 6 mg daily are methylprednisolone 32 mg and prednisone 40 mg.

- Severity definition: *Severe illness is defined as patients with SpO2 ≤94% on room air, including patients on supplemental oxygen.
Recommendation 7: Among hospitalized patients with non-severe* COVID-19 without hypoxemia requiring supplemental oxygen, the IDSA guideline panel suggests against the use of glucocorticoids. (Conditional recommendation, Low certainty of evidence)

- **Severity definition:** *Non-severe illness is defined as patient with a SpO2 > 94% not requiring supplemental oxygen.

Recommendation 8: Among hospitalized adults with progressive severe* or critical** COVID-19 who have elevated markers of systemic inflammation, the IDSA guideline panel suggests tocilizumab in addition to standard of care (i.e., steroids) rather than standard of care alone. (Conditional recommendation, Low certainty of evidence)

Remarks:

- Patients, particularly those who respond to steroids alone, who put a high value on avoiding possible adverse events of tocilizumab and a low value on the uncertain mortality reduction, would reasonably decline tocilizumab.
- In the largest trial on the treatment of tocilizumab, criterion for systemic inflammation was defined as CRP ≥75 mg/L.

Severity definitions:

- *Severe illness is defined as patients with SpO2 ≤94% on room air, including patients on supplemental oxygen.
- **Critical illness is defined as patients on mechanical ventilation and ECMO. Critical illness includes end organ dysfunction as is seen in sepsis/septic shock. In COVID-19, the most commonly reported form of end organ dysfunction is ARDS.

Recommendation 9: When tocilizumab is not available, for patients who would otherwise qualify for tocilizumab, the IDSA guideline panel suggests sarilumab in addition to standard of care.
care (i.e., steroids) rather than standard of care alone. (Conditional recommendation, Very low certainty of evidence)

- **Remark:** Patients, particularly those who respond to steroids alone, who put a high value on avoiding possible adverse events of sarilumab and a low value on the uncertain mortality reduction, would reasonably decline sarilumab.

**Recommendation 10:** Among patients hospitalized with COVID-19, the IDSA guideline panel recommends against COVID-19 convalescent plasma. (Strong recommendation, Moderate certainty of evidence)

**Recommendation 11:** Among ambulatory patients with mild to moderate COVID-19, the IDSA guideline panel suggests against COVID-19 convalescent plasma outside of the context of a clinical trial. (Conditional recommendation, Low certainty of evidence)

*SPECIAL UPDATE ALERT (2/8/2022):* This recommendation has been updated based on newly available literature and approvals. This update will be fully integrated into this document and the IDSA website soon; it is provided here for immediate use.

**Recommendation 11** has been revised to address the use of convalescent plasma in ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease with no other treatment options. The full updated section can be viewed on the [IDSA website](https://www.idsociety.org).

**Recommendation 12 (NEW):** Among ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests remdesivir initiated within seven days of symptom onset rather than no remdesivir. (Conditional recommendation, Low certainty of evidence)

*Remarks:*
• Dosing for remdesivir is 200 mg on day one followed by 100 mg on days two and three.

• Patients with mild to moderate COVID-19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID-19 may also receive remdesivir.

• Options for treatment and management of ambulatory patients include nirmatrelvir/ritonavir, three-day treatment with remdesivir, molnupiravir, and neutralizing monoclonal antibodies. Patient specific factors (e.g., symptom duration, renal function, drug interactions), product availability, and institutional capacity and infrastructure should drive decision-making regarding choice of agent. Data for combination treatment do not exist in this setting.

**SPECIAL UPDATE ALERT:** This recommendation has been updated based on newly available literature and approvals. This update will be fully integrated into this document and the IDSA website soon; it is provided here for immediate use.

**Recommendation 12** has been revised to address the use of remdesivir in patients (ambulatory or hospitalized) with mild-to-moderate COVID-19 at high risk for progression to severe disease. The full updated section can be viewed on the IDSA website.

**Recommendation 13a:** In hospitalized patients with severe* COVID-19, the IDSA panel suggests remdesivir over no antiviral treatment. (Conditional recommendation, Moderate certainty of evidence)

• **Severity definition:** *Severe illness is defined as patients with SpO₂ ≤94% on room air.

**Recommendation 13b:** In patients with COVID-19 on invasive ventilation and/or ECMO, the IDSA panel suggests against the routine initiation of remdesivir (Conditional recommendation, Very low certainty of evidence)
Recommendation 14: In patients on supplemental oxygen but not on mechanical ventilation or ECMO, the IDSA panel suggests treatment with five days of remdesivir rather than 10 days of remdesivir. (Conditional recommendation, Low certainty of evidence)

Recommendation 15: In patients with COVID-19 admitted to the hospital without the need for supplemental oxygen and oxygen saturation >94% on room air, the IDSA panel suggests against the routine use of remdesivir. (Conditional recommendation, Very low certainty of evidence)

Recommendation 16: Among hospitalized patients with severe COVID-19, the IDSA panel suggests against famotidine use for the sole purpose of treating COVID-19 outside of the context of a clinical trial. (Conditional recommendation, Very low certainty of evidence)

Recommendation 17 (NEW): In moderately or severely immunocompromised individuals* at increased risk for inadequate immune response to COVID-19 vaccine or for whom COVID-19 vaccine is not recommended due to a documented serious adverse reaction to the vaccine, the IDSA guideline panel suggests pre-exposure prophylaxis with tixagevimab/cilgavimab rather than no tixagevimab/cilgavimab. (Conditional recommendation, Low certainty of evidence)

Remarks:
- Dosing for tixagevimab/cilgavimab is 150 mg of tixagevimab & 150 mg of cilgavimab administered as two separate consecutive intramuscular injections once.
- Local SARS-CoV-2 variant susceptibility should be considered.

Recommendation 18: In persons exposed to COVID-19 who are at high risk of progression to severe COVID-19, the IDSA guideline panel suggests post-exposure casirivimab/imdevimab rather than no casirivimab/imdevimab. (Conditional recommendation, low certainty of evidence)

Remarks:
- Dosing for casirivimab/imdevimab is casirivimab 600 mg & imdevimab 600 mg IV or SC once.
- In the trial considered for this recommendation, participants were enrolled within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection.

**Recommendation 19:** Among ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab rather than no neutralizing antibody treatment. (Conditional recommendation, Moderate certainty of evidence)

**Remarks:**

- Dosing for casirivimab/imdevimab is casirivimab 600 mg and imdevimab 600 mg IV. Subcutaneous injection is a reasonable alternative in patients for whom it cannot be given intravenously.
- Dosing for sotrovimab is sotrovimab 500 mg IV once.
- Dosing for bamlanivimab/etesevimab is bamlanivimab 700 mg and etesevimab 1400 mg IV once.
- Patients with mild to moderate COVID-19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID-19 may also receive bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab.
- Local variant susceptibility should be considered in the choice of the most appropriate neutralizing antibody therapy. Local availability of different monoclonal antibody combinations may be affected by predominance of local variants.
- There are limited data on efficacy of bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab in high-risk patients under 18 years of age.
Recommendation 20: Among hospitalized patients with severe COVID-19, the IDSA guideline panel recommends against bamlanivimab monotherapy. (Strong recommendation, Moderate certainty of evidence)

Recommendation 21: Among hospitalized adults with severe* COVID-19 having elevated inflammatory markers, the IDSA panel suggests baricitinib rather than no baricitinib. (Conditional recommendation, Moderate certainty of evidence)

Remarks:
- Baricitinib 4 mg per day (or appropriate renal dosing) up to 14 days or until discharge from hospital.
- Baricitinib appears to demonstrate the most benefit in those with severe COVID-19 on high-flow oxygen/non-invasive ventilation at baseline.
- Limited additional data suggest a mortality reduction even among patients requiring mechanical ventilation.
- Patients who receive baricitinib for treatment of COVID-19 should not receive tocilizumab or other IL-6 inhibitors.

Severity definition: *Severe illness is defined as patients with SpO₂ ≤ 94% on room air, including patients on supplemental oxygen, oxygen through a high-flow device, or non-invasive ventilation.

Recommendation 22: Among hospitalized patients with severe* COVID-19 who cannot receive a corticosteroid (which is standard of care) because of a contraindication, the IDSA guideline panel suggests use of baricitinib with remdesivir rather than remdesivir alone. (Conditional recommendation, Low certainty of evidence)

• Remark: Baricitinib 4 mg daily dose for 14 days or until hospital discharge. The benefits of baricitinib plus remdesivir for persons on mechanical ventilation are uncertain.
• **Severity definition:** *Severe illness is defined as patients with $\text{SpO}_2 \leq 94\%$ on room air, including patients on supplemental oxygen, oxygen through a high-flow device, or non-invasive ventilation.

**Recommendation 23:** Among hospitalized adults with severe* COVID-19, but not on non-invasive or invasive mechanical ventilation, the IDSA panel suggests tofacitinib rather than no tofacitinib. (Conditional recommendation, Low certainty of evidence)

**Remarks:**
- Tofacitinib appears to demonstrate the most benefit in those with severe COVID-19 on supplemental or high-flow oxygen.
- Patients treated with tofacitinib should be on at least prophylactic dose anticoagulant.
- Patients who receive tofacitinib should not receive tocilizumab or other IL-6 inhibitor for treatment of COVID-19.
- The STOP-COVID Trial did not include immunocompromised patients.

**Severity definition:** *Severe illness is defined as patients with $\text{SpO}_2 \leq 94\%$ on room air, including patients on supplemental oxygen or oxygen through a high-flow device.

**Recommendation 24:** In hospitalized patients with COVID-19, the IDSA panel suggests against ivermectin outside of the context of a clinical trial. (Conditional recommendation, very low certainty of evidence)

**Recommendation 25:** In ambulatory persons with COVID-19, the IDSA panel suggests against ivermectin outside of the context of a clinical trial. (Conditional recommendation, very low certainty of evidence)
Recommendation 26: Among ambulatory patients with COVID-19, the IDSA guideline panel recommends fluvoxamine only in the context of a clinical trial. (Knowledge gap)

Recommendation 27 (NEW): In ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests nirmatrelvir/ritonavir initiated within five days of symptom onset rather than no nirmatrelvir/ritonavir. (Conditional recommendation, Low certainty of evidence)

Remarks:

- Patients’ medications need to be screened for serious drug interactions (i.e., medication reconciliation). Patients on ritonavir- or cobicistat-containing HIV or HCV regimens should continue their treatment as indicated.

- Dosing based on renal function:
  - Estimated glomerular filtration rate (eGFR) > 60 ml/min: 300 mg nirmatrelvir/100 ritonavir every 12 hours for five days
  - eGFR ≤60 and ≥30 mL/min: 150 mg nirmatrelvir/100 mg ritonavir every 12 hours for five days
  - eGFR <30 mL/min: not recommended

- Patients with mild to moderate COVID-19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID-19 may also receive nirmatrelvir/ritonavir

- Options for treatment and management of ambulatory patients include nirmatrelvir/ritonavir, three-day treatment with remdesivir, molnupiravir, and neutralizing monoclonal antibodies. Patient-specific factors (e.g., symptom duration, renal function, drug interactions) as well as product availability should drive decision-making regarding choice of agent. Data for combination treatment do not exist in this setting.
Recommendation 28 (NEW): In ambulatory patients (≥18 years) with mild to moderate COVID-19 at high risk for progression to severe disease who have no other treatment options*, the IDSA guideline panel suggests molnupiravir initiated within five days of symptom onset rather than no molnupiravir. (Conditional recommendation, Low certainty of evidence)

Remarks:

- Patients who put a higher value on the putative mutagenesis, adverse events or reproductive concerns, and a lower value on the uncertain benefits, would reasonably decline molnupiravir.
- Molnupiravir 800 mg for five days.
- Patients with mild to moderate COVID-19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID-19 may also receive molnupiravir.
- Molnupiravir is not authorized under the FDA EUA for use in patients <18 years, because it may affect bone and cartilage growth.
- Molnupiravir is not recommended under the FDA EUA for use during pregnancy.
- Molnupiravir is not authorized under the FDA EUA for pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19, because benefit of treatment has not been observed in individuals when treatment is started after hospitalization due to COVID-19.

*Other options for treatment and management of ambulatory patients include nirmatrelvir/ritonavir, three-day treatment with remdesivir, and neutralizing monoclonal antibodies. Patient-specific factors (e.g., symptom duration, renal function, drug interactions) as well as product availability should drive decision-making regarding choice of agent. Data for combination treatment do not exist in this setting.
Since the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19. The panel has determined that when an explicit trade-off between highly uncertain benefits and known putative harms of these therapeutic agents were considered, a net positive benefit was not reached and could possibly be negative (risk of excess harm). The panel acknowledges that enrolling patients in randomized controlled trials (RCTs) might not be feasible for many frontline providers due to limited access and infrastructure. Should lack of access to clinical trials exist, we encourage setting up local or collaborative registries to systematically evaluate the efficacy and safety of drugs to contribute to the knowledge base. Each clinician can play a role in advancing our understanding of this disease through a local registry or other data collection efforts.

**Background**

The first cases of COVID-19 were reported from Wuhan, China in early December 2019 [1], now known to be caused by a novel beta-coronavirus, named as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a span of months, COVID-19 has become pandemic due to its transmissibility, spreading across continents with the number of cases and deaths rising daily [2]. Although most infected individuals exhibit a mild illness (80%+), 14% have serious and 5% have critical illness. Approximately 10% will require hospital admission due to COVID-19 pneumonia, of which approximately 10% will require ICU care, including invasive ventilation due to acute respiratory distress syndrome (ARDS) [3]. While mortality appears to be more common in older individuals and those with comorbidities, such as chronic lung disease, cardiovascular disease, hypertension and diabetes, young people with no comorbidities also appear to be at risk for critical illness including multi-organ failure and death.

There has been an expanding number of studies rapidly published online and in academic journals; however, some of these may be of limited quality and are pre-published without sufficient peer-review. Critical appraisal of the existing studies is needed to determine if the existing evidence is sufficient to support currently proposed management strategies.
Given the rapid global spread of SARS-CoV-2 and the difficulty for the overburdened front-line providers and policymakers to stay up to date on emerging literature, IDSA has recognized the necessity of developing a rapid guideline for the treatment of COVID-19. The guideline panel is using a methodologically rigorous process for evaluating the best available evidence and providing treatment recommendations. Two additional guidelines on diagnostic testing and infection prevention also have been developed. These guidelines will be frequently updated as substantive literature becomes available and are accessible on an easy to navigate web and device interface at http://www.idsociety.org/covid19guidelines.

There continue to be several ongoing trials evaluating therapeutic agents for the treatment of COVID-19. As data becomes available from these trials and if there is a preponderance of evidence to suggest the use of a therapeutic agent even in the context of clinical trials is no longer warranted it will be removed from future updates of the guideline (and the removal will be noted in the updated guidelines). If there is emerging evidence on the efficacy or safety of a therapeutic agent not mentioned in the current version of the guideline it will be included in future updates of the guideline.

These recommendations are intended to inform patients, clinicians, and other health professionals by providing the latest available evidence.
Methods

This guideline was developed using the GRADE approach for evidence assessment. In addition, given the need for an urgent response to a major public health crisis, the methodological approach was modified according to the Guidelines International Network/McMaster checklist for the development of rapid recommendations [4].

Panel composition

The initial guideline panel assembled in March 2020 was composed of nine members including infectious diseases specialists as well as experts in public health as well as other front-line clinicians, specializing in pharmacology, pediatrics, medical microbiology, preventive care, critical care, hepatology, nephrology and gastroenterology. Organizational representatives were included from the Society for Healthcare Epidemiology of America (SHEA) and the Pediatric Infectious Diseases Society (PIDS). In May 2020, an additional panel member was included as a representative from the Society of Infectious Diseases Pharmacists (SIDP). The Evidence Foundation provided technical support and guideline methodologists for the development of this guideline.

Disclosure and management of potential conflicts of interest

The conflict of interest (COI) review group for this guideline includes two representatives from IDSA who are responsible for reviewing, evaluating and approving all disclosures. All members of the expert panel have complied with the COI process for reviewing and managing conflicts of interest, which requires disclosure of any financial, intellectual, or other interest that might be construed as constituting an actual, potential, or apparent conflict, regardless of relevancy to the guideline topic. The assessment of disclosed relationships for possible COI is based on the relative weight of the financial relationship (i.e., monetary amount) and the relevance of the relationship (i.e., the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The COI review group has ensured that the majority of the panel and chair is without potential relevant (related to the topic) conflicts for the duration of their term on the
panel. The chair and all members of the technical team have been determined to be unconflicted.

**Question generation**

Clinical questions included in this guideline were developed into a PICO format (Population, Intervention, Comparison, Outcomes) [5] and prioritized according to available evidence that met the minimum acceptable criteria (i.e., the body of evidence reported on at least a case-series design, case reports were excluded). Panel members prioritized patient-important outcomes such as mortality, development of ARDS (need for non-invasive or invasive ventilation) and clinical improvement (such as disease-oriented outcomes inferred by radiological findings or virologic cure), and severe adverse events leading to treatment discontinuation. Serious adverse events are death, life threatening reactions, those that require hospitalization, result in disability or permanent damage or require an intervention to prevent permanent impairment [6]. Additional drug specific harms were evaluated when clinically relevant, including possible drug-drug reactions, if applicable.

**Search strategy**

The National Institute for Health and Care Excellence (NICE) highly-sensitive search was reviewed by the methodologist in consultation with the technical team information specialist and was determined to have high sensitivity [7]. An additional term, COVID, was added to the search strategy used in addition to the treatment terms identified in the PICO questions ([Supplementary Table s1](#)). Ovid Medline and Embase were searched from 2019 through September 18, 2020. Horizon scans have been performed regularly during the evidence assessment and recommendation process to locate additional grey literature and manuscript pre-prints. Reference lists and literature suggested by panelists were reviewed for inclusion. No restrictions were placed on language or study type.

**Screening and study selection**

Two reviewers independently screened titles and abstracts, as well as eligible full-text studies. When acceptable RCTs of effectiveness were found, no additional non-randomized
studies or non-comparative evidence (i.e., single-arm case series) were sought. Evidence from single arm studies reporting on non-comparative rates of outcomes of interest were included if a historical control event rate could be estimated from the literature. Reviewers extracted relevant information into a standardized data extraction form.

For several interventions, no direct evidence was available other than case reports or mechanistic considerations. The panel either decided to include plausible indirect evidence and make a recommendation (e.g., from studies of SARS-CoV) or to provide a short narrative discussion of the intervention.

**Data collection and analysis**

Data extracted from the available evidence included: mortality, clinical progression or improvement as reported in the studies, virologic clearance, and adverse events. Where applicable, data were pooled using random effects model (fixed effects model for two or fewer trials or pooling of rates) using RevMan [8].

**Risk of bias and certainty of evidence**

Risk of bias was assessed using the Cochrane Risk of Bias Tool for RCTs and the Risk of Bias Instrument for Non-randomized Studies – of Interventions (ROBINS-I) [9, 10]. The certainty of evidence was assessed using the GRADE approach [11]. Within GRADE, the body of evidence across each outcome is assessed for domains that may reduce or increase one’s certainty in the evidence. Factors that may reduce one’s certainty include risk of bias (study limitations), inconsistency (unexplained heterogeneity across study findings), indirectness (applicability or generalizability to the research question), imprecision (the confidence in the estimate of an effect to support a particular decision) or publication bias (selective publication of studies). One’s certainty in the evidence may be strengthened if the following considerations are present: large or very large magnitude of effect, evidence of a dose-response gradient, or opposing residual confounding. GRADE summary of findings tables were developed in GRADEpro Guideline Development Tool [12].
As higher quality direct evidence for clinical outcomes becomes available, outcomes previously deemed critical by the panel became less important for decision-making. For example, at the time of the first guideline, clinical improvement outcomes (e.g., need for mechanical ventilation) were not reported, only the results of radiographic findings. However, with the recent publication of RCTs and non-randomized studies reporting on direct measures of clinical improvement, results of radiographic studies were deemed to be less critical for decision making.

Evidence to recommendations

The panel considered core elements of the GRADE evidence in the decision process, including Certainty of evidence and balance between desirable and undesirable effects. Additional domains were acknowledged where applicable (feasibility, resource use, acceptability). For all recommendations, the expert panelists reached consensus. Voting rules were agreed on prior to the panel meetings for situations when consensus could not be reached.

As per GRADE methodology, recommendations are labeled as “strong” or “conditional”. The words “we recommend” indicate strong recommendations and “we suggest” indicate conditional recommendations. Figure 1 provides the suggested interpretation of strong and weak recommendations for patients, clinicians, and healthcare policymakers. For recommendations where the comparators are not formally stated, the comparison of interest is implicitly referred to as “not using the intervention”. These recommendations acknowledge the current “knowledge gap” and aim at avoiding premature favorable recommendations for their use and to avoid encouraging the rapid diffusion of potentially ineffective or harmful interventions. Detailed suggestions about the specific research questions that should be addressed are found in the table (see Supplementary Table s2).
Figure 1. Approach and implications to rating the quality of evidence and strength of recommendations using GRADE methodology (unrestricted use of figure granted by the U.S. GRADE Network)
Review process

This guideline has been rapidly reviewed and approved by the IDSA Board of Directors Executive Committee external to the guideline development panel. SHEA, PIDS, and SIDP have reviewed and provided endorsement of its contents.

Updating process and terminology

Regular, frequent screening of the literature will take place to determine the need for revisions based on the likelihood that any new data will have an impact on the recommendations. When necessary, the entire expert panel is reconvened to discuss potential changes.

Changes to these guidelines will fall into one of two categories: update or amendment. An update involves a search for new studies, and if any new studies are found, they will be critically appraised and the pertinent section will be removed and replaced with the updated section. An amendment involves a change or correction to the document, without any search for new studies and their appraisal. It will also involve changes made to clarify or explain a section based on “living” feedback from the readers.

Guideline revisions may result in major, minor, or “patch” version changes, defined as follows:

- **Major version** (e.g., 1.0.0): Synonymous with a newly published version in the journal. This is usually called a "breaking version", i.e., prior recommendations may not be valid anymore.
- **Minor version** (e.g., 1.1.0): Includes new information, maybe even added PICOs, but not a breaking version, i.e., existing recommendations are still valid, although new recommendations may be available.
- **Patch version** (e.g., 1.0.1): Small changes, i.e., typos, adding words, removing words, but there are no material changes to the document or changes in recommendations.
Results

Systematic review and horizon scan of the literature identified 2030 references of which 48 informed the evidence base for these recommendations (Supplementary Figure s1). Characteristics of the included studies can be found in the supplementary materials.

Hydroxychloroquine/Chloroquine; Hydroxychloroquine/Chloroquine plus Azithromycin

Section last reviewed and updated 12/23/2020

Last literature search conducted 12/14/2020

Recommendation 1: Among hospitalized patients with COVID-19, the IDSA guideline panel recommends against hydroxychloroquine*. (Strong recommendation, Moderate certainty of evidence)

- Remark: Chloroquine is considered to be class equivalent to hydroxychloroquine.

Recommendation 2: Among hospitalized patients with COVID-19, the IDSA guideline panel recommends against hydroxychloroquine* plus azithromycin. (Strong recommendation, Low certainty of evidence)

- Remark: Chloroquine is considered to be class equivalent to hydroxychloroquine.

Why are hydroxychloroquine and hydroxychloroquine plus azithromycin considered for treatment?

Hydroxychloroquine (HCQ) and chloroquine are 4-aminoquinoline drugs developed in the mid-20th century for the treatment of malaria [13]. Hydroxychloroquine differs from chloroquine only in the addition of a hydroxyl group and is associated with a lower incidence of adverse effects with chronic use [13]. Both drugs have been used in the treatment of autoimmune diseases because of their immunomodulatory effects on several cytokines,
including interleukin-1 (IL-1) and IL-6 [13]. There is some evidence that these drugs also have antiviral properties against many different viruses, including the coronaviruses [14, 15]. They have demonstrated in vitro activity against SARS-CoV-2, which range considerably between studies, but are generally within the range of predicted achievable tissue concentrations [14, 16-18]. The in vitro activity, the extensive use for other conditions, and widespread availability of generic versions of the drug made it an attractive option for treatment of COVID-19. Interest in combinations of HCQ with azithromycin (AZ) began when investigators in a small, uncontrolled study of hydroxychloroquine use for COVID-19 noticed a higher frequency of patients achieving virologic response in the six subjects who received AZ to prevent bacterial infection [19]. Azithromycin, widely utilized as an antibacterial agent, has also been shown to have in vitro antiviral activity against a variety of ribonucleic acid viruses [20-22]. While the exact mechanism of antiviral activity is unknown, possibilities include inhibiting endocytosis and limiting viral replication [23] and the induction of interferon [22, 24]. Macrolides have also been shown to have anti-inflammatory activity [25, 26].

**Summary of the evidence**

Our search identified eight RCTs and seven comparative cohort studies of hospitalized patients with confirmed COVID-19 treated with HCQ with reported mortality, clinical progression or clinical improvement, and adverse events outcomes [27-41] (Supplementary Table s3a) (Table 1).

In addition, we identified two RCTs, four comparative cohort studies, one case-control study, and three single-arm studies reporting adjusted analyses of hospitalized patients with confirmed COVID-19 treated with HCQ plus AZ with reported mortality, failure of virologic clearance (assessed with polymerase chain reaction [PCR] test), clinical improvement, and adverse events (i.e., significant QT prolongation leading to treatment discontinuation) [19, 27, 28, 37, 39, 41-45] (Supplementary Table s3b) (Table 2).

**Benefits**

Hydroxychloroquine
Five RCTs showed a trend toward mortality among patients with COVID-19 treated with HCQ compared to those who were not (relative risk [RR]: 1.08; 95% confidence interval [CI]: 0.99, 1.19, Moderate certainty in the evidence) (Table 1) [28, 29, 33].

Hydroxychloroquine + Azithromycin

One RCT could not exclude the risk of in-hospital mortality among patients treated with HCQ+AZ compared to those not receiving HCQ or HCQ+AZ (hazard ratio [HR]: 0.64; 95% CI: 0.18, 2.21; Low certainty of evidence [CoE]) [28]. Three non-randomized studies failed to identify an association between treatment with HCQ+AZ and mortality: Ip reported an adjusted HR of 0.98 (95% CI: 0.75, 1.28); Magagnoli reported an adjusted HR in a subset after propensity score adjustment of 0.89 (95% CI: 0.45, 1.77); Rosenberg 2020 reported an adjusted HR of 1.35 (95% CI: 0.79, 2.40) [37, 39, 41]. As stated in the HCQ section, one non-randomized study reported a reduction in mortality among patients receiving HCQ+AZ (HR: 0.29; 95% CI: 0.22, 0.40); however, it failed to adjust for the critical confounder of disease severity and imbalances in steroid use [27]. As described in the HCQ section, similar methodologic concerns exist among patients allocated to HCQ+AZ in the Arshad study, leading to several sources of bias in interpreting their favorable results.

Harms

Hydroxychloroquine

One RCT reported that persons treated with HCQ experienced a longer time until hospital discharge (median 16 days compared with 13 days) and lower probability of being discharged alive within the 28-day study period (rate ratio: 0.92; 95% CI: 0.85, 0.99) [29]. In addition, persons treated with HCQ who were not on mechanical ventilation at baseline were more likely to be placed on mechanical ventilation during follow up (rate ratio: 1.10; 95% CI: 0.92, 1.31; Low CoE) [29, 32]. Across the body of evidence from four RCTs, treatment with HCQ may increase the risk of experiencing adverse events (RR: 2.36; 95% CI: 1.49, 3.75; Low CoE) and severe adverse events (adjusted odds ratio: 1.26; 95% CI: 0.56, 2.84; Low CoE) [28, 30, 31, 35]. One RCT and two non-randomized studies suggest increased risk of QT prolongation among
patients treated with HCQ compared to those not receiving HCQ (RR: 8.47; 95% CI: 1.14, 63.03; Low CoE and RR: 2.89; 95% CI: 1.62, 5.16; Very low CoE, respectively) [28, 38, 39]. In addition, Rosenberg 2020 reported 16% of patients in the HCQ arm experienced arrhythmias compared with 10% in the non-HCQ arm (RR: 1.56; 95% CI: 0.97, 2.50; Very low CoE).

Gastrointestinal side effects occurred in 7% of patients in a prospective cohort study in 224 COVID-19 uninfected patients with systemic lupus erythematosus (SLE) who received either chloroquine or hydroxychloroquine for routine care [46].

While the 4-aminoquinolines, chloroquine and HCQ, have not been demonstrated to cause hemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency [47, 48], case reports of hemolysis have emerged when these agents have been used for the treatment of COVID-19 [49-51]. It is possible that infection with SARS-CoV-2 may trigger hemolysis in G6PD deficient individuals in the absence of a 4-aminoquinolone. Caution should be exercised in administering these agents to G6PD deficient individuals with COVID-19, particularly if used for extended durations.

Renal clearance accounts for 15-25% of total clearance of HCQ; however, dose adjustments are not recommended with kidney dysfunction. Chloroquine and HCQ are metabolized by cytochrome P450 isoenzymes 2C8, 2D6, and 3A4 [52]. Therefore, inhibitors and inducers of these enzymes may result in altered pharmacokinetics of these agents.

**Hydroxychloroquine + Azithromycin**

One RCT suggests increased risk of QT prolongation among patients treated with HCQ+AZ compared to those not receiving HCQ (RR: 8.50; 95% CI: 1.16, 62.31; Low CoE) [28]. Two studies described significant QT prolongation in 10 of 95 patients treated with HCQ+AZ, illustrating the high risk for clinically relevant arrhythmias with this treatment [43, 45]. In addition, several case reports of QT prolongation related to HCQ have also been published [53-56]. A case-control study of persons with COVID-19 treated with HCQ+AZ compared to healthy, untreated controls reported higher values of minimum (415 vs. 376 ms), mean (453 vs. 407 ms) and maximum QTc-interval (533 vs. 452 ms) among COVID-19 cases (n=22) compared to controls (n=34) [42].
Additional case reports have cited the risk of a prolonged QT prolongation, torsades de pointes, and ventricular tachycardia in patients without COVID-19 receiving AZ alone. In a large cohort study, patients taking a five-day course of AZ had an increased risk of sudden cardiac death with a HR of 2.71 (1.58-4.64) vs. 0.85 (0.45-1.60), compared to patients receiving either no antibiotic or amoxicillin, respectively [57]. Given the cumulative effect on cardiac conduction seen with HCQ and AZ, if this combination was used, baseline and follow-up electrocardiogram (ECG) monitoring would be indicated, as well as careful surveillance for other concomitant medications known to prolong the QT interval.

Azithromycin has a low risk for cytochrome P450 interactions [58]; however, additional pharmacologic adverse events including gastrointestinal effects and QT prolongation need to be carefully considered, particularly in the outpatient setting where frequent ECG monitoring is not feasible.

Providers are encouraged to visit resources such as https://www.covid19-druginteractions.org/ to aid in the evaluation and management of drug interactions with current and emerging investigational agents for COVID-19.

**Other considerations**

The panel agreed that the overall certainty of evidence against treatment with HCQ was moderate due to concerns with imprecision around the risk for a trend towards harms from increased mortality. When considering the addition of AZ, the overall certainty of the evidence was low; however, the panel recognized even greater concern with the toxicity. In addition, based on the moderate certainty of increased QT prolongation, the panel determined that this demonstrated certain harm with uncertain benefit; therefore, the panel made a strong recommendation against HCQ+AZ.

**Conclusions and research needs for this recommendation**

The guideline panel recommends against the use of either HCQ alone or in combination with AZ in the hospital setting as higher certainty benefits (e.g., mortality reduction) are now highly unlikely even if additional high quality RCTs would become available.
This recommendation does not address the use of azithromycin for secondary bacterial pneumonia in patients with COVID-19 (Supplementary Table s2).
Table 1. GRADE evidence profile, Recommendation 1

**Question:** Hydroxychloroquine compared to no hydroxychloroquine for hospitalized patients with COVID-19

*Last reviewed and updated 12/23/2020*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nr of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
<td>Indirectness</td>
</tr>
<tr>
<td>Mortality (RCTs) (follow up: range 22 days to 49 days)</td>
<td>5</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Clinical status (assessed with: 7-point scale; higher signifies worsening severity)</td>
<td>1 2</td>
<td>randomized trials</td>
<td>serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Progression to invasive mechanical ventilation</td>
<td>2 1 3</td>
<td>randomized trials</td>
<td>serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>1 6</td>
<td>observational studies</td>
<td>very serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Adverse events, any</td>
<td>4 2 7 9</td>
<td>randomized trials</td>
<td>serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>
Severe adverse events (assessed with: untoward medical event leading to death, a life-threatening experience, prolongation of hospitalization, or persistent or significant disability or incapacity)

<table>
<thead>
<tr>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients hydroxychloroquine</th>
<th>No of patients no hydroxychloroquine</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious</td>
<td>none</td>
<td>14/242 (5.8%)</td>
<td>11/237 (4.6%)</td>
<td>OR 1.26 (0.56 to 2.84)</td>
<td>11 more per 1,000 (from 20 fewer to 75 more)</td>
<td>✱✱ ◯ ◯</td>
<td>LOW</td>
</tr>
<tr>
<td>QT prolongation (RCTs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious</td>
<td>none</td>
<td>13/89 (14.6%)</td>
<td>1/58 (1.7%)</td>
<td>RR 8.47 (1.14 to 63.03)</td>
<td>129 more per 1,000 (from 2 more to 1,000 more)</td>
<td>✱✱ ◯ ◯</td>
<td>LOW</td>
</tr>
<tr>
<td>QT prolongation (NRS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>observational studies</td>
<td>very serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>46/355 (13.0%)</td>
<td>13/311 (4.2%)</td>
<td>RR 2.89 (1.62 to 5.16)</td>
<td>79 more per 1,000 (from 26 more to 174 more)</td>
<td>◯ ◯ ◯ ◯</td>
<td>VERY LOW</td>
</tr>
</tbody>
</table>

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

Risk of bias: Study limitations

Inconsistency: Unexplained heterogeneity across study findings

Indirectness: Applicability or generalizability to the research question

Imprecision: The confidence in the estimate of an effect to support a particular decision

Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio

Explanations

a. Co-interventions were provided to patients in both studies but balanced across arms.

b. Cavalcanti 2020 excludes persons receiving supplemental oxygen at a rate of more than 4 liters per minute.

c. The 95% CI cannot exclude the potential for no benefit or harm.
d. Cavalcanti was an open-label trial.
e. The 95% CI includes the potential for both benefit and harm. Few events suggest the potential for fragility in the estimate.
f. Few events suggest the potential for fragility in the estimate.
g. Concerns with unmeasured and residual confounding. Multiple co-interventions received across arms.
h. Few events reported do not meet the optimal information size and suggest fragility in the estimate.
i. Did not report on blinding (including outcome adjudication committee), sequence generation or allocation concealment; Chen J 2020: all patients received nebulized alpha-interferon, 80% vs. 67.7% of subjects received Abidiol in the hydroxychloroquine vs. placebo arm, respectively. Two subjects in the control arm received lopinavir/ritonavir.
j. Chen J 2020: 4 AEs include diarrhea, fatigue and transient AST elevation. Chen Z 2020: 1 rash, 1 headache. Tang 2020: 21 AEs include disease progression (1%), URI (1%), diarrhea (10%), vomiting (3%).
k. Three AEs reported in two patients include: AST elevation, creatinine elevation and anemia
l. aOR: age, sex, baseline COVID Outcome Scale category, baseline Sequential Organ Failure Assessment score, and duration of acute respiratory infection symptoms prior to randomization
m. Mahevas 2020 does not report on AEs in the comparator arm.

References
Table 2. GRADE evidence profile, Recommendation 2

**Question:** Hydroxychloroquine and azithromycin compared to no hydroxychloroquine/azithromycin for hospitalized patients with COVID-19

*Last updated 8/20/2020; last reviewed 12/23/2020*

<table>
<thead>
<tr>
<th></th>
<th>Nr of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality (RCTs) (follow up: range 22 days to 49 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (^1) randomized trials</td>
<td>5/172 (2.9%)</td>
<td>HR 0.64 (0.18 to 2.21)</td>
<td>12 fewer per 1,000 (from 28 fewer to 40 more)</td>
<td>✤✤ ◯◯ LOW CRITICAL</td>
</tr>
<tr>
<td>3 (^2,3,4) observational studies</td>
<td>6/173 (3.5%)</td>
<td>None</td>
<td>Three non-randomized studies failed to identify an association between persons treated with HCQ + AZ and mortality: Ip reported an adjusted HR of 0.98 (95% CI: 0.75, 1.28); Magagnoli reported an adjusted HR in a subset after propensity score adjustment of 0.89 (95% CI: 0.45, 1.77); Rosenberg 2020 reported an adjusted hazard ratio (HR) of 1.35 (95% CI: 0.79, 2.40) (Ip, Magagnoli 2020, Rosenberg 2020).</td>
<td>✤ ◯◯◯ VERY LOW CRITICAL</td>
</tr>
</tbody>
</table>

| **Mortality (NRS)** |                |        |             |            |
| 3 \(^2,3,4\) observational studies | 5/172 (2.9%) | HR 0.64 (0.18 to 2.21) | 12 fewer per 1,000 (from 28 fewer to 40 more) | ✤✤ ◯◯ LOW CRITICAL |

| **Clinical status (assessed with: 7-point scale, higher values represent worse clinical outcomes)** |                |        |             |            |
| 1 \(^1\) randomized trials | 172 | MD 0.99 higher (0.57 higher to 1.73 higher) | ✤✤✤✤ LOW CRITICAL |

| **Virologic failure (follow up: range 5 days to 6 days; assessed with: PCR test)** |                |        |             |            |
| 2 \(^5,6,7\) observational studies | 29/71 (40.8%) | 12/12 (100.0%) | Not estimable | ✤✤✤✤ LOW IMPORTANT |

**QT prolongation (RCTs)**
<table>
<thead>
<tr>
<th>Nr of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>hydroxychloroquine</th>
<th>no hydroxychloroquine</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious ( ^{m,n} )</td>
<td>serious ( ^{c} )</td>
<td>none</td>
<td>17/116 (14.7%)</td>
<td>1/58 (1.7%)</td>
<td>RR 8.50 (1.16 to 62.31)</td>
<td>129 more per 1,000 (from 3 more to 1,000 more)</td>
<td>☒ ☒ ☐</td>
<td>IMPORTANT</td>
</tr>
<tr>
<td>QT prolongation (NRS)</td>
<td>2 (^{7,8} )</td>
<td>observational studies</td>
<td>very serious (^{h} )</td>
<td>not serious</td>
<td>serious (^{n} )</td>
<td>serious (^{c} )</td>
<td>none</td>
<td>10/95 (10.5%)</td>
<td>-</td>
<td>-</td>
<td>☒ ☒ ☒ ☒</td>
<td>VERY LOW</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>1 (^{1} )</td>
<td>randomized trials</td>
<td>serious (^{f} )</td>
<td>not serious</td>
<td>not serious (^{a} )</td>
<td>serious (^{c,d} )</td>
<td>none</td>
<td>5/239 (2.1%)</td>
<td>0/50 (0.0%)</td>
<td>RR 2.34 (0.13 to 41.61)</td>
<td>0 fewer per 1,000 (from 0 fewer to 0 fewer)</td>
<td>☒ ☒ ☐</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

*High certainty:* We are very confident that the true effect lies close to that of the estimate of the effect

*Moderate certainty:* We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

*Low certainty:* Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

*Very low certainty:* We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Risk of bias:** Study limitations

**Inconsistency:** Unexplained heterogeneity across study findings

**Indirectness:** Applicability or generalizability to the research question

**Imprecision:** The confidence in the estimate of an effect to support a particular decision

**Publication bias:** Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; HR: Hazard Ratio; RR: Risk ratio

**Explanations**

a. Co-interventions were provided to patients but balanced across arms. Cavalcanti 2020 was open label; however, likely did not influence the outcome of mortality.

b. Cavalcanti 2020 excludes persons receiving supplemental oxygen at a rate of more than 4 liters per minute.

c. A very small number of events. Optimal information size not met.

d. The 95% CI includes the potential for both benefit and harm.

e. Concerns with unmeasured and residual confounding. Multiple co-interventions received across arms.

f. Cavalcanti was an open-label trial.
g. Optimal information size not met.

h. No contemporaneous control groups; no adjustment for baseline severity, resulting in high risk for residual confounding

i. Two case series from France showed divergent results.

j. Surrogate marker for mortality or resolution of COVID-19.

k. Gautret reported 21/61 patients as positive at day 6 (estimate from supplied graph); Molina reported 8/10 patients positive at day 5 or 6. Pooled rates of virologic failure using fixed effects inverse variance method resulted in a 43% failure rate (95% CI, 32% to 54%)

l. Gautret reported on a historical viral clearance rate in symptomatic patients from a separate hospital. Criteria for selection of patients remains unclear, as presumably a sizable number of untreated patients could have been available with data on viral clearance.

m. Indirect measure of arrhythmia-specific mortality.

n. Azithromycin and hydroxychloroquine can independently cause QT prolongation. Used together there can be an additive effect. Caution should be exercised with other agents known to prolong the QT interval.

o. Molina 2020: 1/11 leading to treatment discontinuation; Chorin 2020: 9/84 with significant QTc prolongation of more than 500 ms.

p. Cavalcanti 2020 serious adverse events included pulmonary embolism, QTc prolongation, myocardial infarction, abdominal-wall hemorrhage.

References
Hydroxychloroquine as Post-Exposure Prophylaxis

Section last reviewed and updated 9/23/2021

Last literature search conducted 9/21/2021

Recommendation 3: In persons exposed to COVID-19, the IDSA guideline panel recommends against hydroxychloroquine. (Strong recommendation, Moderate certainty of evidence)

Why is hydroxychloroquine considered for post-exposure prophylaxis?

There is some evidence that HCQ has antiviral properties against many different viruses, including the coronaviruses [14, 15]. It has demonstrated in vitro activity against SARS-CoV-2, which ranges considerably between studies, but is generally within the range of predicted achievable tissue concentrations [14, 16-18]. The in vitro activity, the extensive use for other conditions, and widespread availability of generic versions of the drug made it an attractive option for treatment and prophylaxis of COVID-19; however, at this point, HCQ has not been identified as effective for treatment of COVID-19.

Summary of the evidence

Our search identified three RCTs that reported on HCQ post-exposure prophylaxis of contacts of those diagnosed with SARS-CoV-2 infection [59-61]. Patients in these studies were randomized to HCQ or placebo or no additional treatment. All three studies evaluated for the presence of SARS-CoV-2 at day 14, two of the studies required a positive test for SARS-CoV-2, while one allowed symptoms suggestive of COVID-19 to meet the outcome when a test was not completed. Additional outcomes included hospitalization, mortality, and serious adverse events.

Benefits

Outpatients
Hydroxychloroquine appears to have trivial or no effect on the development of symptomatic SARS-CoV-2 infection at day 14 compared to no HCQ (RR: 0.95; 95% CI: 0.77, 1.16; moderate CoE). In addition, HCQ showed trivial or no effect on the rate of hospitalization (RR: 1.00; 95% CI: 0.47, 2.12; three fewer to seven more hospitalizations in 1,000; low CoE) or mortality (RR: 0.45; 95% CI: 0.16, 1.28; five fewer to two more deaths in 1,000; low CoE).

**Harms**

There was no difference in serious adverse events in the HCQ rather than no HCQ for post-exposure prophylaxis (RR: 0.91; 95% CI: 0.47, 1.76; low CoE). Additional side effects and harms of HCQ (e.g., QT prolongation, arrhythmias, gastrointestinal effects) have been summarized in recommendation 1 (HCQ for treatment of hospitalized persons with COVID-19).

**Other considerations**

The panel made an explicit decision that:

a. The primary outcome driving the decision for any post-exposure prophylaxis is the ability to prevent infection

b. When the evidence demonstrates a very low likelihood of effective post-exposure prophylaxis, other outcomes become secondary

c. When healthy persons are considered for preventive medications (such as would occur in post-exposure settings), a higher threshold for benefits is required and (even putative) harms become more important

The panel agreed that the overall certainty of the evidence against prophylaxis treatment with HCQ was moderate (failure to prevent infection) due to concerns with imprecision. The panel balanced the lack of clear benefit with the increased risk of harms from the body of evidence reported in the treatment section, in addition to the side effects reported in the trials to make a strong recommendation.

**Conclusions and research needs for this recommendation**
The guideline panel recommended against the use of HCQ as post-exposure prophylactic treatment for persons exposed to COVID-19.
Table 3. GRADE evidence profile, Recommendation 3

**Question:** Hydroxychloroquine compared to no hydroxychloroquine for post-exposure prophylaxis of COVID-19

*New evidence profile developed 9/23/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>(95% CI)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Relative</td>
<td>Absolute</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>RR</td>
<td>CI</td>
<td></td>
</tr>
</tbody>
</table>

**Symptomatic SARS-CoV-2 infection (follow-up: 14 days)**

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>hydroxychloroquine</th>
<th>no hydroxychloroquine</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious b</td>
<td>none</td>
<td>166/1883 (8.8%)</td>
<td>177/1941 (9.1%)</td>
<td>RR 0.95 (0.77 to 1.16)</td>
<td>5 fewer per 1,000 (from 21 fewer to 15 more)</td>
<td>MODERATE</td>
<td>CRITICAL</td>
<td></td>
</tr>
</tbody>
</table>

**Hospitalization (follow-up: 14 days)**

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>hydroxychloroquine</th>
<th>no hydroxychloroquine</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious b</td>
<td>none</td>
<td>13/2018 (0.6%)</td>
<td>14/2129 (0.7%)</td>
<td>RR 1.00 (0.47 to 2.12)</td>
<td>0 fewer per 1,000 (from 3 fewer to 7 more)</td>
<td>LOW</td>
<td>CRITICAL</td>
<td></td>
</tr>
</tbody>
</table>

**Mortality (follow-up: 14 days)**

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>hydroxychloroquine</th>
<th>no hydroxychloroquine</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious b</td>
<td>none</td>
<td>5/2018 (0.2%)</td>
<td>12/2129 (0.6%)</td>
<td>RR 0.45 (0.16 to 1.28)</td>
<td>3 fewer per 1,000 (from 5 fewer to 2 more)</td>
<td>LOW</td>
<td>CRITICAL</td>
<td></td>
</tr>
</tbody>
</table>

**Serious adverse events (follow-up: 14 days)**

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>hydroxychloroquine</th>
<th>no hydroxychloroquine</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious b</td>
<td>none</td>
<td>16/2018 (0.8%)</td>
<td>19/2129 (0.9%)</td>
<td>RR 0.91 (0.47 to 1.76)</td>
<td>1 fewer per 1,000 (from 5 fewer to 7 more)</td>
<td>LOW</td>
<td>CRITICAL</td>
<td></td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect

**Risk of bias:** Study limitations

- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision
- **Publication bias:** Selective publication of studies

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

**CI:** Confidence interval; **RR:** Risk ratio

**Explanations**
a. Boulware included both laboratory-confirmed COVID-19 as well as probable COVID-19; 11/49 patients receiving HCQ were laboratory confirmed and 9/58 receiving placebo were laboratory confirmed.

b. The 95% CI includes both the potential of benefit and the risk of harm.

References
Lopinavir/Ritonavir

_Special Update Alert:_ The following section has been updated based on newly available literature and approvals. This update will be fully integrated into this document and the IDSA website soon; it is provided here for immediate use.

Two new recommendations on the use of lopinavir/ritonavir (prophylaxis for persons exposed to SARS-CoV-2; treatment for ambulatory patients with mild-to-moderate COVID-19) have been developed. The full updated section featuring the new recommendations can be viewed on the [IDSA website](https://www.idsociety.org).

---

**Section last reviewed and updated 11/22/2020**

**Last literature search conducted 11/18/2020**

**Recommendation 4:** Among hospitalized patients with COVID-19, the IDSA guideline panel recommends against the use of the combination lopinavir/ritonavir. (Strong recommendation, Moderate certainty of evidence)

**Why is lopinavir plus ritonavir considered for treatment?**

Lopinavir/ritonavir is a protease inhibitor that was U.S. Food and Drug Administration (FDA)-approved for the treatment of HIV in September 2000. Ritonavir is added to the combination as a pharmacokinetic enhancer due to its strong inhibition of cytochrome P450 3A4, a metabolic pathway for lopinavir metabolism. Lopinavir/ritonavir demonstrated in vitro inhibition of SARS-CoV-1 and MERS-CoV replication (Chen, 2004 #167; Wu, 2004 #689; Chan, 2015 #170). A trial of lopinavir/ritonavir and ribavirin versus historical controls in SARS-CoV-1 patients, showed a reduced rate of ARDS and mortality in those receiving lopinavir/ritonavir. This study had limitations including a control group from early in the outbreak when management strategies likely differed significantly (Chu, 2004 #169). During the MERS outbreak, case reports cited efficacy of lopinavir/ritonavir with interferon in the management
of MERS patients {Spanakis, 2014 #692;Kim, 2016 #693}. During the early phase of COVID-19, triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin shortened the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19 in an open-label, randomized, phase II trial {Hung, 2020 #560}.

**Summary of the evidence**

Three RCTs reported on treatment with combination lopinavir/ritonavir or placebo for hospitalized patients with COVID-19 {Cao, 2020 #80;RECOVERY Collaborative Group, 2020 #695;WHO Solidarity Trial Consortium, 2021 #699} ([Table 4](#)). The trials reported on the following outcomes: mortality, failure of clinical improvement (measured using a 7-point scale or hospital discharge), need for mechanical ventilation, and adverse events leading to treatment discontinuation.

**Benefits**

Among hospitalized patients with COVID-19, treatment with lopinavir/ritonavir failed to show or exclude a beneficial effect on mortality or need for invasive mechanical ventilation (RR: 1.00; 95% CI: 0.89, 1.13; moderate CoE and RR: 1.12; 95% CI: 0.93, 1.34; low CoE). Similarly, lopinavir/ritonavir may reduce failure of clinical improvement at 14 days, but it is uncertain (RR: 0.78; 95% CI: 0.63, 0.97; very low CoE).

**Harms**

RECOVERY reported 1/1588 serious adverse event due to treatment with lopinavir-ritonavir {RECOVERY Collaborative Group, 2020 #695}; however, nearly 14% of lopinavir/ritonavir recipients in Cao 2020 were unable to complete the full 14-day course of administration. This was due primarily to gastrointestinal adverse events, including anorexia, nausea, abdominal discomfort, or diarrhea, as well as two serious adverse events, both acute gastritis. Two recipients had self-limited skin eruptions. Such side effects, including the risks of hepatic injury, pancreatitis, more severe cutaneous eruptions, and QT prolongation, and the potential for multiple drug interactions due to CYP3A inhibition, are well documented with this
drug combination. The side-effect profile observed in these trials raise concerns about the use of higher or more prolonged lopinavir–ritonavir dose regimens in efforts to improve outcomes.

**Other considerations**

The panel determined the certainty of evidence to be moderate due to concerns with imprecision. The guideline panel made a strong recommendation against treatment with the combination of lopinavir/ritonavir for hospitalized patients with COVID-19.

**Conclusions and research needs for this recommendation**

The guideline panel recommends against treatment with lopinavir/ritonavir in hospitalized patients with COVID-19.
Table 4. GRADE evidence profile, Recommendation 4  
Question: Lopinavir-ritonavir compared to no Lopinavir-ritonavir for hospitalized patients with severe COVID-19  
Last reviewed and updated 11/22/2020

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>Nr of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mortality (follow up: 28 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 1,2,3 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious b</td>
<td>none</td>
</tr>
</tbody>
</table>

| **Invasive mechanical ventilation (follow up: 28 days)** |                 |        |            |            |
| 2 1,3 randomized trials | serious a, d | not serious | not serious | serious b | none | 166/1655 (10.0%) | 297/3380 (8.8%) | RR 1.12 (0.93 to 1.34) | 11 more per 1,000 (from 6 fewer to 30 more) | ☓ ☓ ☓ ☓ | LOW | CRITICAL |

| **Adverse events leading to treatment discontinuation** |                 |        |            |            |
| 1 1 randomized trials | serious a | not serious | not serious | very serious e | none | Nearly 14% of lopinavir–ritonavir recipients were unable to complete the full 14-day course of administration. This was due primarily to gastrointestinal adverse events, including anorexia, nausea, abdominal discomfort, or diarrhea, as well as two serious adverse events, both acute gastritis. Two recipients had self-limited skin eruptions. Such side effects, including the risks of hepatic injury, pancreatitis, more severe cutaneous eruptions, and QT prolongation, and the potential for multiple drug interactions due to CYP3A inhibition, are well documented with this drug combination. The side-effect profile observed in the current trial arouses concern about the use of higher or more prolonged lopinavir–ritonavir dose regimens in efforts to improve outcomes. | ☓ ☓ ☓ ☓ | VERY LOW | IMPORTANT |

| **Failure of clinical improvement at 14 days (follow up: 14 days)** |                 |        |            |            |
| 1 1 randomized trials | serious a | not serious | not serious | very serious f | none | 54/99 (54.5%) | 70/100 (70.0%) | RR 0.78 (0.62 to 0.97) | 154 fewer per 1,000 (from 266 fewer to 21 fewer) | ☓ ☓ ☓ ☓ | VERY LOW | CRITICAL |
GRADE Working Group grades of evidence

<table>
<thead>
<tr>
<th>Grade of Evidence</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>High certainty:</td>
<td>We are very confident that the true effect lies close to that of the estimate of the effect.</td>
</tr>
<tr>
<td>Moderate certainty:</td>
<td>We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.</td>
</tr>
<tr>
<td>Low certainty:</td>
<td>Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.</td>
</tr>
<tr>
<td>Very low certainty:</td>
<td>We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.</td>
</tr>
</tbody>
</table>

Risk of bias:

- Study limitations
- Inconsistency: Unexplained heterogeneity across study findings
- Indirectness: Applicability or generalizability to the research question
- Imprecision: The confidence in the estimate of an effect to support a particular decision
- Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; RR: Risk ratio

Explanations

a. Unblinded studies which can affect outcomes that require judgment, such as how investigators judge clinical improvement or decide to stop the treatment in patients with side effects.
b. 95% CI may not include a meaningful difference.
c. Modified intention to treat data from Cao 2020 used for this outcome; some deaths were excluded when drug was not given.
d. One patient randomized to the lopinavir-ritonavir arm in Cao 2020 was mechanically ventilated at baseline.
e. Small number of events making estimates highly uncertain
f. The upper boundary of the 95% confidence interval crosses the threshold of meaningful improvement as the worst case estimate is a 3% RRR.

References

Glucocorticoids

Section last reviewed and updated 9/25/2020

Last literature search conducted 9/4/2020

Recommendation 5: Among hospitalized critically ill patients* with COVID-19, the IDSA guideline panel recommends dexamethasone rather than no dexamethasone. (Strong recommendation, Moderate certainty of evidence)

• Remark: If dexamethasone is unavailable, equivalent total daily doses of alternative glucocorticoids may be used. Dexamethasone 6 mg IV or PO for 10 days (or until discharge) or equivalent glucocorticoid dose may be substituted if dexamethasone unavailable. Equivalent total daily doses of alternative glucocorticoids to dexamethasone 6 mg daily are methylprednisolone 32 mg and prednisone 40 mg.

Recommendation 6: Among hospitalized patients with severe**, but non-critical, COVID-19 the IDSA guideline panel suggests dexamethasone rather than no dexamethasone. (Conditional recommendation, Moderate certainty of evidence)

• Remark: Dexamethasone 6 mg IV or PO for 10 days (or until discharge) or equivalent glucocorticoid dose may be substituted if dexamethasone unavailable. Equivalent total daily doses of alternative glucocorticoids to dexamethasone 6 mg daily are methylprednisolone 32 mg and prednisone 40 mg.

Recommendation 7: Among hospitalized patients with non-severe*** COVID-19 without hypoxemia requiring supplemental oxygen, the IDSA guideline panel suggests against the use of glucocorticoids. (Conditional recommendation, Low certainty of evidence)

Severity definitions:
*Critical illness is defined as patients on mechanical ventilation and ECMO. Critical illness includes end organ dysfunction as is seen in sepsis/septic shock. In COVID-19, the most commonly reported form of end organ dysfunction is ARDS

**Severe illness is defined as patients with SpO2 ≤94% on room air, including patients on supplemental oxygen.

***Non-severe illness is defined as patient with a SpO2 > 94% not requiring supplemental oxygen.

The last literature search was conducted on September 4, 2020 and we identified eight RCTs and seven comparative non-randomized studies.

**Why are corticosteroids considered for treatment?**

In the early days of the SARS-CoV-2 pandemic, based on experience in both SARS and MERS, recommendations [71] cautioned against the use of systemic corticosteroids due to risk of worsening clinical status, delayed viral clearance, and adverse events [72-74]. Given the hyper-inflammatory state in COVID-19, immunomodulatory approaches, including steroids, continue to be evaluated to address both ARDS and systemic inflammation. ARDS stemming from dysregulated systemic inflammation may translate into prolonged ventilatory requirements and in-hospital mortality. In non-viral ARDS settings, there is increasing support for the role of steroids in the management of ARD [75]. A recent multicenter RCT in patients with moderate to severe ARDS demonstrated a reduced number of ventilatory days and reduction in mortality with use of a 10-day regimen of dexamethasone [76].

**Summary of the evidence**

Critical illness

Our search identified one systematic review that analyzed eight RCTs reporting on treatment with glucocorticoids among 1,844 critically ill patients with COVID-19 [77]. Three RCTs reported on patients treated with low- and high-dose dexamethasone [76, 78, 79]; three RCTs reported on patients treated with low-dose hydrocortisone [80-82]; and two RCTs reported on patients treated with high-
dose methylprednisolone [77, 83]. The definition of critically ill varied across trials; however, the majority of patients had ARDS.

**Severe and non-severe illness**

Our search identified one RCT, one “partially” randomized trial, one prospective cohort, and five retrospective cohort studies [78, 84-90]. The RCT provided the best available evidence on treatment with corticosteroids for persons with COVID-19 [78] (Tables 5-7). Corral-Gudino et al. reported on a study that randomized patients to receive methylprednisolone or standard of care; however, patients expressing a preference for methylprednisolone or standard of care; therefore, succumbing to the same potential for bias as reported subsequently for the non-randomized studies. The non-randomized studies had significant limitations with controlling for multiple co-interventions and disease severity at baseline [85-90]. All non-randomized studies had concerns with risk of bias due to lack of adjustment for critical confounders or potential for residual confounding. Timing of receipt, dose and duration of corticosteroids varied across studies.

The RECOVERY trial is a randomized trial among hospitalized patients in the United Kingdom [78]. In that study, 2,104 participants were randomized to receive dexamethasone (6 mg daily for up to 10 days) and 4,321 were randomized to usual care. The RECOVERY trial reported on the outcomes of mortality and hospital discharge. Participants and study staff were not blinded to the treatment arms.

**Benefits**

**Critical illness**

Among hospitalized, critically ill patients, the odds of mortality at 28 days was 34% less among patients treated with glucocorticoids than among patients not treated with glucocorticoids (OR: 0.66; 95% CI: 0.54; 0.82; high CoE). In addition, at 28 days, patients receiving dexamethasone were more likely to be discharged from the hospital (RR: 1.11; 95% CI: 1.04, 1.19; moderate CoE).

**Severe illness**

Among hospitalized patients, 28-day mortality was 17% lower in the group that received dexamethasone than in the group that did not receive dexamethasone (RR 0.83; 0.74-0.92; moderate
CoE). In addition, at 28 days, patients receiving dexamethasone were more likely to be discharged from the hospital (RR: 1.11; 95% CI: 1.04, 1.19; moderate CoE).

**Non-severe illness**

In a sub-group analyses of patients without hypoxia not receiving supplemental oxygen, there was no evidence for benefit and a trend toward harm with dexamethasone in participants who were not on supplemental oxygen (RR 1.22; 0.86, 1.75; low CoE).

**Harms**

A systematic review of six studies did not report a difference in the events of serious adverse events experienced by patients randomized to receive treatment with glucocorticoids or no treatment with glucocorticoids (64/354 among those receiving glucocorticoids versus 80/342 among those not receiving glucocorticoids).

Patients receiving a short course of steroids may experience hyperglycemia, neurological side effects (e.g., agitation/confusion), adrenal suppression, and risk of bacterial and fungal infection [85, 91, 92].

**Other considerations**

**Critical illness**

The panel agreed that the overall certainty of the evidence for treatment with glucocorticoids for patients with critical COVID-19 was moderate due to concerns with indirectness and imprecision.

**Severe illness**

The panel agreed the overall certainty of evidence for treatment with glucocorticoids for patients with severe COVID-19 as moderate due to concerns with indirectness since the evidence was from dexamethasone.

**Non-severe illness**
The panel agreed that the overall certainty of evidence for patients without hypoxemia requiring supplemental oxygen as low due to concerns with risk of bias (post hoc analysis) and imprecision.

The panel agreed the overall certainty of evidence for treatment with glucocorticoids for patients with severe COVID-19 as moderate due to concerns with indirectness since the evidence was from dexamethasone. The panel agreed that the overall certainty of evidence for patients without hypoxemia requiring supplemental oxygen as low due to concerns with risk of bias (post hoc analysis) and imprecision.

**Conclusions and research needs for this recommendation**

The guideline panel recommends dexamethasone for patients with critical COVID-19. The guideline panel suggests dexamethasone for patients with severe COVID-19. If dexamethasone is not available, then alternative glucocorticoids may be used (see details above). The guideline panel suggests against glucocorticoids for patients with COVID-19 without hypoxemia requiring supplemental oxygen.

Additional research is needed to inform the generalizability of treatment with different glucocorticoids for patients with COVID-19 (Supplementary Table s2).
Table 5. GRADE evidence profile, Recommendation 5

**Question:** Glucocorticoids compared to no glucocorticoids for critically ill patients with COVID-19

**Last reviewed and updated 9/25/2020**

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>№ of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
<td>Indirectness</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Mortality (follow up: 28 days)

| | 8 | randomized trials | not serious | not serious | not serious | none | 280/749 (37.4%) | 485/1095 (44.3%) | OR 0.66 (0.54 to 0.82) | 99 fewer per 1,000 (from 143 fewer to 48 fewer) | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| | | | | | | | | | | |

### Hospital discharge (follow up: 28 days)

| | 1 | randomized trials | not serious a | not serious | serious b | not serious | none | 1360/2104 (64.6%) | 2639/4321 (61.1%) | RR 1.11 (1.04 to 1.19) | 67 more per 1,000 (from 24 more to 116 more) | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| | | | | | | | | | | |

### Serious adverse events

| | 6 | randomized trials | not serious | not serious | not serious | serious c | none | 6 trials reported 64 events among 354 patients randomized to corticosteroids and 80 events among 342 patients randomized to standard care (Stern 2020) | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| | | | | | | | | | |

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Risk of bias:** Study limitations

- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision
- **Publication bias:** Selective publication of studies

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

**CI:** Confidence interval; **OR:** Odds ratio; **RR:** Risk ratio

**Explanations**

- a. Analysis adjusted for baseline age.
- b. Indirectness due to different health care system (allocation of intensive care resources in an unblinded study). Indirectness to other corticosteroids.
- c. The 95% CI includes the potential for both harm as well as benefit. Few events reported do not meet the optimal information size and suggest fragility in the estimate.

**References**

Table 6. GRADE evidence profile, Recommendation 6

**Question:** Glucocorticoids compared to no glucocorticoids for hospitalized patients with severe but not critical COVID-19

*Last reviewed and updated 9/25/2020*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>Nr of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>gluocorticoids</td>
<td>no gluocorticoids</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
</tr>
<tr>
<td><strong>Mortality (follow up: 28 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious b</td>
<td>not serious</td>
</tr>
<tr>
<td><strong>Hospital discharge (follow up: 28 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious b</td>
<td>not serious</td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients receiving a short course of steroids may experience hyperglycemia, neurological side effects (e.g., agitation/confusion), adrenal suppression, and risk of infection (Salton 2020; Henzen 2000; Siemieniuk 2015).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

**Risk of bias:** Study limitations
- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision
- **Publication bias:** Selective publication of studies

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

**CI:** Confidence interval; **RR:** Risk ratio

**Explanations**

a. Analysis adjusted for baseline age.

b. Indirectness due to different health care system (allocation of intensive care resources in an unblinded study). Indirectness to other corticosteroids.

**Reference**

Table 7. GRADE evidence profile, Recommendation 7

**Question:** Glucocorticoids compared to no glucocorticoids for hospitalized patients with COVID-19 not receiving supplemental oxygen

*Last reviewed and updated 9/25/2020*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nº of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td>Mortality (follow up: 28 days)</td>
<td>1</td>
<td>randomized trials</td>
<td>serious a</td>
<td>not serious</td>
</tr>
<tr>
<td>Hospital discharge (follow up: 28 days)</td>
<td>1</td>
<td>randomized trials</td>
<td>serious a</td>
<td>not serious</td>
</tr>
<tr>
<td>Adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

**Risk of bias:** Study limitations
- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision
- **Publication bias:** Selective publication of studies

*NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.*

**CI:** Confidence interval; **RR:** Risk ratio

**Explanations**
- a. Risk of bias due to post hoc subgroup effect among persons not receiving supplemental oxygen.
- b. The 95% CI includes the potential for appreciable harm and cannot exclude the potential for benefit. Few events reported do not meet the optimal information size and suggest fragility in the estimate.
- c. The 95% CI cannot exclude the potential for either appreciable harm or benefit.

**Reference**
Interleukin-6 Inhibitors

Section last reviewed and updated on 9/14/2021

Last literature search conducted 8/31/2021

Recommendation 8: Among hospitalized adults with progressive severe* or critical** COVID-19 who have elevated markers of systemic inflammation, the IDSA guideline panel suggests tocilizumab in addition to standard of care (i.e., steroids) rather than standard of care alone. (Conditional recommendation, Low certainty of evidence)

Remarks:

- Patients, particularly those who respond to steroids alone, who put a high value on avoiding possible adverse events of tocilizumab and a low value on the uncertain mortality reduction, would reasonably decline tocilizumab.
- In the largest trial on the treatment of tocilizumab, criterion for systemic inflammation was defined as CRP ≥75 mg/L.

Recommendation 9: When tocilizumab is not available for patients who would otherwise qualify for tocilizumab, the IDSA guideline panel suggests sarilumab in addition to standard of care (i.e., steroids) rather than standard of care alone. (Conditional recommendation, Very low certainty of evidence)

- Remark: Patients, particularly those who respond to steroids alone, who put a high value on avoiding possible adverse events of sarilumab and a low value on the uncertain mortality reduction, would reasonably decline sarilumab.
Severity definitions:

*Severe illness is defined as patients with SpO₂ ≤ 94% on room air, including patients on supplemental oxygen.

**Critical illness is defined as patients on mechanical ventilation and ECMO. Critical illness includes end organ dysfunction as is seen in sepsis/septic shock. In COVID-19, the most commonly reported form of end organ dysfunction is ARDS.

Why are interleukin-6 (IL-6) receptor antagonists considered for treatment?

Some patients with COVID-19 develop a hyperinflammatory syndrome that is characterized by elevations in proinflammatory cytokines and multiorgan dysfunction also known as the immunopathology of SARS-CoV-2 infection. The significance of these findings is unclear, however early descriptions found that those with elevated IL-6 levels and evidence of hyperinflammation had increased rates of more severe disease [93, 94]. Tocilizumab, a monoclonal anti-IL-6-receptor blocking antibody, has been proposed as a therapeutic agent to mitigate hyperinflammation associated with COVID-19. Tocilizumab is FDA-approved for various rheumatologic conditions as well as cytokine release syndrome associated with CAR-T cell therapy.

Sarilumab, another IL-6 receptor antagonist, is currently FDA-approved for rheumatoid arthritis (RA).

Summary of the evidence

Tocilizumab

Our search identified eight RCTs (including pre-prints) that reported on patients with severe COVID-19 randomized to treatment with tocilizumab (8 mg/kg) or placebo/usual care [95-102]. Gordon 2020, Horby 2021, Rosas 2020, and Veiga 2021 allowed for patients to be on mechanical ventilation at randomization, whereas the other trials included patients with a lower disease severity
(e.g., allowed supplemental oxygen but excluded those on higher levels of oxygen support) or included patients with severe COVID with an inflammatory phenotype.

One trial, RECOVERY, contributed the majority of the weight in the analysis [97]. RECOVERY trial participants must have demonstrated clinical evidence of progressive COVID-19, which was defined as <92% oxygen saturation on room air or receiving oxygen and C-reactive protein (CRP) ≥75 mg/L. Use of steroids was balanced across both the participants receiving tocilizumab or not receiving tocilizumab. Following recommendations for treatment with glucocorticoids, 82% of participants in both arms received dexamethasone. While RECOVERY did not blind participants or healthcare personnel to the randomized treatment arm, this likely would not introduce bias in the objective measurement of the outcome of mortality; however, it was considered as a risk of bias for more subjectively measured outcomes, clinical deterioration, along with the total body of evidence contributing to those outcomes (Table 8). There are limited safety data in the preliminary report.

Both RECOVERY and REMAP CAP (the two tocilizumab trials that reported a benefit) initiated treatment early (randomization at median of two days of hospitalization in RECOVERY; <24 hours in the ICU for REMAP-CAP), suggesting tocilizumab may be more beneficial early in people with rapidly progressive disease.

Sarilumab

We identified three RCTs that reported on patients with severe or critical COVID-19 randomized to treatment with sarilumab or placebo/usual care [95, 103, 104]. In addition, a pre-print network meta-analysis of 18 RCTs was identified that reported network estimates for sarilumab plus corticosteroids compared with usual care alone [105].

Benefits

Tocilizumab

Among hospitalized patients, tocilizumab showed a trend toward reduced mortality at 28 days compared to no tocilizumab treatment (RR: 0.91; 95% CI: 0.79, 1.04; moderate CoE). Tocilizumab demonstrated a lower relative risk of clinical deterioration, defined as death, need for mechanical ventilation, ECMO, or ICU admission, compared to placebo/usual care, RR: 0.83 (95% CI:
0.77, 0.89; moderate CoE). Four studies were not blinded, while in the remaining three trials healthcare personnel and outcome assessors were blinded. The panel noted that tocilizumab causes a decline in CRP levels, which if obtained would reveal the treatment arm designations of the patients, therefore introducing bias for the more subjectively measured outcomes of clinical deterioration and serious adverse events.

Sarilumab

Among hospitalized patients, sarilumab showed a trend toward reduced mortality at 28 days compared to usual care (network estimate OR: 0.80; 95% CI: 0.61, 1.04; low certainty of evidence). Sarilumab may reduce clinical deterioration, defined as progression to intubation, ECMO or death compared to usual care (RR: 0.67; 95% CI: 0.42, 1.05; very low CoE).

Harms

Serious adverse events among patients receiving tocilizumab or sarilumab did not differ from those receiving usual care (RR: 0.89; 95% CI: 0.74, 1.07; low CoE and RR: 1.03; 95% CI: 0.89, 1.18; low CoE, respectively). An additional trial attributed treatment with tocilizumab to three serious adverse events; however, did not report events among patients not receiving tocilizumab [97]. Previously, tocilizumab has been associated with gastrointestinal perforations in non-COVID-19 settings, and case reports of bowel perforations have recently emerged with the use of tocilizumab for COVID-19 [106-109]. Increased infection risks have been noted in uncontrolled studies, and it is possible that this risk may be compounded by the combination of glucocorticoids and tocilizumab. [110, 111].

Other considerations

While the overall certainty of evidence for the trend toward a reduction in mortality was moderate, the panel believes that differences in mortality rates across the trials may be the result of the differences in baseline severity of study participants and timing of tocilizumab receipt in the disease course. In REMAP-CAP, tocilizumab was administered within 24 hours of participants’ initiating organ support in an intensive care unit, raising the possibility that this may be the optimal time to administer the drug. In RECOVERY, tocilizumab was administered to participants with oxygen saturation <92% on room air or receiving oxygen therapy, and CRP ≥75 mg/L. Given the reduction in
clinical deterioration and trend toward mortality reduction, the guideline panel made a conditional recommendation for treatment of adults with tocilizumab.

The use of tocilizumab, as with other therapeutic agents that can suppress the immune system, presents additional considerations and potential concerns when used in immunocompromised hosts. The panel did not conduct an analysis of available data to assess differences in efficacy and/or adverse effects of tocilizumab among oncology or other immunocompromised patients at this time.

The panel recognized the current shortage of tocilizumab and possible net benefit of treatment with sarilumab.

**Conclusions and research needs for this recommendation**

The guideline panel suggests tocilizumab for hospitalized adults with COVID-19. When tocilizumab is not available and baricitinib is either not appropriate or available, the guideline panel suggests sarilumab for persons who would otherwise qualify for tocilizumab; however, it is acknowledged that patients, particularly those responding to steroids alone or baricitinib, who put a high value on avoiding the possible adverse events of sarilumab and a low value on the uncertain mortality reduction would reasonably decline sarilumab.

Additional research is needed to understand the efficacy of tocilizumab when taken at different times during the course of disease. For example, there are no data to guide recommendations in patient <18 years of age at this time. In addition, future studies are needed to inform the generalizability of tocilizumab with different IL-6 receptor inhibitors for patients with COVID-19 ([Supplementary Table s2](#)). At the time of update, preliminary data from a trial of treatment with sarilumab has been shared as a pre-print [95]; however, number of patients who received sarilumab is limited (n=45) and the published manuscript was not available for analysis or inclusion to inform this recommendation. Other studies of sarilumab have not been made available.
Table 8. GRADE evidence profile, Recommendation 8

**Question:** Tocilizumab compared to no tocilizumab for hospitalized patients with COVID-19  

*Last updated 2/17/2021; last reviewed 9/14/2021*

<table>
<thead>
<tr>
<th>Mortality (follow up: range 28 days to 30 days)</th>
<th>始建</th>
<th>訃号</th>
<th>避患</th>
<th>胚和</th>
<th>其他</th>
<th>脑化</th>
<th>确定性</th>
<th>重要性</th>
</tr>
</thead>
<tbody>
<tr>
<td>№ of patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Design</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk of bias</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inconsistency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indirectness</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imprecision</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other considerations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tocolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No tocolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relative (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absolute (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Certainty</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RR 0.91 (0.79 to 1.04)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26 fewer per 1,000 (from 61 fewer to 12 more)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRITICAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clinical deterioration (follow up: range 14 days to 30 days)

<table>
<thead>
<tr>
<th>Serious adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>№ of patients</td>
</tr>
<tr>
<td>Study</td>
</tr>
<tr>
<td>Design</td>
</tr>
<tr>
<td>Risk of bias</td>
</tr>
<tr>
<td>Inconsistency</td>
</tr>
<tr>
<td>Indirectness</td>
</tr>
<tr>
<td>Imprecision</td>
</tr>
<tr>
<td>Other considerations</td>
</tr>
<tr>
<td>tocolizumab</td>
</tr>
<tr>
<td>No tocolizumab</td>
</tr>
<tr>
<td>Relative (95% CI)</td>
</tr>
<tr>
<td>Absolute (95% CI)</td>
</tr>
<tr>
<td>Certainty</td>
</tr>
<tr>
<td>Impact</td>
</tr>
<tr>
<td>RR 0.83 (0.77 to 0.89)</td>
</tr>
<tr>
<td>64 fewer per 1,000 (from 86 fewer to 41 fewer)</td>
</tr>
<tr>
<td>CRITICAL</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect  

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect  

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect  

**Risk of bias:** Study limitations  

**Inconsistency:** Unexplained heterogeneity across study findings  

**Indirectness:** Applicability or generalizability to the research question  

**Imprecision:** The confidence in the estimate of an effect to support a particular decision  

**Publication bias:** Selective publication of studies  

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.  

**CI:** Confidence interval; **RR:** Risk ratio  

**Explanations**  

a. Although some studies did not blind participants or investigators, this is unlikely to affect the mortality outcome.  

b. 95% CI includes benefits as well as harms.  

c. Some studies lacked blinding and due to the mechanism of tocilizumab (reduction in inflammatory marker), unblinding likely occurred in the blinded studies.
d. Definition of clinical deterioration varied, with all studies including need for ventilation and death, but other studies included need for ICU admission (2 studies) or PaO2/FiO2 ratio of less than 150 mmHg (1 study).

e. The 95% CI includes both potential for harm as well as benefit; Few events reported do not meet the optimal information size and suggest fragility in the estimate.

References


Table 9. GRADE evidence profile, Recommendation 9

**Question:** Sarilumab compared to no sarilumab for hospitalized patients with COVID-19

*New evidence profile developed 9/14/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>Nº of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nº of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
<td>Indirectness</td>
</tr>
<tr>
<td>Mortality (assessed with: indirect estimate from network meta-analysis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| | | | | | | | | Indirect estimate: OR: 0.72; 95% CI: 0.52, 0.99 | | CRITICAL LOW
| Clinical deterioration (follow up: 21 days; assessed with: progression to intubation, ECMO, or death) |
| 2 | randomized trials | serious | not serious | not serious | very serious | none | 72/305 (23.6%) | 157/341 (46.0%) | RR 0.67 (0.42 to 1.05) | 152 fewer per 1,000 (from 267 fewer to 23 more) | VERY LOW CRITICAL |
| Serious adverse events (follow up: 21 days) |
| 4 | randomized trials | serious | not serious | not serious | serious | none | 566/1520 (37.2%) | 158/795 (19.9%) | RR 1.03 (0.89 to 1.16) | 6 more per 1,000 (from 22 fewer to 36 more) | LOW CRITICAL |

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Risk of bias:** Study limitations

**Inconsistency:** Unexplained heterogeneity across study findings

**Indirectness:** Applicability or generalizability to the research question

**Imprecision:** The confidence in the estimate of an effect to support a particular decision

**Publication bias:** Selective publication of studies

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

**CI:** Confidence interval; **OR:** Odds ratio; **RR:** Risk ratio

**Explanations**

a. 18 trials included in the network.
b. The direct network estimate crosses the line of no effect; however, the indirect estimate in the network demonstrates a trend toward mortality reduction when sarilumab + corticosteroids rather than corticosteroids alone is given. Few events reported in the direct network estimate suggesting fragility.

c. Lack of blinding of study personnel, participants, and outcome assessors.

d. Substantial heterogeneity present ($I^2=57\%$); however, likely contributes to the wide CI and accounted for within imprecision.

e. Definition of clinical deterioration varied, with all studies including need for ventilation; however, one study included ECMO and death and the other study included use of high-flow cannula.

f. 95% CI cannot exclude the possibility of harm. Few events suggest fragility of the estimate.

g. Analysis includes participants free of invasive mechanical ventilation at baseline for Gordon and patients free of high-flow cannula at baseline.

h. 95% CI cannot exclude the possibility of harms.

References


Convalescent Plasma

**SPECIAL UPDATE ALERT:** The following section has been updated based on newly available literature and approvals. This update will be fully integrated into this document and the IDSA website soon; it is provided here for immediate use.

Recommendation 11 has been revised to address the use of convalescent plasma in ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease with no other treatment options. The full updated section can be viewed on the IDSA website.

Section last reviewed and updated 11/11/2021

Last literature search conducted 10/31/2021

Recommendation 10: Among patients hospitalized with COVID-19, the IDSA guideline panel recommends against COVID-19 convalescent plasma. (Strong recommendation, Moderate certainty of evidence)

Recommendation 11: Among ambulatory patients with mild to moderate COVID-19, the IDSA guideline panel suggests against COVID-19 convalescent plasma outside of the context of a clinical trial. (Conditional recommendation, Low certainty of evidence)

*Why is convalescent plasma considered for treatment?*

Convalescent plasma has been used as passive immunotherapy for prevention and treatment of infections for over 100 years [112, 113]. The predominant proposed protective mechanism is thought to be pathogen neutralization, although antibody-dependent cellular cytotoxicity and enhanced phagocytosis may also play a role. With the advent of effective antimicrobial therapy (i.e., “the antibiotic era”), convalescent plasma fell out of favor. In recent years, interest in this approach has been revived as a means of addressing viral epidemics such as Ebola, SARS-CoV-1, and MERS. Studies of convalescent plasma derived from people who had recovered from those specific infections showed encouraging results but were typically small,
non-randomized, and largely descriptive [114-116]. In the current pandemic, convalescent plasma obtained from individuals who have recovered from COVID-19 has been used in over 100,000 patients with moderate to severe infection as part of an expanded access program [117, 118]. When measurement of neutralizing antibody titers is available, the FDA recommends neutralizing antibody titers of ≥1:160. Assays to measure neutralizing antibody titers were not widely available early in the pandemic, so it is unclear if the plasma used in the context of the expanded access program had adequate titers of neutralizing antibodies meeting the FDA targets. Multiple prospective clinical trials are in progress utilizing plasma with an IgG enzyme-linked immunosorbent assay (ELISA) titer cutoff of ≥1:320. Titers at that level are seen in about 80% of donors [119]. The probability of obtaining a neutralizing antibody titer of ≥1:160 is highest (80% or greater) when the ELISA IgG titer is ≥1:1,350 [120]. In an analysis of the convalescent plasma expanded access program, higher levels of antibodies were associated with significant improvements in mortality compared to those receiving convalescent plasma with lower concentrations of neutralizing antibodies [117]. However, there was no placebo group in the study, so this result could be from increased mortality with low antibody titer plasma rather than improved mortality with high antibody titer plasma. Subgroup data from one open-label RCT reporting on plasma with anti-receptor-binding domain ELISA values corresponding to a high antibody titer cutoff resulted in a non-significant relative risk reduction in mortality of 5% (RR: 0.95; 95% CI: 0.73, 1.25) [121]. An additional subgroup analysis suggested unselected convalescent plasma (i.e., not limited to high-titer antibodies) may increase the relative risk for mortality by 49% (RR: 1.42; 95% CI: 0.92, 1.69).

An analysis of the convalescent plasma expanded access program suggests the most benefit is seen when convalescent plasma is given in the first three days from diagnosis [117]. In August 2020, the FDA issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients [122]. In early February 2021, the FDA issued a revision to the EUA to limit the authorization to the use of high-titer COVID-19 convalescent plasma for the treatment of hospitalized patients early in the disease course [123].

**Summary of the evidence**
Our search identified and was informed by evidence from 20 RCTs and a large (n=20,000), single-arm registry study [112-116, 119, 120, 124-130], as they provided the best available evidence for the outcomes of mortality, need for mechanical ventilation, serious adverse events, and adverse events. Eighteen of those RCTs reported on convalescent plasma transfusions for patients hospitalized with COVID-19 (Table 10) [112-115, 119, 120, 124-127] and two RCTs[129, 130] reported on receipt of convalescent plasma by ambulatory persons with mild COVID-19 disease (Table 11) [116].

Eighteen trials randomized 17,232 patients hospitalized with COVID-19 to receive a transfusion with COVID-19 convalescent plasma [112-115, 119, 120, 124-127]. Several trials were open-label and/or had concerns with risk of bias due to lack of adjustment for critical confounders or potential for residual confounding (Supplementary Table s14a). Timing of receipt of COVID-19 convalescent plasma during the clinical course of the patients’ illness varied across studies (Supplementary Table s13). One trial reported on 160 persons who received high-titer convalescent plasma less than 72 hours after the onset of symptoms of COVID-19 (mean age: 77.2 years; standard deviation: ±8.6 years) [116]. In addition, Joyner 2020 reported on safety outcomes of over 20,000 patients enrolled in the same FDA Expanded Access Program for COVID-19 convalescent plasma study.

**Benefits**

**Hospitalized patients**

Convalescent plasma transfusion appears to have trivial or no effect on mortality based on the body of evidence from RCTs (RR: 0.98; 95% CI: 0.93, 1.03; moderate CoE). Recipients of COVID-19 convalescent plasma may have a greater need for mechanical ventilation (RR: 1.10; 95% CI: 0.94, 1.29; low CoE); however, the evidence is uncertain because of concerns with risk of bias imprecision.

**Ambulatory persons**

Receipt of COVID-19 convalescent plasma failed to demonstrate or exclude a beneficial effect on COVID-19 related hospitalizations or medically-attended visits (emergency room or
urgent care; RR 0.94; 95% CI: 0.73 to 1.22). Prior evidence showed a possible reduction of progression to severe respiratory disease (RR: 0.52; 95% CI: 0.29, 0.94; low CoE); however, the evidence remains uncertain, as oxygenation and respiration rates are surrogate measures of need for ventilation, morbidity, and death, and because of the fragility of the estimate due to the small number of events reported. Convalescent plasma transfusion failed to show or exclude a beneficial effect on mortality based on the body of evidence from two RCTs (RR: 0.78; 95% CI: 0.2, 3.1; low CoE); however, the evidence is uncertain due to concerns with fragility of the estimate due to the small number of events reported. Additional deaths beyond 15 days were reported in one RCT and included five deaths in the plasma group versus one in the placebo arm.

**Harms**

In the largest safety study (n=20,000), within four hours of completion of convalescent plasma transfusion, authors reported 146 serious adverse events classified as transfusion reactions (<1% of all transfusions) [128]. Of these, 63 deaths were reported (0.3%) with 13 judged as possibly or probably related to the transfusion. The non-mortality serious adverse events include 37 reports of transfusion-associated circulatory overload, 20 cases of transfusion-related acute lung injury, and 26 cases of severe allergic transfusion reactions.

Within seven days of transfusion, 1711 deaths were reported (mortality rate: 8.56%; 95% CI: 8.18, 8.95). In addition, 1136 serious adverse events were reported: 643 cardiac events (569 judged as unrelated to the transfusion), 406 sustained hypotensive events requiring intravenous (IV) pressor support, and 87 thromboembolic or thrombotic events (55 judged as unrelated to the transfusion).

Eleven trials among patients hospitalized for COVID-19 suggest increased adverse events among patients receiving convalescent plasma (RR: 1.08; 95% CI: 0.94, 1.26; low CoE); however, the evidence was uncertain due to concerns with lack of blinding. In addition, included studies lacked a standard definition for what met the definition of an adverse event. In ambulatory patients, serious adverse events were higher in the convalescent plasma group due to serious...
transfusion reactions (RR 5.9; 95% CI: 0.30, 118.0; low CoE), although the evidence is uncertain due to few events.

**Other considerations**

**Hospitalized patients**

The panel agreed that the overall certainty of evidence is moderate due to some remaining imprecision as the 95% CI crossed the threshold of 1% for plausible mortality reduction. The guideline panel recognized that unselected use of convalescent plasma appeared to have trivial to no beneficial effect from the now existing large body of evidence.

**Ambulatory persons**

The panel agreed that the overall certainty of evidence is low due to concerns with risk of bias and imprecision, which recognized the limited events and concerns with fragility. The guideline panel recognized the inability to exclude a meaningful beneficial or detrimental effect when plasma is given early in the course of COVID-19 disease.

**Conclusions and research needs for this recommendation**

The guideline panel suggests against COVID-19 convalescent plasma for persons hospitalized with COVID-19. In addition, the guideline panel suggests against COVID-19 convalescent plasma for ambulatory persons outside of the context of a clinical trial. Based on limited studies and mechanistic reasoning, COVID-19 convalescent plasma may be more effective if given at high titers early in course of hospitalization, in patients with undetectable or low levels of SARS-CoV-2 neutralizing antibodies, or in those with a humoral immune deficiency [131-136]. Current RCTs have not reported outcomes in such pre-specified subpopulations. Future studies in hospitalized patients should focus on patients with humoral immunodeficiencies early in the course of COVID-19. Future studies in hospitalized patients should also consider screening for SARS-CoV-2 neutralizing antibodies in all patients at entry into RCTs and assessing outcomes based on antibody levels.
Similarly, in ambulatory patients, convalescent plasma may be more effective if the product used contains high titers of neutralizing antibodies and is used early in clinical presentation or in subpopulations of patients who do not have an adequate humoral immune response even at later stages of disease [131]. There is a paucity of trials in this specific population of patients. Future studies in ambulatory patients should target these populations.

Additional clinical trials may be needed to also determine whether there is a benefit of treatment with COVID-19 convalescent plasma and at what dose (neutralizing antibody titers), especially for patients early in the disease course of COVID-19 (Supplementary Table s2)
Table 10. GRADE evidence profile, Recommendation 10  
**Question:** Convalescent plasma compared to no convalescent plasma for hospitalized patients with COVID-19  
*Last reviewed and updated 11/4/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>№ of patients</td>
<td>convalescent plasma</td>
<td>no convalescent plasma</td>
<td>Relative (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
<td>RR</td>
</tr>
</tbody>
</table>

**Mortality (RCTs) (follow-up: range 15 days to 60 days)**

<table>
<thead>
<tr>
<th>№ of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>convalescent plasma</th>
<th>no convalescent plasma</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>RR</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 1-18</td>
<td>randomized trials</td>
<td>not serious a,b</td>
<td>not serious</td>
<td>not serious</td>
<td>serious c</td>
<td>none</td>
<td>2163/9082 (23.8%)</td>
<td>2007/8150 (24.6%)</td>
<td>RR 0.98 (0.93 to 1.03)</td>
<td>5 fewer per 1,000 (from 17 fewer to 7 more)</td>
<td>MODERATE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Need for mechanical ventilation**

<table>
<thead>
<tr>
<th>№ of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>convalescent plasma</th>
<th>no convalescent plasma</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>RR</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 3,6,9,14</td>
<td>randomized trials</td>
<td>serious d</td>
<td>not serious</td>
<td>not serious</td>
<td>serious e</td>
<td>none</td>
<td>184/581 (31.7%)</td>
<td>166/471 (35.2%)</td>
<td>RR 1.10 (0.94 to 1.29)</td>
<td>35 more per 1,000 (from 21 fewer to 102 more)</td>
<td>LOW</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Serious adverse events (transfusion-associated circulatory overload, transfusion-related acute lung injury, severe allergic transfusion reaction) (follow-up: 4 hours)**

<table>
<thead>
<tr>
<th>№ of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>convalescent plasma</th>
<th>no convalescent plasma</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>RR</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 19</td>
<td>observational studies</td>
<td>extremely serious f</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>none</td>
<td>SAEs from 20,000 transfused patients: Within first 4 hours, of the SAEs, 63 deaths were reported (0.3% of all transfusions) and 13 of those deaths were judged as possibly or probably related to the transfusion of COVID-19 convalescent plasma. There were 83 non-death SAEs reported, with 37 reports of transfusion-associated circulatory overload (TACO), 20 reports of transfusion-related acute lung injury (TRALI), and 26 reports of severe allergic transfusion reaction.</td>
<td>SAEs from 20,000 transfused patients: Within 7 days of transfusion, 1711 deaths (8.56%) and 1136 serious adverse events (5.68%) were reported. Non-mortality SAEs included: 643 cardiac events (569 judged as unrelated to the transfusion); 406 sustained hypotensive events requiring intravenous pressor support; and 87 thromboembolic or thrombotic events (55 judged as unrelated to the transfusion).</td>
<td>CRITICAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Serious adverse events (mortality, cardiac, thrombotic, sustained hypotensive events requiring intervention) (follow-up: 7 days)**

<table>
<thead>
<tr>
<th>№ of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>convalescent plasma</th>
<th>no convalescent plasma</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>RR</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 19</td>
<td>observational studies</td>
<td>extremely serious f</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>none</td>
<td>SAEs from 20,000 transfused patients: Within 7 days of transfusion, 1711 deaths (8.56%) and 1136 serious adverse events (5.68%) were reported. Non-mortality SAEs included: 643 cardiac events (569 judged as unrelated to the transfusion); 406 sustained hypotensive events requiring intravenous pressor support; and 87 thromboembolic or thrombotic events (55 judged as unrelated to the transfusion).</td>
<td>CRITICAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Any adverse events (RCTs)**

<table>
<thead>
<tr>
<th>№ of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>convalescent plasma</th>
<th>no convalescent plasma</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>RR</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 3,4,6,8,11-12,15-18</td>
<td>randomized trials</td>
<td>serious d</td>
<td>not serious</td>
<td>not serious g</td>
<td>serious h</td>
<td>none</td>
<td>574/2843 (20.2%)</td>
<td>307/1959 (15.7%)</td>
<td>RR 1.08 (0.94 to 1.26)</td>
<td>13 more per 1,000 (from 9 fewer to 41 more)</td>
<td>LOW</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Version 6.0.2

71
GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect

Risk of bias: Study limitations

Inconsistency: Unexplained heterogeneity across study findings

Indirectness: Applicability or generalizability to the research question

Imprecision: The confidence in the estimate of an effect to support a particular decision

Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; HR: Hazard ratio; OR: Odds ratio; RR: Risk ratio; SAEs: Serious adverse events

Explanations

a. Li 2020 time between symptom onset and randomization was over 14 days for >90% (median 30 days), no adjustment for co-interventions, allocation concealment methods not reported and participants and healthcare professionals not blinded.

b. Many trials had concerns due to open-label trial, allocation concealment not reported, and no adjustments for co-interventions.

c. The 95% CI includes the potential for appreciable benefit; however, cannot exclude the potential for no effect.

d. Concerns include open-label trial design and assessment of outcome.

e. The 95% CI may not include a clinically meaningful reduction in need for mechanical ventilation.

f. No comparative effects available. Some subjectivity in classification of outcomes as transfusion related.

g. Lack standard definition for adverse events. Studies report on mild to severe events.

h. The 95% CI includes the potential for both increased harms, as well as no increased harms. Few events suggests fragility of the estimate.

References


Table 11. GRADE evidence profile, Recommendation 11

**Question:** Convalescent plasma compared to no convalescent plasma for ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease

*Last reviewed and updated 10/11/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>№ of patients</td>
<td>convalescent plasma</td>
<td>no convalescent plasma</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19 related hospitalizations, ED/urgent care visits, or death (follow-up: 15 days)</td>
<td></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>77/257 (30.0%)</td>
<td>81/254 (31.9%)</td>
<td>RR 0.94 (0.73 to 1.22)</td>
</tr>
<tr>
<td>All-cause mortality (follow-up: 15 days)</td>
<td></td>
<td>2</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious</td>
<td>none</td>
<td>3/337 (0.9%)</td>
<td>4/334 (1.2%)</td>
<td>RR 0.78 (0.20 to 3.10)</td>
</tr>
<tr>
<td>Progression to severe respiratory disease (follow-up: 15 days; assessed with: defined as a respiratory rate of ≥30 breaths/minute, SaO₂ &lt;93% on room air, or both)</td>
<td></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>serious</td>
<td>none</td>
<td>13/80 (16.3%)</td>
<td>25/80 (31.3%)</td>
<td>RR 0.52 (0.29 to 0.94)</td>
</tr>
<tr>
<td>Serious adverse events: serious transfusion reactions (requiring treatment or admission) (follow-up: 15 days)</td>
<td></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious</td>
<td>none</td>
<td>3/257 (1.2%)</td>
<td>0/254 (0.0%)</td>
<td>RR 5.9 (0.3 to 118.0)</td>
</tr>
<tr>
<td>Any adverse events (follow-up: 15 days)</td>
<td></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>93/257 (36.2%)</td>
<td>94/254 (37.0%)</td>
<td>RR 0.98 (0.78 to 1.23)</td>
</tr>
</tbody>
</table>

*Notes:

1. RR = Relative Risk
2. CI = Confidence Interval
3. MODERATE
4. IMPORTANT
5. CRITICAL
6. LOW
7. MILD
8. CRITICAL
9. MODERATE
10. CRITICAL
11. MODERATE
12. CRITICAL
13. MODERATE
14. CRITICAL
15. MODERATE
16. CRITICAL
17. MODERATE
18. CRITICAL
19. MODERATE
20. CRITICAL
21. MODERATE
22. CRITICAL
23. MODERATE
24. CRITICAL
25. MODERATE
26. CRITICAL
27. MODERATE
28. CRITICAL
29. MODERATE
30. CRITICAL
31. MODERATE
32. CRITICAL
33. MODERATE
34. CRITICAL
35. MODERATE
36. CRITICAL
37. MODERATE
38. CRITICAL
39. MODERATE
40. CRITICAL
41. MODERATE
42. CRITICAL
43. MODERATE
44. CRITICAL
45. MODERATE
46. CRITICAL
47. MODERATE
48. CRITICAL
49. MODERATE
50. CRITICAL
51. MODERATE
52. CRITICAL
53. MODERATE
54. CRITICAL
55. MODERATE
56. CRITICAL
57. MODERATE
58. CRITICAL
59. MODERATE
60. CRITICAL
61. MODERATE
62. CRITICAL
63. MODERATE
64. CRITICAL
65. MODERATE
66. CRITICAL
67. MODERATE
68. CRITICAL
69. MODERATE
70. CRITICAL
71. MODERATE
72. CRITICAL
73. MODERATE
74. CRITICAL
75. MODERATE
76. CRITICAL
77. MODERATE
78. CRITICAL
79. MODERATE
80. CRITICAL
81. MODERATE
82. CRITICAL
83. MODERATE
84. CRITICAL
85. MODERATE
86. CRITICAL
87. MODERATE
88. CRITICAL
89. MODERATE
90. CRITICAL
91. MODERATE
92. CRITICAL
93. MODERATE
94. CRITICAL
95. MODERATE
96. CRITICAL
97. MODERATE
98. CRITICAL
99. MODERATE
100. CRITICAL
101. MODERATE
102. CRITICAL
103. MODERATE
104. CRITICAL
105. MODERATE
106. CRITICAL
107. MODERATE
108. CRITICAL
109. MODERATE
110. CRITICAL
111. MODERATE
112. CRITICAL
113. MODERATE
114. CRITICAL
115. MODERATE
116. CRITICAL
117. MODERATE
118. CRITICAL
119. MODERATE
120. CRITICAL
121. MODERATE
122. CRITICAL
123. MODERATE
124. CRITICAL
125. MODERATE
126. CRITICAL
127. MODERATE
128. CRITICAL
129. MODERATE
130. CRITICAL
131. MODERATE
132. CRITICAL
133. MODERATE
134. CRITICAL
135. MODERATE
136. CRITICAL
137. MODERATE
138. CRITICAL
139. MODERATE
140. CRITICAL
141. MODERATE
142. CRITICAL
143. MODERATE
144. CRITICAL
145. MODERATE
146. CRITICAL
147. MODERATE
148. CRITICAL
149. MODERATE
150. CRITICAL
151. MODERATE
152. CRITICAL
153. MODERATE
154. CRITICAL
155. MODERATE
156. CRITICAL
157. MODERATE
158. CRITICAL
159. MODERATE
160. CRITICAL
161. MODERATE
162. CRITICAL
163. MODERATE
164. CRITICAL
165. MODERATE
166. CRITICAL
167. MODERATE
168. CRITICAL
169. MODERATE
170. CRITICAL
171. MODERATE
### GRADE Working Group grades of evidence

<table>
<thead>
<tr>
<th>Certainty Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>High certainty</td>
<td>We are very confident that the true effect lies close to that of the estimate of the effect.</td>
</tr>
<tr>
<td>Moderate certainty</td>
<td>We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.</td>
</tr>
<tr>
<td>Low certainty</td>
<td>Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.</td>
</tr>
<tr>
<td>Very low certainty</td>
<td>We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.</td>
</tr>
</tbody>
</table>

### Risk of bias: Study limitations
- Inconsistency: Unexplained heterogeneity across study findings
- Indirectness: Applicability or generalizability to the research question
- Imprecision: The confidence in the estimate of an effect to support a particular decision
- Publication bias: Selective publication of studies

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

**CI:** Confidence interval; **ED:** Emergency department; **RR:** Risk ratio; **SaO2:** Saturated oxygen

### Explanations
- a. 95% CI includes benefits as well as harms; OIS not met.
- b. Deaths beyond 15 days and up to 30 days: an additional 5 deaths occurred in the plasma group and 1 death in placebo (normal saline) group.
- c. Only one event.
- d. Using 0.5 event continuity correction.
- e. Zero events in the control group. Absolute risk difference not informed by relative risk.
- f. Trial was terminated early due to futility.
- g. Oxygenation and respiration rates are surrogate measures of need for ventilation, morbidity and death.
- h. Few events reported do not meet the optimal information size and suggest fragility of the estimate.

### References
Remdesivir

*SPECIAL UPDATE ALERT:* The following section has been updated based on newly available literature and approvals. This update will be fully integrated into this document and the IDSA website soon; it is provided here for immediate use.

**Recommendation 12** has been revised to address the use of remdesivir in patients (ambulatory or hospitalized) with mild-to-moderate COVID-19 at high risk for progression to severe disease. The full updated section can be viewed on the [IDSA website](https://www.idsociety.org/COVID19guidelines).

---

*Section last reviewed and updated 12/23/2021*

*Last literature search conducted 11/30/2021*

**Recommendation 12 (NEW, 12/23/2021):** Among ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests remdesivir initiated within seven days of symptom onset rather than no remdesivir.

(Conditional recommendation, Low certainty of evidence)

**Remarks:**

- Dosing for remdesivir is 200 mg on day one followed by 100 mg on days two and three.
- Patients with mild to moderate COVID-19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID-19 may also receive remdesivir.
- Options for treatment and management of ambulatory patients include nirmatrelvir/ritonavir, three-day treatment with remdesivir, molnupiravir, and neutralizing monoclonal antibodies. Patient specific factors (e.g., symptom duration, renal function, drug interactions), product availability, and institutional capacity and infrastructure should drive decision-making regarding choice of agent. Data for combination treatment do not exist in this setting.
Recommendation 13a: In hospitalized patients with severe* COVID-19, the IDSA panel suggests remdesivir over no antiviral treatment. (Conditional recommendation, Moderate certainty of evidence)

*Severe illness is defined as patients with SpO$_2$ $\leq$94% on room air.

Recommendation 13b: In patients with COVID-19 on invasive ventilation and/or ECMO, the IDSA panel suggests against the routine initiation of remdesivir (Conditional recommendation, Very low certainty of evidence)

Recommendation 14: In patients on supplemental oxygen but not on mechanical ventilation or ECMO, the IDSA panel suggests treatment with five days of remdesivir rather than 10 days of remdesivir. (Conditional recommendation, Low certainty of evidence)

Recommendation 15: In patients with COVID-19 admitted to the hospital without the need for supplemental oxygen and oxygen saturation $>$94% on room air, the IDSA panel suggests against the routine use of remdesivir. (Conditional recommendation, Very low certainty of evidence)

Why is remdesivir considered for treatment?

Remdesivir (GS-5734) is an antiviral drug with potent *in vitro* activity against a range of RNA viruses including MERS-CoV, SARS-CoV 1 & 2 [137-139]. Remdesivir acts by causing premature termination of viral RNA transcription [139]. Its use improved disease outcomes and reduced viral loads in SARS-CoV-1 infected mice [138]. In rhesus macaques, therapeutic treatment with remdesivir showed reduction in SARS-CoV-2 loads, pathologic changes, and progression of clinical disease [140]. In this same animal model, remdesivir treatment initiated 12 hours post-inoculation reduced clinical signs, virus replication in the lungs, and decreased the presence and severity of lung lesions.

Summary of the evidence
Ambulatory patients with mild to moderate disease who are at high risk for progression to severe COVID-19

One RCT compared treatment with three days of intravenous (IV) remdesivir (200 mg on day one followed by 100 mg on days two and three) or no remdesivir in unvaccinated patients [141]. The study enrolled patients at high risk for progression (e.g., obesity, diabetes mellitus, hypertension, immune compromise etc.) or age 60 years or older who were symptomatic seven days or less without prior treatment (e.g., monoclonal antibodies), but were not expected to receive oxygen at time of enrollment (>94% on room air). The outcomes assessed were mortality, hospitalizations for any cause, and COVID-19-related medically as well as serious adverse events.

Hospitalized patients with oxygen saturation >94% without supplemental oxygen

Three RCTs compared treatment with five days of remdesivir (200 mg day one, 100 mg daily days 2-5), 10 days of remdesivir (200 mg day one, 100 mg daily days 2-10), or no remdesivir for patients hospitalized with oxygen saturation >94% on room air [32, 142, 143] (Table 15). The outcomes assessed were mortality, clinical improvement, and serious adverse events. Adaptive Covid-19 Treatment Trial (ACTT-1) and SOLIDARITY provided subgroup analyses among patients with mild to moderate disease [32, 142]. Randomization and lack of blinding failed to control for or balance receipt of co-interventions (e.g., treatment with dexamethasone, tocilizumab, hydroxychloroquine, and lopinavir/ritonavir) equally across arms in Spinner et al (2020) [143]. In addition, the Spinner et al did not adjust for severity of disease.

Hospitalized patients with SpO₂ ≤94% on room air

Three RCTs comparing treatment with remdesivir (200 mg day one, 100 mg daily days 2-10) against no remdesivir treatment [32, 142, 144], and one RCT comparing five days of treatment (200 mg day one, 100 mg daily days 2-5) against 10 days (200 mg day one, 100 mg daily days 2-10) of treatment [145] served as the best available evidence among hospitalized persons with severe COVID-19 (Table 13a, Table 13b, Table 14). The outcomes assessed were
mortality, time to clinical improvement, need for mechanical ventilation, serious adverse events, and adverse events leading to treatment discontinuation.

All trials used different definitions of severe disease for participants. ACTT-1 participants were considered to have severe disease if they required mechanical ventilation, supplemental oxygen, if SpO₂ was 94% or lower while breathing ambient air, or if they had tachypnea (respiratory rate >24 breaths per minute) [142]. Within the SOLIDARITY trial (available only as a pre-print at this time), participants with severe disease were receiving mechanical ventilation [32]. In Wang 2020, severe participants had a SpO₂ ≤94% while breathing room air or a ratio of arterial oxygen partial pressure to fractional inspired O₂ of ≤300 mm Hg and radiologically confirmed pneumonia.

Updated analyses include the final analysis from the ACTT-1 and the interim analysis of the SOLIDARITY trial [32, 142]. SOLIDARITY reported mortality among persons remaining in hospital up to the duration of the study; however, among patients discharged before the end of the study, mortality may not have been collected completely. The study by Wang et al (2020) was stopped early due to lack of recruitment into the trial due to decreased incidence in China.

Randomization performed in Goldman 2020 failed to establish prognostic balance between baseline clinical status among the 397 patients randomized into the treatment arms, with patients in the 10-day arm more severely ill at study entry. Even with the adjusted analysis, residual confounding is possible. In addition, participants, healthcare workers, and outcome assessors were not blinded to the treatment arms.

**Hospitalized patients on invasive ventilation and/or ECMO**

Subgroups from SOLIDARITY and ACTT-1 reported on the outcomes of mortality, time to recovery and serious adverse events among patients on invasive ventilation or ECMO [32, 142] ([Table 13b]). The duration of ventilation at time of treatment with remdesivir was not reported in ACTT-1. This may introduce uncertainty when assessing outcomes of mortality or time to recovery.
In ACTT-1 [142], randomization was stratified by study site and disease severity at enrollment. Disease severity groups were mild to moderate COVID-19 (SpO2 >94%) and severe COVID-19 (SpO2 ≤94%). The severe COVID-19 stratum included patients who were hypoxemic with various degrees of severity including those requiring low flow oxygen by nasal cannula, those needing high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation and ECMO. In addition to analyses on established strata, authors performed post hoc analyses for subgroups within the strata (e.g., receiving oxygen, receiving high-flow oxygen or noninvasive mechanical ventilation, or receiving mechanical ventilation or ECMO), which may introduce concerns with risk of bias and imprecision when making inferences on efficacy of remdesivir among these subgroups including mechanically ventilated patients.

**Benefits**

**Ambulatory patients with mild to moderate disease who are at high risk for progression to severe COVID-19**

Treatment with remdesivir for three days in ambulatory patients reduced hospitalizations and COVID-19-related medically attended visits throughout day 28 (HR: 0.28; 95% CI: 0.1, 0.75, low CoE; and HR: 0.19; 95% CI: 0.07, 0.56, low CoE, respectively). No deaths were observed.

**Hospitalized patients with oxygen saturation >94% without supplemental oxygen**

Treatment with a five- or ten-day course of remdesivir failed to show or to exclude a reduction in mortality when compared with no remdesivir (RR: 0.69; 95% CI: 0.36, 1.34; very low CoE). A five-day course of remdesivir may increase clinical improvement over no remdesivir (RR: 1.16; 95% CI: 1.00, 1.34; very low CoE) but a 10-day course of remdesivir was not associated with improved clinical status as compared with no remdesivir. Patients with mild to moderate disease receiving treatment with remdesivir had similar median time to recovery (median 5 vs. 5 days; Rate ratio: 1.22; 95% CI: 0.82, 1.81; very low CoE).

**Hospitalized patients with SpO2 ≤94% on room air**
The pooled analysis failed to show a mortality benefit at 28 days (RR: 0.92; 95% CI: 0.77, 1.10; low CoE) [32, 142, 144]. Patients receiving treatment with remdesivir trend toward greater clinical improvement at 28 days than patients not receiving remdesivir (RR: 1.13; 95% CI: 0.91, 1.41; low CoE) [144]. In addition, based on a post hoc analysis of patients with severe COVID-19, receiving treatment with remdesivir had a shorter median time to recovery (median 11 vs. 18 days; rate ratio: 1.31; 95% CI: 1.12, 1.52; low CoE) and decreased need for mechanical ventilation (RR: 0.57; 95% CI: 0.42, 0.79; moderate CoE) [142].

In the study by Goldman et al that compared five and ten days of treatment, the shorter course of remdesivir showed a trend toward decreased mortality (RR: 0.75; 95% CI: 0.51, 1.12; low CoE) and increased clinical improvement at 14 days (RR: 1.19; 95% CI: 1.01, 1.40; low CoE); however, the evidence is uncertain because the persons in the 10-day group had more severe disease at baseline and there is the possibility of residual confounding despite the adjusted analysis [145].

Hospitalized patients on invasive ventilation and/or ECMO

Treatment with remdesivir failed to show a reduction in mortality (RR: 1.23; 95% CI: 0.99, 1.53; low CoE). Similarly, remdesivir failed to show or exclude a reduction in time to recovery among patients on invasive ventilation and/or ECMO (HR: 0.98; 95% CI: 0.70, 1.36; very low CoE).

Harms

Ambulatory patients with mild to moderate disease who are at high risk for progression to severe COVID-19

As with other remdesivir studies published so far, three days of remdesivir infusions did not appear to be associated with a greater risk of serious adverse events compared to no remdesivir (RR: 0.27; 95% CI: 0.1, 0.7; moderate CoE).

Hospitalized patients with oxygen saturation >94% without supplemental oxygen
Patients treated with five days of remdesivir do not appear to experience greater serious adverse events than those not receiving remdesivir (RR: 0.64; 95% CI: 0.31, 1.31; very low CoE).

Hospitalized patients with SpO₂ ≤94% on room air

Patients treated with remdesivir do not appear to experience greater serious adverse events (grade 3/4) than those not receiving remdesivir (RR: 0.87; 95% CI: 0.59, 1.28; moderate CoE) [142, 144].

Patients receiving five days of remdesivir may experience fewer serious adverse events and adverse events leading to treatment discontinuation than patients receiving 10 days of remdesivir (RR: 0.61; 0.44, 0.85; low CoE and RR: 0.44; 95% CI: 0.21, 0.95; low CoE, respectively); however, this evidence is uncertain because of the increased severity of disease among patients in the 10-day arm [145].

Hospitalized patients on invasive ventilation and/or ECMO

Patients on invasive ventilation and/or ECMO treated with remdesivir do not appear to experience greater serious adverse events than those not receiving remdesivir (RR: 0.79; 95% CI: 0.54, 1.16; moderate CoE).

Other considerations

Ambulatory patients with mild to moderate disease who are at high risk for progression to severe COVID-19

The panel agreed that the overall certainty of evidence for the treatment of ambulatory patients was low due to concerns about imprecision, as less than half of the original projected sample size was enrolled leading to few events and fragility of the effect estimate. However, compared to prior trials, giving remdesivir early in the course of the viral infection appears to have a robust effect within the limitation of a limited sample size. The panel agreed that benefits are likely to outweigh any potential harms in patients with COVID-19 who are at high risk for severe disease. The evidence confirms that using remdesivir early in the disease process
when viral loads are high confers maximum benefit. It is critical to make a rapid diagnosis and treat ambulatory patients with COVID-19 early in the disease course.

**Hospitalized patients with oxygen saturation >94% without supplemental oxygen**

The panel agreed that the overall certainty of the evidence for treatment of patients with an oxygen saturation >94% with remdesivir compared to no remdesivir was very low due to concerns with study limitations and imprecision. Because of the study limitations and the relatively small effect of remdesivir in patients with moderate COVID-19, the panel suggests remdesivir not be used routinely in these patients. There is a need for more rigorous trials to assess the benefits and harms of remdesivir in patients with moderate COVID-19.

**Hospitalized patients with SpO₂ ≤94% on room air**

The panel agreed that the overall certainty of the evidence for treatment of persons with severe disease with remdesivir compared to no remdesivir treatment was moderate due to concerns with imprecision. Given the inconsistent definition used in the evidence to describe baseline severity, the panel recognized a knowledge gap when assessing whether greater benefit could be attained for patients with oxygen saturation >94% and no supplemental oxygen; however, they agreed that the reported data supported the prioritization of remdesivir among persons with severe but not critical COVID-19.

The panel agreed on the overall certainty of the evidence for treatment with a five-day course compared to a 10-day course of treatment as low due to concerns with risk of bias and imprecision. The panel recognized the benefit of a shorter course of treatment, if providing similar or greater efficacy, on the availability of remdesivir. However, in a subgroup analysis of mechanically ventilated patients, the duration of treatment was 10 days in ACCT-1 trial; therefore, the panel recognized that a longer course of treatment could be desirable in this population.

**Hospitalized patients on invasive ventilation and/or ECMO**

The panel agreed on the overall certainty of the evidence for treatment of patients on invasive ventilation and/or ECMO with remdesivir as very low due to concerns with risk of bias.
and imprecision. The panel recognized that the estimates of effect for mortality and time to recovery exclude almost any benefit.

**Pediatric use**

The evidence for the use of remdesivir in children is limited. For ambulatory children at risk for severe disease, the RCT included 8 children age 12 to 18 years limiting our confidence in the available direct evidence for ambulatory care.

There are no randomized controlled data assessing efficacy of remdesivir for treatment of hospitalized pediatric patients with COVID-19. A report of 77 children who received remdesivir through compassionate use early in the pandemic found good tolerability in this population with a low rate of serious adverse events [146].

An ongoing study of remdesivir in children [147] is using 5 mg/kg on day one (maximum dose 200 mg) followed by 2.5 mg/kg daily in patients over 14 days of age, gestational age more than 37 weeks, and weight greater than or equal to 2.5 kg. The FDA EUA applies to patients weighing over 3.5 kg and applies to the lyophilized powder formulation only.

**Conclusions and research needs for this recommendation**

The guideline panel suggests remdesivir for ambulatory patients with mild to moderate disease who are at high risk for severe COVID-19.

The guideline panel suggests against remdesivir for routine treatment of patients with oxygen saturation >94% and no supplemental oxygen; however, strongly urges continued study through recruitment into RCTs.

The guideline panel suggests remdesivir rather than no remdesivir for treatment of severe COVID-19 in hospitalized patients with SpO₂ ≤94% on room air. However, the guideline panel suggests against the routine initiation of remdesivir among patients on invasive ventilation and/or ECMO. Additional clinical trials are needed to provide increased certainty about the potential for both benefit and harms of treatment with remdesivir, as well as to understand the benefit of treatment based on disease severity.
Prescribing information in the United States recommends against use of remdesivir in patients with estimated glomerular filtration rate less than 30 mL per minute. This recommendation arises from concern about accumulation of the excipient (betadex sulfobutyl ether sodium) in such patients with potential for hepatic and renal toxicity due to that substance. Additional research into safety of remdesivir in patients with reduced renal function is needed to ascertain whether this concern is substantiated.

Immunocompromised patients who are unable to control viral replication may still benefit from remdesivir despite SpO₂ that exceeds 94% on room air or a requirement for mechanical ventilation. Management of immunocompromised patients with uncontrolled viral replication is a knowledge gap and additional research into such populations is needed.

In addition, research is needed to address gaps in the evidence of effectiveness of remdesivir based on viral load.
Table 12. GRADE evidence profile, Recommendation 12

**Question:** Remdesivir compared to no remdesivir for ambulatory patients at high risk for severe COVID-19

*New evidence profile developed 12/23/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>№ of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td>Mortality (follow-up: 28 days)</td>
<td>1 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Hospitalization (all-cause) (follow-up: 28 days)</td>
<td>1 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>COVID-19-related medically attended visits (follow-up: 28 days)</td>
<td>1 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>1 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Risk of bias:** Study limitations

- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision
- **Publication bias:** Selective publication of studies

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.
**Explanations**

a. Zero events and relatively small sample size (less than half the patients of the planned sample size were enrolled).

b. Few events do not meet the optimal information size and suggest fragility in the estimate (less than half the patients of the planned sample size were enrolled).

**Reference**

Table 13a. GRADE evidence profile, Recommendation 13a
Question: Remdesivir compared to no antiviral treatment for hospitalized patients with severe COVID-19

<table>
<thead>
<tr>
<th>Mortality (follow up: range 28 days to 29 days)</th>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients remdesivir</th>
<th>No of patients no remdesivir</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 ^1,2,3</td>
<td>randomized</td>
<td>serious ^a,b,c</td>
<td>not serious</td>
<td>not serious</td>
<td>serious ^d</td>
<td>none</td>
<td>369/2726 (13.5%)</td>
<td>374/2593 (14.4%)</td>
<td>RR 0.92 (0.77 to 1.10)</td>
<td>12 fewer per 1,000 (from 33 fewer to 14 more)</td>
<td>LOW</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>Time to recovery (follow up: 29 days)</td>
<td>1 ^2</td>
<td>randomized</td>
<td>serious ^c</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>none</td>
<td>345/486 (71.0%)</td>
<td>306/471 (65.0%)</td>
<td>Rate ratio 1.31 (1.12 to 1.52)</td>
<td>97 more per 1,000 (from 41 more to 147 more)</td>
<td>MODERATE</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>Clinical improvement (follow up: 28 days)</td>
<td>1 ^1</td>
<td>randomized</td>
<td>not serious ^a,b</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious ^d</td>
<td>none</td>
<td>103/158 (65.2%)</td>
<td>45/78 (57.7%)</td>
<td>RR 1.13 (0.91 to 1.41)</td>
<td>75 more per 1,000 (from 52 fewer to 237 more)</td>
<td>LOW</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>Need for mechanical ventilation (follow up: 29 days)</td>
<td>1 ^2</td>
<td>randomized</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious ^g</td>
<td>none</td>
<td>52/402 (12.9%)</td>
<td>82/364 (22.5%)</td>
<td>RR 0.57 (0.42 to 0.79)</td>
<td>97 fewer per 1,000 (from 131 fewer to 47 fewer)</td>
<td>MODERATE</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>Serious adverse events (grade 3/4)</td>
<td>2 ^1,2</td>
<td>randomized</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious ^l</td>
<td>none</td>
<td>44/632 (7.0%)</td>
<td>53/545 (8.9%)</td>
<td>RR 0.79 (0.54 to 1.16)</td>
<td>20 fewer per 1,000 (from 45 fewer to 16 more)</td>
<td>MODERATE</td>
<td>CRITICAL</td>
</tr>
</tbody>
</table>
### Certainty assessment

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Hospitalization

1. Remdesivir vs. no remdesivir

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious</td>
<td>none</td>
<td>158</td>
<td>78</td>
<td>-</td>
<td>MD 1 day higher (0.12 higher to 1.88 higher)</td>
<td>LOW</td>
<td>IMPORTANT</td>
<td></td>
</tr>
</tbody>
</table>

#### Duration of mechanical ventilation

1. Remdesivir vs. no remdesivir

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>158</td>
<td>78</td>
<td>-</td>
<td>MD 8.5 days lower (9.14 lower to 7.86 lower)</td>
<td>MODERATE</td>
<td>IMPORTANT</td>
<td></td>
</tr>
</tbody>
</table>

### GRADE Working Group grades of evidence

- **High certainty**: We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty**: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty**: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty**: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.

### Risk of bias

- **Study limitations**
- **Inconsistency**: Unexplained heterogeneity across study findings
- **Indirectness**: Applicability or generalizability to the research question
- **Imprecision**: The confidence in the estimate of an effect to support a particular decision

### Publication bias

- **Selective publication of studies**

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; HR: Hazard Ratio; RR: Risk ratio; OR: Odds ratio; MD: Mean difference

### Explanations

1. Co-interventions received in Wang 2020 include: interferon alpha-2b, lopinavir/ritonavir, vasopressors, antibiotics, corticosteroid therapy and were balanced between arms.
2. Wang 2020 stopped early due to lack of recruitment. Trial initiated after reduction in new patient presentation (most patients enrolled later in the disease).
3. Post hoc analysis of patients with severe disease from Pan 2020 and Beigel 2020 may introduce bias.
4. The 95% CI may not include a clinically meaningful effect.
5. Few events do not meet the optimal information size and suggest fragility in the estimate.
6. The 95% CI cannot exclude the potential for benefit or harm. Also, few events do not meet the optimal information size.

### References

Table 13b. GRADE evidence profile, Recommendation 13b

**Question:** Remdesivir compared to no antiviral treatment for hospitalized patients with critical COVID-19 (IV/ECMO)

**Last updated 4/5/2021; last reviewed 5/16/2021**

### Mortality (follow up: range 28 days to 29 days)

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>remdesivir</td>
<td>no remdesivir</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
</tr>
<tr>
<td></td>
<td>126/385 (32.7%)</td>
<td>100/387 (25.8%)</td>
<td>RR 1.23 (0.99 to 1.53)</td>
<td>59 more per 1,000 (from 3 fewer to 137 more)</td>
</tr>
</tbody>
</table>

### Time to recovery (follow up: 29 days)

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>63/131 (48.1%)</td>
<td>77/154 (50.0%)</td>
<td>HR 0.98 (0.70 to 1.36)</td>
<td>7 fewer per 1,000 (from 116 fewer to 110 more)</td>
</tr>
</tbody>
</table>

### Serious adverse events (grade 3/4)

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>44/632 (7.0%)</td>
<td>53/545 (9.7%)</td>
<td>RR 0.79 (0.54 to 1.16)</td>
<td>20 fewer per 1,000 (from 45 fewer to 16 more)</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

**Risk of bias:** Study limitations

- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision
- **Publication bias:** Selective publication of studies

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

**CI:** Confidence interval; **RR:** Risk ratio; **HR:** Hazard Ratio

**Explanations**

- a. Post hoc analysis of patients with severe disease from Pan 2020 and Beigel 2020 may introduce bias.
- b. The 95% CI may not include a clinically meaningful effect.
- c. OIS for mortality: 1682
d. The 95% CI cannot exclude the potential for benefit or harm. Also, few events do not meet the optimal information size.
e. SAEs calculated from severe study groups in Beigel 2021 & Wang 2020, not invasive mechanical ventilation/ECMO subgroup.

References
Table 14. GRADE evidence profile, Recommendation 14

**Question:** Remdesivir 5 days compared to remdesivir 10 days for hospitalized patients with severe but not critical COVID-19

**Last updated 9/10/2020; last reviewed 5/16/2021**

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>№ of patients</td>
<td>Effect</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>remdesivir 5 days</td>
<td>remdesivir 10 days</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
</tr>
<tr>
<td>Mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (^1) randomized trials</td>
<td>serious (^b)</td>
<td>not serious</td>
<td>not serious</td>
<td>serious (^a)</td>
</tr>
<tr>
<td>Clinical improvement at 14 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (^1) randomized trials</td>
<td>serious (^b)</td>
<td>not serious</td>
<td>not serious</td>
<td>serious (^c)</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (^1) randomized trials</td>
<td>serious (^b)</td>
<td>not serious</td>
<td>not serious</td>
<td>serious (^c)</td>
</tr>
<tr>
<td>Adverse events leading to treatment discontinuation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (^1) randomized trials</td>
<td>serious (^b,d)</td>
<td>not serious</td>
<td>not serious</td>
<td>serious (^c)</td>
</tr>
</tbody>
</table>

GRADE Working Group grades of evidence

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
Risk of bias: Study limitations
Inconsistency: Unexplained heterogeneity across study findings
Indirectness: Applicability or generalizability to the research question
Imprecision: The confidence in the estimate of an effect to support a particular decision
Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; RR: Risk ratio

Explanations

a. The 95% CI includes the potential for both appreciable benefit, as well as appreciable harm. Few events reported do not meet the optimal information size and suggest fragility in the estimate.

b. Goldman 2020 did not blind participants, healthcare workers or outcome assessors. After randomization, disease severity was greater in the 10-day arm; while the analysis adjusted for baseline characteristics including disease severity, there is still the potential for residual confounding.

c. The lower boundary of the 95% CI may not include a clinically meaningful effect. Few events reported do not meet the optimal information size and suggest fragility in the estimate.

d. Goldman stratified adverse events by days 1-5, 6-10. AEs leading to treatment discontinuation during days 1-5 were 9 (4%) in the 5-day arm and 14 (7%) in the 10-day arm.

Reference

Table 15. GRADE evidence profile, Recommendation 15

**Question:** Remdesivir compared to no antiviral treatment for hospitalized patients with COVID-19 and oxygen saturation >94% without supplemental oxygen

*Last reviewed and updated 5/16/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>№ of patients</td>
<td>Remdesivir</td>
<td>no Remdesivir</td>
<td>Relative (95% CI)</td>
</tr>
</tbody>
</table>

**Mortality (follow up: range 11 days to 29 days)**

<table>
<thead>
<tr>
<th>Nr. of studies (design)</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Remdesivir</th>
<th>No Remdesivir</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 (1,2,3) randomized trials</td>
<td>very serious a,b,c</td>
<td>not serious</td>
<td>not serious</td>
<td>serious d</td>
<td>none</td>
<td>15/1100 (1.4%)</td>
<td>20/914 (2.2%)</td>
<td>RR 0.69 (0.36 to 1.34)</td>
<td>7 fewer per 1,000 (from 14 fewer to 7 more)</td>
<td>💧◯◯◯ ◯</td>
<td>VERY LOW CRITICAL</td>
</tr>
</tbody>
</table>

**Time to recovery (follow up: 29 days)**

<table>
<thead>
<tr>
<th>Nr. of studies (design)</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Remdesivir</th>
<th>No Remdesivir</th>
<th>Rate ratio (95% CI)</th>
<th>Number more per 1,000 (from number fewer to number more)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (2) randomized trials</td>
<td>serious c</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious d</td>
<td>none</td>
<td>54/55 (98.2%)</td>
<td>46/50 (92.0%)</td>
<td>Rate ratio 1.22 (0.82 to 1.81)</td>
<td>34 more per 1,000 (from 46 fewer to 70 more)</td>
<td>💧◯◯◯ ◯</td>
<td>VERY LOW CRITICAL</td>
</tr>
</tbody>
</table>

**Clinical improvement at day 11 (assessed with >2-pt improvement on 7-pt scale; higher = better)**

<table>
<thead>
<tr>
<th>Nr. of studies (design)</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Remdesivir</th>
<th>No Remdesivir</th>
<th>Rate ratio (95% CI)</th>
<th>Number more per 1,000 (from number fewer to number more)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (1) randomized trials</td>
<td>very serious a,b</td>
<td>not serious</td>
<td>not serious</td>
<td>serious e</td>
<td>none</td>
<td>134/191 (70.2%)</td>
<td>121/200 (60.5%)</td>
<td>RR 1.16 (1.00 to 1.34)</td>
<td>97 more per 1,000 (from 0 fewer to 206 more)</td>
<td>💧◯◯◯ ◯</td>
<td>VERY LOW CRITICAL</td>
</tr>
</tbody>
</table>

**Serious adverse events**

<table>
<thead>
<tr>
<th>Nr. of studies (design)</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Remdesivir</th>
<th>No Remdesivir</th>
<th>Rate ratio (95% CI)</th>
<th>Number more per 1,000 (from number fewer to number more)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 (1,2) randomized trials</td>
<td>very serious a,b,c</td>
<td>not serious</td>
<td>not serious</td>
<td>serious d</td>
<td>none</td>
<td>11/246 (4.5%)</td>
<td>18/249 (7.2%)</td>
<td>RR 0.64 (0.31 to 1.31)</td>
<td>26 fewer per 1,000 (from 50 fewer to 22 more)</td>
<td>💧◯◯◯ ◯</td>
<td>VERY LOW CRITICAL</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
Risk of bias: Study limitations

Inconsistency: Unexplained heterogeneity across study findings

Indirectness: Applicability or generalizability to the research question

Imprecision: The confidence in the estimate of an effect to support a particular decision

Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; RR: Risk ratio

Explanations

b. Spinner et al. co-treatments were not balanced between arms: 45% of patients randomized to control arm received HCQ or CQ compared to 11% in 10-day arm or 8% in 5-day arm; lopinavir/ritonavir was 22% in control arm, 6% in 10-day arm, and 5% in 5-day arm.

c. Open-label trial design may have led to different clinical practices (co-interventions and time of hospital discharge).

d. Post hoc analysis of patients with mild to moderate disease from ACTT-1 (Beigel 2020) and SOLIDARITY (Pan 2020) may introduce bias.

e. The 95% CI includes the potential for both appreciable benefit as well as the potential for harm. Few events reported do not meet the optimal information size and suggest fragility in the estimate.

f. The 95% CI may not include a clinically meaningful benefit.

g. Spinner 2020 reported an odds ratio of 1.65 (95% CI: 1.09, 2.48); however, compared to relative risks, odds ratios tend to overestimate the effect with baseline risk is high.

References


Famotidine

Section last reviewed and updated 6/22/2020

Last literature search conducted 6/18/2020

Recommendation 16: Among hospitalized patients with severe COVID-19, the IDSA panel suggests against famotidine use for the sole purpose of treating COVID-19 outside of the context of a clinical trial. (Conditional recommendation, very low certainty of evidence)

The last literature search was conducted on June 18, 2020 and we identified one non-randomized study in OVID. There were no new non-indexed RCTs available.

Why is famotidine considered for treatment?

Anecdotal reports from China suggest that patients infected with coronavirus who were receiving famotidine, a H2 receptor antagonist to treat conditions such as acid reflux and peptic ulcer disease, had improved survival versus those receiving proton pump inhibitors (PPIs) [148]. This post hoc finding summarized below has led to interest in the drug, though no predominant theory describing a mechanism for its efficacy yet exists. One theory is that famotidine, like many other compounds, binds and therefore inhibits the coronavirus main protease, 3C-like main protease (3CLpro) [149].

Summary of the evidence

Our search identified one cohort study that compared 84 patients treated with famotidine against 1,536 patients not receiving treatment with famotidine [150] (Table 16). Fifteen percent of patients in the famotidine group (13/84) started famotidine at home before presenting to the hospital. In addition, a subset of 420 patients not treated with famotidine were matched on baseline characteristics to the treated patients.

Benefits
Famotidine may decrease the composite outcome of death or intubation (HR: 0.42; 95% CI: 0.21, 0.85; very low CoE); however, the evidence is very uncertain (Table 16).

**Harms**

Famotidine is well tolerated. Common adverse events include diarrhea or constipation but occur in less than 5% of people. Severe adverse events occur in less than 1% of persons taking famotidine.

**Other considerations**

The panel determined that the certainty of evidence to be very low due to concerns with risk of bias, imprecision, and possible publication bias. The panel agreed that critically ill patients (i.e., mechanically ventilated) may have been more likely to receive PPIs than famotidine, thus potentially allocating more prognostically favorable patients to the famotidine group; however, the study did not report a protective effect associated with the use of PPIs.

**Conclusions and research needs for this recommendation**

The guideline panel suggests against famotidine for the sole purpose of treating COVID-19, unless in the context of a clinical trial. Additional clinical trials are needed to inform research for treatment with famotidine for patients with COVID-19 (Supplementary Table s2).
Table 16. GRADE evidence profile, Recommendation 16

**Question:** Famotidine compared to no famotidine for hospitalized patients with severe COVID-19

*Last reviewed and updated 6/22/2020*

<table>
<thead>
<tr>
<th># of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th># of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>observational studies</td>
<td>serious a</td>
<td>not serious</td>
<td>not serious</td>
<td>serious b</td>
<td>publication bias strongly suspected c</td>
<td>8/84 (9.5%)</td>
<td>332/1536</td>
<td>HR 0.42</td>
<td>0.21 to 0.85</td>
</tr>
</tbody>
</table>

**Death or intubation (follow up: 30 days)**

### Serious adverse events

<table>
<thead>
<tr>
<th># of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th># of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>observational studies</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Post-marketing and registrational reported common adverse events include constipation (1.2%-1.4%), diarrhea (1.7%), dizziness (1.3%) and headache (1%-4.7%), but overall famotidine is well tolerated. Rare but serious adverse events (&lt;1%) include Stevens-Johnson syndrome, toxic epidermal necrolysis, necrotizing enterocolitis, anaphylaxis, angioedema, rhabdomyolysis, seizure, hospital-acquired pneumonia, interstitial pneumonia. (Micromedex)</td>
<td>-</td>
<td>CRITICAL</td>
<td></td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect

**Risk of bias:** Study limitations

- Inconsistency: Unexplained heterogeneity across study findings
- Indirectness: Applicability or generalizability to the research question
- Imprecision: The confidence in the estimate of an effect to support a particular decision
- Publication bias: Selective publication of studies

**Explanations**

a. Freedberg analysis adjusted for baseline characteristics of age, sex, race/ethnicity, BMI, comorbidities, and initial oxygen requirement (room air, nasal cannula, non-rebreather); however, 27% in the control arm were missing information on BMI. Potential residual confounding due to provision of famotidine being used in less sick/severe cases and PPIs in severe cases. Co-interventions/treatments were not reported (HCQ provided but not disaggregated across arms) and could modify the effect of the intervention. Approximately 15% of patients started famotidine at home, prior to hospitalization, which may lead to earlier co-interventions.
b. Number of events is less than the optimal information size, which may suggest fragility in the estimate of effect.
c. Concerns about selective reporting due to unavailability of disaggregated data for outcomes of mortality or intubation, missing supplemental files, and raw data for primary outcome from propensity-matched control group.

Reference
Neutralizing Antibodies for Pre-Exposure and Post-Exposure Prophylaxis

Section last reviewed and updated 12/23/2021

Last literature search conducted 11/30/2021

Resources:
- CDC: SARS-CoV-2 variants
- FDA: Qualifications for SARS-CoV-2 exposure
- FDA: EUA for Evusheld™ (tixagevimab co-packaged with cilgavimab)
- NIH: National Center for Advancing Translational Science

Recommendation 17 (NEW): In moderately or severely immunocompromised individuals* at increased risk for inadequate immune response to COVID-19 vaccine or for whom COVID-19 vaccine is not recommended due to a documented serious adverse reaction to the vaccine, the IDSA guideline panel suggests pre-exposure prophylaxis with tixagevimab/cilgavimab rather than no tixagevimab/cilgavimab. (Conditional recommendation, Low certainty of evidence)

Remarks:
- Dosing for tixagevimab/cilgavimab is 150 mg of tixagevimab & 150 mg of cilgavimab administered as two separate consecutive intramuscular injections once.
- Local SARS-CoV-2 variant susceptibility should be considered.

*See Figure 2 below
Figure 2. FDA EUA criteria for the use of tixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 in moderately or severely immunocompromised patients ¹

According to the FDA Emergency Use Authorization of Evusheld, medical conditions or treatments that may result in moderate to severe immune compromise include but are not limited to:

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200 mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
- Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, chancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)

Reference


Figure 3. FDA EUA criteria for the use of tixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 ¹

This EUA for the use of the unapproved products tixagevimab and cilgavimab for pre-exposure prophylaxis in adults and pediatric individuals (12 years of age and older weighing at least 40 kg) who are:

- Not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 AND:
  - have moderate to severe immune compromise due to a medical condition OR receipt of immunosuppressive medications or treatments AND may not mount an adequate immune response to COVID-19 vaccination OR
  - For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or a COVID-19 vaccine component(s).

Reference

Recommendation 18: In persons exposed to COVID-19 who are at high risk of progression to severe COVID-19, the IDSA guideline panel suggests post-exposure casirivimab/imdevimab rather than no casirivimab/imdevimab. (Conditional recommendation, Low certainty of evidence)

Remarks:
- Dosing for casirivimab/imdevimab is casirivimab 600 mg & imdevimab 600 mg IV or SC once.
- In the trial considered for this recommendation, participants were enrolled within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection.
- Local SARS-CoV-2 variant susceptibility should be considered.

Figure 4. FDA EUA criteria for the use of casirivimab/imdevimab for post-exposure prophylaxis of COVID-19

This EUA is for the use of the unapproved products casirivimab and imdevimab for post-exposure prophylaxis of COVID-19 in adult and pediatric individuals (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death, and are:

- Not fully vaccinated OR who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (e.g., individuals with immunocompromising conditions including those taking immunosuppressive medications) AND
  - Have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per CDC criteria OR
  - Who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (e.g., nursing homes, prisons).

Reference
Why are neutralizing antibodies considered for prophylaxis?

Neutralizing antibodies directed at the receptor-binding domain of SARS-CoV-2 spike protein have been evaluated as prophylactic agents for COVID-19. In animal models there is evidence that antibody therapy may more rapidly reduce viral load in the upper and lower airways of infected animals resulting in reduced viral-induced pathology, demonstrating in vivo prophylactic and treatment efficacy [151, 152]. Additionally, antibody mediated enhancement of disease has not been detected in animal models [152] but this potential phenomenon should be closely monitored in the future studies. In a large, randomized study of unvaccinated nursing home patients and staff where there was at least one confirmed case of COVID-19 at the facility, a single dose of either bamlanivimab appeared to significantly reduce the incidence of “mild or worse” COVID-19 amongst the nursing home residents [153].

Potential advantages of neutralizing antibodies include the ability to standardize the amount of neutralizing activity and the possibility of conferring protection more rapidly than with vaccine-induced immune responses (which generally take several weeks).

Summary of the evidence

Tixagevimab/cilgavimab

Our search identified one RCT reporting on pre-exposure prophylaxis (PrEP) with a single dose of intramuscular tixagevimab/cilgavimab administration in adults ≥18 years of age who are at increased risk of inadequate response to COVID-19 vaccination or SARS-CoV-2 infection [154, 155]. Patients included were those that were either age ≥60 years, immunocompromised, had severe renal or liver impairment, COPD, or those who had an increased risk of exposure including those working in healthcare or living in congregate living settings. All participants had a negative SARS-CoV-2 serology test result at screening, had no history of SARS-CoV-2 infection, and had not received vaccine or biologic indicated for prevention of SARS-CoV-2 or COVID-19. Study participants received a single combined 300 mg intramuscular dose of the combination of tixagevimab (150 mg) /cilgavimab (150 mg).

Casirivimab/imdevimab
Our search identified one RCT reporting on post-exposure prophylaxis (PEP) with neutralizing antibodies (combination of casirivimab/imdevimab) for patients exposed to COVID-19 who are at high risk of progression to severe disease [156] (Table 18).

One RCT reported on 1,505 persons testing negative for SARS-CoV-2 infection (by reverse-transcriptase-quantitative polymerase-chain-reaction assay [RT-qPCR]) within 96 hours following household contact with a diagnosis of SARS-CoV-2 infection [156]. Of those included in the trial, 30.5% participants were categorized as having a high risk of COVID-19 (e.g., ≥65 years of age, body mass index [BMI] ≥35, chronic kidney disease, etc.). Participants in the treatment group received a total dose of 1200 mg of casirivimab/imdevimab subcutaneously.

**Benefits**

**Tixagevimab/cilgavimab**

PrEP with tixagevimab/cilgavimab appears to have little or no effect on mortality through a median of 6 months (RR: 0.50; 95% CI: 0.13, 2.0; absolute risk reduction: 1 fewer per 1,000 [from 2 fewer to 2 more]; moderate CoE). Symptomatic COVID-19 infection within six months after administration was reduced in those who received tixagevimab/cilgavimab compared to placebo (RR: 0.18; 95% CI: 0.09, 0.35; moderate CoE).

**Casirivimab/imdevimab**

Persons receiving post-exposure prophylaxis with casirivimab/imdevimab reduced symptomatic SARS-CoV-2 infection from 7.8% to 1.5% (RR: 0.19; 95% CI: 0.10, 0.35; moderate CoE). Of the 70 persons who developed symptomatic infection, those who received casirivimab/imdevimab rather than placebo experienced a shorter duration of symptoms (mean difference [MD]: -2.0 weeks; 95% CI: -2.91, -1.09; low CoE).

**Harms**

**Tixagevimab/cilgavimab**

Serious adverse events were not meaningfully different in those that received PrEP with tixagevimab/cilgavimab compared to placebo (RR: 1.09; 95% CI: 0.67, 1.78; moderate CoE).
Casirivimab/imdevimab

Serious treatment-emergent adverse events may be less frequent among persons receiving casirivimab/imdevimab compared to those receiving placebo; however, this may not be meaningfully different from those receiving placebo (RR: 0.66; 95% CI: 0.30, 1.47; low CoE).

Other considerations

Tixagevimab/cilgavimab

The panel agreed that the overall certainty of evidence for PrEP with tixagevimab/cilgavimab was low due to concerns with the generalizability of the trial population to the FDA-authorized indications (e.g., immunocompromised persons) and low number of events (fragility of results). The panel noted concerns with feasibility at different centers given the large number of potentially eligible individuals and supply constraints.

Casirivimab/imdevimab

The panel agreed that the overall certainty of evidence for post-exposure prophylaxis with casirivimab/imdevimab was low due to low number of events (fragility of results). The panel notes some indirectness between the trial participants (30.5% with any high-risk factor for COVID) and the current approved indications for post-exposure prophylaxis within the EUA.

Conclusions and research needs for this recommendation

Tixagevimab/cilgavimab

The guideline panel suggests PrEP with tixagevimab/cilgavimab in moderately or severely immunocompromised individuals at increased risk for inadequate immune response to COVID-19 vaccine or for whom COVID-19 vaccine is not recommended due to documented severe reactions to the COVID-19 vaccine. Data on the efficacy of pre-exposure prophylaxis specifically in immunocompromised individuals who have received COVID-19 vaccines are needed.

Casirivimab/imdevimab
The guideline panel suggests PEP using casirivimab/imdevimab in persons exposed to COVID-19, who are at high risk of progression.
Table 17. GRADE evidence profile, Recommendation 17

**Question:** Tixagevimab/cilgavimab compared to no tixagevimab/cilgavimab for pre-exposure prophylaxis in adults at increased risk for inadequate immune response to COVID-19 vaccine or for whom COVID-19 vaccine is not recommended

*New evidence profile developed 12/23/2021*

<table>
<thead>
<tr>
<th>Nr of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>tixagevimab/ cilgavimab</th>
<th>no tixagevimab/ cilgavimab</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality (follow-up: median 6 months)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,2</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>serious</td>
<td>none</td>
<td>4/3461 (0.1%)</td>
<td>4/1736 (0.2%)</td>
<td>RR 0.50 (0.13 to 2.00)</td>
<td>1 fewer per 1,000 (from 2 fewer to 2 more)</td>
<td>⬤⬤⬤◯</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>Symptomatic COVID-19 (follow-up: median 6 months; assessed with: RT-PCR-positive symptomatic illness)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,2</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>serious</td>
<td>none</td>
<td>11/3441 (0.3%)</td>
<td>31/1731 (1.8%)</td>
<td>HR 0.17 (0.08 to 0.33)</td>
<td>15 fewer per 1,000 (from 16 fewer to 12 fewer)</td>
<td>⬤⬤⬤◯</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>Serious adverse events (follow-up: median 83 days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,2</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>serious</td>
<td>none</td>
<td>50/3461 (1.4%)</td>
<td>23/1736 (1.3%)</td>
<td>RR 1.09 (0.67 to 1.78)</td>
<td>1 more per 1,000 (from 4 fewer to 10 more)</td>
<td>⬤⬤⬤◯</td>
<td>CRITICAL</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Risk of bias:** Study limitations

**Inconsistency:** Unexplained heterogeneity across study findings

**Indirectness:** Applicability or generalizability to the research question

**Imprecision:** The confidence in the estimate of an effect to support a particular decision

**Publication bias:** Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; HR: Hazard ratio; RR: Risk ratio

Last updated February 3, 2022 and posted online at [www.idsociety.org/COVID19guidelines](http://www.idsociety.org/COVID19guidelines). Please check website for most updated version of these guidelines.
Explanations
a. Possible misclassification bias due to unequal rate of drop-outs after unblinding.
b. 2 deaths in the control arm were attributed to COVID-19.
c. Trial population indirect to the population indicated within the FDA EUA (e.g., immunocompromised).
d. Small number of events; fragility present.

References
Table 18. GRADE evidence profile, Recommendation 18

**Question:** Prophylactic casirivimab/imdevimab compared to no prophylactic casirivimab/imdevimab for persons exposed to COVID-19 at high risk for progression to severe disease

*Developed 8/17/2021; last reviewed 9/19/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No of studies</strong></td>
<td><strong>Study design</strong></td>
<td><strong>Risk of bias</strong></td>
<td><strong>Inconsistency</strong></td>
<td><strong>Indirectness</strong></td>
</tr>
<tr>
<td>1 🟢🟢🟢</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>1 🟢🟢🟢</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>1 🟢🟢🟢</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious b</td>
</tr>
<tr>
<td>1 🟢🟢🟢</td>
<td>randomized trials</td>
<td>not serious</td>
<td>serious d</td>
<td>serious a,c</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
Risk of bias: Study limitations
Inconsistency: Unexplained heterogeneity across study findings
Indirectness: Applicability or generalizability to the research question
Imprecision: The confidence in the estimate of an effect to support a particular decision
Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.
CI: Confidence interval; RR: Risk ratio; MD: Mean difference

Explanations
a. Small number of events; fragility present
b. COVID-19 related hospitalizations is a surrogate for ICU admission, mechanical ventilation and death. Not rated down.
c. 95% CI cannot exclude meaningful harm
d. Serious treatment emergent adverse events reported for entire study population (including symptomatic and asymptomatic) and may not be generalizable to seronegative population.

Reference
Neutralizing Antibodies for Treatment

Section last reviewed and updated 9/19/2021

Last literature search conducted 7/31/2021

Resources:

- CDC: SARS-CoV-2 variants
- FDA: Qualifications for SARS-CoV-2 exposure

Recommendation 19: Among ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab rather than no neutralizing antibody treatment. (Conditional recommendation, Moderate certainty of evidence)

Remarks:

- Dosing for casirivimab/imdevimab is casirivimab 600 mg and imdevimab 600 mg IV. Subcutaneous injection is a reasonable alternative in patients for whom it cannot be given intravenously.
- Dosing for sotrovimab is sotrovimab 500 IV once.
- Dosing for bamlanivimab/etesevimab is bamlanivimab 700 mg and etesevimab 1400 mg IV.
- Patients with mild to moderate COVID-19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID-19 may also receive bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab.
- Local variant susceptibility should be considered in the choice of the most appropriate neutralizing antibody therapy. Local availability of different monoclonal antibody combinations may be affected by predominance of local variants.
- There are limited data on efficacy of bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab in high-risk patients under 18 years of age.
Recommendation 20: Among hospitalized patients with severe COVID-19, the IDSA guideline panel recommends against bamlanivimab monotherapy. (Strong recommendation, Moderate certainty of evidence)

Figure 5. Risk factors for the progression to severe COVID-19 or hospitalization per FDA EUA

The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40 kg) at higher risk for progression to severe COVID-19:

- Older age (for example ≥65 years of age)
- Obesity or being overweight (for example, adults with BMI >25 kg/m²), or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate to severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])

a. These criteria refer to Recommendations 19 and 20

References

Why are neutralizing antibodies considered for treatment?

Neutralizing antibodies directed at the receptor-binding domain of SARS-CoV-2 spike protein have been evaluated as therapeutic agents for COVID-19. In animal models there is evidence that antibody therapy may more rapidly reduce viral load in the upper and lower airways of infected animals resulting in reduced viral-induced pathology [151, 152]. Additionally, antibody mediated enhancement of disease has not been detected in animal models [152] but this potential phenomenon should be closely monitored in the future studies.

Potential advantages of neutralizing antibodies include the ability to standardize the amount of neutralizing activity and the possibility of conferring protection more rapidly than with vaccine-induced immune responses (which generally take several weeks).

Antibody treatments have been and continue to be evaluated in both hospitalized and ambulatory patients. For outpatients, logistical challenges exist since the infrastructure for administration of IV infusions does not exist in most ambulatory care settings. There may also be concerns about spread of contagion when administering IV infusions in clinics. However, these challenges are being addressed in a number of outpatient infusion centers and availability of subcutaneous, or intramuscular administration options.

Summary of the evidence

Our search identified six publications of five RCTs reporting on treatment with neutralizing antibodies (bamlanivimab, combination of casirivimab/imdevimab, combination of bamlanivimab/etesevimab, or sotrovimab) for patients with COVID-19 [157-162] (Tables 19-21). Due to clinical heterogeneity of the outcome measures across studies, meta-analyses combining the different neutralizing antibodies were not considered appropriate.

One RCT, stopped early for futility, reported on hospitalized patients with COVID-19 randomized to treatment with either a single infusion of bamlanivimab (7000 mg) or placebo (ACTIV-3/TICO) [158]. One phase II/III RCT reported on non-hospitalized patients (adults as well as children age 12 and up) considered at high risk for progression to severe disease who were within three days of their first positive test for SARS-CoV-2 who were randomized to a single
infusion of bamlanivimab 2800 mg/etesevimab 2800 mg or placebo [159]. One phase II RCT reported on non-hospitalized patients with recently diagnosed mild or moderate COVID-19 randomized to treatment with either a single infusion of neutralizing antibody bamlanivimab in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo [157].

One phase III RCT assessed a single infusion of either 1200 mg or 2400 mg of casirivimab/imdevimab in non-hospitalized participants with mild to moderate COVID-19 [161]. In the original phase of this trial, participants without risk factors for severe disease were included; however, 1,040 participants were removed after randomization and not analyzed as they had no risk factors for severe disease. In the amended phase of this investigation all participants were considered at high risk for severe disease. Another phase III RCT also reported on non-hospitalized participants with mild to moderate COVID-19 who were at risk for severe disease [160]. Participants in this study received a single infusion of sotrovimab 500 mg. Unlike previous studies, this study did exclude participants with immunocompromising conditions.

**Benefits**

**Bamlanivimab/etesevimab**

In ambulatory persons at high risk for severe COVID-19, bamlanivimab/etesevimab demonstrated an absolute mortality reduction of 1.9% (95% CI includes a minimum of 0.7% reduction in mortality) as no deaths were seen by day 29 in the 518 persons treated with bamlanivimab/etesevimab compared to 10 deaths in the 517 persons who received placebo. However, due to the small number of events (10, of which nine were believed to the result of COVID-19), the certainty of evidence was low due to imprecision. Bamlanivimab/etesevimab demonstrated a lower relative risk of COVID-19 related hospitalizations (defined as ≥24 hours of acute care) through day 29 compared to no bamlanivimab/etesevimab (RR: 0.30; 95% CI: 0.16, 0.59; low CoE). Ambulatory persons who received bamlanivimab/etesevimab had a lower relative risk of persistently high viral load at day seven compared to no bamlanivimab/etesevimab (RR: 0.34; 95% CI: 0.25-0.46; low CoE).

**Casirivimab/imdevimab**
Concerns were raised by the panel whether bias could have been introduced by excluding 1040 persons post-randomization (2400-mg dose group) due to lack of risk factors for severe disease. Therefore, the panel used the amended phase (1200-mg dose) full data set to inform the effect estimates as no exclusions were reported. Sensitivity analyses were carried out to test the robustness of this approach by either adding the 2400-mg to the 1200-mg dose data set or by formally pooling both effect estimates using fixed effects model; these sensitivity analyses resulted in little to no relevant differences in the findings. In addition, the amended phase lower dose (1200 mg) results also served as confirmation that the latest EUA recommended dosing appears to be equally effective as the previously authorized higher dose.

Among ambulatory persons with at least one risk factor for severe disease, there was no difference in 29-day mortality in persons treated with casirivimab/imdevimab compared to no casirivimab/imdevimab 1200 mg (RR: 1.02; 95% CI: 0.06, 16.20; low CoE). However, there was a lower relative risk of hospitalization in persons treated with casirivimab/imdevimab 1200 mg (RR: 0.27; CI: 0.11, 0.65; moderate CoE).

Sotrovimab

Among ambulatory persons with at least one risk factor for severe disease, sotrovimab demonstrated a lower relative risk of mortality compared to no sotrovimab (RR: 0.33; 95% CI: 0.01-8.19, low CoE). The low certainty of evidence was due to imprecision as there were no mortality events in those who received sotrovimab and one death in the placebo arm. Among ambulatory persons, sotrovimab use was associated with a lower relative risk of hospitalization, compared to no sotrovimab (RR: 0.14; 95% CI: 0.04-0.48; moderate CoE). Persons receiving sotrovimab had a lower progression to severe or critical disease compared to no sotrovimab (RR: 0.11; 95% CI: 0.02, 0.45; moderate CoE).

Bamlanivimab monotherapy

[NOTE: On April 16, 2021, FDA revoked EUA for monoclonal antibody bamlanivimab.] [163]

Among ambulatory persons, bamlanivimab demonstrated a lower relative risk of hospitalization, including visits to the emergency room, compared to no bamlanivimab (RR:
0.26; 95% CI: 0.09, 0.75; very low CoE). The very low certainty of evidence was due to indirectness, as the treatment may not have been provided to enough persons at risk of developing severe disease to be representative of the general population, and imprecision, due to few events recorded. Bamlanivimab may increase viral clearance at three days (MD: -0.49; 95% CI: -0.87, -0.11; low CoE); however, there may not be a meaningful difference at 11 days as measured by change from baseline SARS-CoV-2 viral load (MD: -0.22; 95%: -0.60, 0.15; low CoE).

Among patients hospitalized for COVID-19, treatment with bamlanivimab compared to placebo failed to show or exclude a beneficial effect on mortality (HR: 2.00; 95% CI: 0.67, 5.99; moderate CoE). Clinical improvement, as defined as a decrease in a pulmonary ordinal scale, may not be meaningfully different among patients hospitalized for COVID-19 who received treatment with bamlanivimab or placebo (OR: 0.85; 0.56, 1.29; moderate CoE).

**Harms**

**Bamlanivimab/etesevimab**

Persons receiving bamlanivimab/etesevimab experienced more serious adverse events. However, this may not be meaningfully different from those receiving placebo (RR: 1.40; 95% CI: 0.45, 4.37; moderate CoE).

**Casirivimab/imdevimab**

Serious adverse events were less frequent among persons receiving casirivimab/imdevimab compared to those receiving placebo (RR: 0.34; 95% CI: 0.24, 0.48; moderate CoE).

**Sotrovimab**

Persons who received sotrovimab were less likely to experience serious adverse events compared to those receiving placebo (RR: 0.27; 95% CI: 0.12-0.63; moderate CoE).

**Bamlanivimab monotherapy**
Serious adverse events among ambulatory persons receiving bamlanivimab monotherapy may not be meaningfully different from those receiving placebo (RR: 0.15; 95% CI: 0.01, 3.78; low CoE). Persons receiving bamlanivimab did experience more infusion-related adverse events, including pruritus, flushing, rash, and facial swelling (RR: 1.62; 95% CI: 0.34, 7.70; low CoE).

Similarly, serious adverse events at five and 28 days among patients hospitalized for COVID-19 receiving bamlanivimab may not be meaningfully different from those receiving placebo (RR: 1.85; 95% CI: 0.34, 9.97; moderate CoE and RR: 0.93, 95% CI: 0.27, 3.14; moderate CoE, respectively). Similarly, infusion-related adverse events may not be meaningfully different between patients hospitalized for COVID-19 receiving bamlanivimab or placebo (OR: 1.64, 95% CI: 0.79, 3.44; moderate CoE).

**Other considerations**

**Neutralizing antibodies for ambulatory persons**

The panel agreed that the overall certainty of evidence for the treatment with bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in ambulatory persons with COVID-19 at high risk for progression to severe disease (at least one risk factor) was moderate due to mostly low number of events (fragility of results). The results were driven by the number of avoided hospitalizations, as the number of deaths that occurred were too sparse to show a clear trend. Neutralizing antibodies were well tolerated, and serious adverse events were comparable or lower than placebo. The panel noted increased feasibility with the option of providing treatment with casirivimab/imdevimab through subcutaneous injections [156, 164].

Casirivimab/imdevimab has been evaluated for the treatment of COVID-19 at doses of 1200 mg, 2400 mg, and 8000 mg. Across all treatment doses, there was a flat dose-response relationship for viral load and clinical outcomes. As part of the FDA Emergency Use Authorization, the use of casirivimab/imdevimab as an IV infusion is strongly recommended, however the subcutaneous route is authorized as an alternate route when IV infusion is not feasible and would result in a delay in treatment. Clinical outcomes of patients receiving
casirivimab/imdevimab via the subcutaneous route for the treatment of COVID-19 have not been reported in available trials. A pre-print manuscript [164] evaluated early casirivimab/imdevimab 1200 mg versus placebo in asymptomatic outpatients with COVID-19 and demonstrated less hospitalizations in those receiving casirivimab/imdevimab compared to those receiving placebo, 0/100 versus 3/104, respectively (RR: 0.15; 95%CI: 0.01-2.84). Peak pharmacokinetic levels in those receiving subcutaneous casirivimab 600 mg/imdevimab 600 mg appear approximately 75% lower than after IV infusion [165].

Bamlanivimab monotherapy

The panel agreed that the overall certainty of evidence for treatment with bamlanivimab for ambulatory persons with COVID-19 is very low due to concerns with indirectness and imprecision.

The panel agreed that the overall certainty of evidence for treatment with bamlanivimab for patients hospitalized for COVID-19 is moderate due to concerns with fragility in the estimate from the small number of events reported. The guideline panel made a strong recommendation against treatment with bamlanivimab for patients hospitalized for COVID-19. The panel was moderately certain that any relevant benefit (reduction in mortality or clinical improvement) could be excluded.

SARS-CoV-2 variants and neutralizing monoclonal antibodies

The emergence and circulation of new SARS-CoV-2 genetic variants has been reported from the United States and other counties. The B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.427/B.1.429 (epsilon) and B.1.617.2 (delta) variants circulating in the United States are classified as variants of concern as they may have potential clinical and public health implications. The B.1.525 (eta), B.1.526 (iota), B.1.526.1, B.1.617, B.1.617.1 (kappa), B.1.617.3 and P.2 (zeta) variants are classified as variants of interest [166]. In vitro neutralizing assays using SARS-CoV-2 or vesicular stomatitis virus-based pseudovirus showed that some of the variants had reduced susceptibility to neutralizing antibodies, either individually or in combination. There is limited data from clinical studies.
Bamlanivimab alone and the combination of bamlanivimab and etesevimab together had activity against pseudovirus expressing del69-70 + N501Y found in the B.1.1.7 variant (alpha). Pseudovirus expressing spike protein from the B.1.351 lineage (beta) or substitutions K417N + E484K + N501Y found in this lineage had reduced susceptibility to bamlanivimab and etesevimab together of >45-fold, and pseudovirus expressing K417T + E484K + N501Y found in the P.1 lineage (gamma) had reduced susceptibility to bamlanivimab and etesevimab together of >511-fold. Pseudovirus expressing spike protein from the B.1.427/B.1.429 lineages (epsilon), or the L452R substitution found in this lineage, had reduced susceptibility to bamlanivimab and etesevimab together of 7.7-fold or 7.4-fold, respectively [167]. In vitro neutralization studies showed that bamlanivimab lost activity against the delta variant, but etesevimab retained activity [168].

Casirivimab and imdevimab individually and together had neutralization activity against pseudovirus expressing all spike protein substitutions found in the B.1.1.7 lineage (alpha) and against pseudovirus expressing only N501Y found in B.1.1.7 (alpha) and other circulating lineages. Casirivimab and imdevimab together had neutralization activity against pseudovirus expressing all spike protein substitutions, or individual substitutions K417N, E484K or N501Y, found in the B.1.1351 lineage (beta), and against K417T+E484K, found in the P.1 lineage (gamma), although casirivimab alone, but not imdevimab, had reduced activity against pseudovirus expressing K417N or E484K, as indicated above. The E484K substitution is also found in the B.1.526 (iota) lineage. Casirivimab and imdevimab, individually and together, retained neutralization activity against the L452R substitution found in the B.1.427/B.1.429 lineages (epsilon) [165]. In in vitro neutralization studies, casirivimab and imdevimab remained active against the delta variant [168].

Pseudotype virus-like particle neutralization assays indicate that sotrovimab retains activity against the B.1.1.7, B.1.315, P.1, B.1.427/B.1.429, B1.526 & B.1.617 variant spike proteins. There is limited nucleotide sequencing data available from COMET ICE to comment on the clinical impact of variants on therapeutic response [169].

We have limited data on how in vitro neutralization activity of monoclonal antibodies against pseudovirus expressing spike protein substitutions or even in vitro neutralization...
activity against the SARS-CoV-2 variants correlates with clinical efficacy. Genotypic and phenotypic testing for variants and their correlation with patient important outcomes is being studied in clinical trials evaluating neutralizing antibodies. We still need further studies and surveillance data to understand the implications of SARS-CoV-2 variants on clinical efficacy of COVID-19 therapies.

**Conclusions and research needs for this recommendation**

The guideline panel suggests using bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab in mild to moderate COVID-19 ambulatory persons at high risk for developing severe disease as the expected benefits likely outweigh any potential harms ([Tables 19-21](#)).

The guideline panel recommends against use of bamlanivimab for patients hospitalized for COVID-19 ([Table 23](#)).

The guideline panel recognized the need for continued research and accrual of evidence, particularly trials on patient important outcomes (hospitalizations progressing to need for ventilation, or death), existing and new neutralizing antibodies, and outcomes with variants of concern ([Supplementary Table s2](#)).
### Table 19. GRADE evidence profile, Recommendation 19

**Question:** Bamlanivimab/etesevimab compared to no bamlanivimab/etesevimab for ambulatory persons with mild to moderate COVID-19 at high risk for progression to severe disease

*Last updated 3/2/2021; last reviewed 9/19/2021*

<table>
<thead>
<tr>
<th></th>
<th>Certainty assessment</th>
<th></th>
<th></th>
<th>Nr of patients</th>
<th></th>
<th></th>
<th>Effect</th>
<th></th>
<th></th>
<th>Certainty</th>
<th></th>
<th></th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
<td>Indirectness</td>
<td>Imprecision</td>
<td>Other considerations</td>
<td>bamlanivimab/etesevimab</td>
<td>no bamlanivimab/etesevimab</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mortality (follow up: 29 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>0/518 (0.0%)</td>
<td>10/517 (1.9%)</td>
<td>RR 0.05 (0.00 to 0.80)</td>
<td>19 fewer per 1,000 (from 31 fewer to 7 fewer)</td>
<td>☢☢☯◯ MODERATE</td>
<td>CRITICAL</td>
<td></td>
</tr>
<tr>
<td><strong>Hospitalization (&gt;24 hours of acute care) with COVID-19 (follow up: 29 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>11/518 (2.1%)</td>
<td>36/517 (7.0%)</td>
<td>RR 0.30 (0.16 to 0.59)</td>
<td>49 fewer per 1,000 (from 58 fewer to 29 fewer)</td>
<td>☢☢☯ MODERATE</td>
<td>CRITICAL</td>
<td></td>
</tr>
<tr>
<td><strong>Persistently high viral load at day 7 (follow up: 7 days; assessed with: RT-PCR)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>serious</td>
<td>none</td>
<td>50/508 (9.8%)</td>
<td>145/499 (29.1%)</td>
<td>RR 0.34 (0.25 to 0.46)</td>
<td>192 fewer per 1,000 (from 218 fewer to 157 fewer)</td>
<td>☢ ☢ ☯ LOW</td>
<td>IMPORTANT</td>
<td></td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>7/518 (1.4%)</td>
<td>5/517 (1.0%)</td>
<td>RR 1.40 (0.45 to 4.37)</td>
<td>4 more per 1,000 (from 5 fewer to 33 more)</td>
<td>☢☢☯ MODERATE</td>
<td>CRITICAL</td>
<td></td>
</tr>
</tbody>
</table>
GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Risk of bias:
Study limitations
Inconsistency: Unexplained heterogeneity across study findings
Indirectness: Applicability or generalizability to the research question
Imprecision: The confidence in the estimate of an effect to support a particular decision
Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; RR: Risk ratio

Explanations
a. Estimate reflects the use of a higher dose than treatment dose approved by the FDA.
b. Fragility present, low number of events.
c. RR estimated by using continuity correction of 0.5.
d. As the RR 95% CI is wide due to sparse data, absolute risk difference recalculated independently and not based on RR.
e. Hospital admission is an intermediary outcome for morbidity, ICU admission, and need for ventilation. Not rated down.
f. Measure of viral clearance is a surrogate outcome for hospital admission, need for intensive care, intubation and death.
g. Disclaimer: Provisional evidence rating based on preliminary evidence from non-peer reviewed publication.

Reference
Table 20. GRADE evidence profile, Recommendation 19

**Question:** Casirivimab/imdevimab compared to no casirivimab/imdevimab for ambulatory persons with mild to moderate COVID-19 at high risk of progression to severe disease

*Last updated 6/16/2021; last reviewed 9/19/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>Nº of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All-cause mortality (1200 mg) (follow up: 29 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious</td>
<td>none</td>
</tr>
<tr>
<td><strong>COVID-19 related hospitalizations (1200 mg) (follow up: 29 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
</tr>
<tr>
<td><strong>Serious adverse events (all doses) (follow up: 29 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Risk of bias:** Study limitations
- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision
- **Publication bias:** Selective publication of studies

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

**CI:** Confidence interval; **RR:** Risk ratio

**Explanations**

- Differential post randomization event exclusions (1040 participants) in the original phase (participants without risk factors) is unknown. Publication did not provide an intention to treat analysis. Not rated down for risk of bias as the data in this evidence profile is limited to the amended phase 1,200 mg dose only and not the entire data set (1,200 mg is the
currently recommended dose). However, sensitivity analysis of the entire data set showed similar results: for hospitalizations 23/2091 vs 59/1341; RR 0.25 (95% CI 0.16, 0.4); deaths: 2/2091 vs 3/1341; RR 0.43 (95% CI 0.08, 2.3).

b. Small number of events; fragility present.
c. 95% CI cannot exclude no difference or increased mortality.
d. As the RR 95% CI is wide due to sparse data, absolute risk difference recalculated independently and not based on RR.
e. COVID-19 related hospitalizations is a surrogate for ICU admission, mechanical ventilation and death. Not rated down.
f. Disclaimer: Provisional evidence rating based on preliminary evidence from non-peer reviewed publication.

Reference
**Figure 6a.** Forest plot for the outcome of hospitalizations for casirivimab/imdevimab vs. no casirivimab/etesevimab (data for 1200-mg dose only)\(^1\)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental Events</th>
<th>Total</th>
<th>Control Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M–H, Fixed, 95% CI</th>
<th>Risk Ratio M–H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weinreich 2021 (1200)</td>
<td>6</td>
<td>736</td>
<td>23</td>
<td>748</td>
<td>100.0%</td>
<td>0.27 [0.11, 0.65]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td>736</td>
<td>23</td>
<td>748</td>
<td>100.0%</td>
<td>0.27 [0.11, 0.65]</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>6</td>
<td>23</td>
<td></td>
<td>23</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Not applicable
Test for overall effect: Z = 2.91 (P = 0.004)

Reference


**Figure 6b.** Forest plot for the outcome of hospitalizations for casirivimab/imdevimab vs. no casirivimab/etesevimab (combining data for 2400-mg dose and 1200-mg dose)\(^1\)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental Events</th>
<th>Total</th>
<th>Control Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M–H, Fixed, 95% CI</th>
<th>Risk Ratio M–H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weinreich 2021</td>
<td>23</td>
<td>2091</td>
<td>59</td>
<td>1341</td>
<td>100.0%</td>
<td>0.25 [0.16, 0.40]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td>2091</td>
<td>59</td>
<td>1341</td>
<td>100.0%</td>
<td>0.25 [0.16, 0.40]</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>23</td>
<td>59</td>
<td></td>
<td>59</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Not applicable
Test for overall effect: Z = 5.70 (P < 0.00001)

Reference


**Figure 6c.** Forest plot for the outcome of hospitalizations for casirivimab/imdevimab vs. no casirivimab/etesevimab (pooling data for 2400-mg dose and 1200-mg dose)\(^1\)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental Events</th>
<th>Total</th>
<th>Control Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M–H, Fixed, 95% CI</th>
<th>Risk Ratio M–H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weinreich 2021</td>
<td>17</td>
<td>1355</td>
<td>36</td>
<td>593</td>
<td>68.7%</td>
<td>0.21 [0.12, 0.36]</td>
<td></td>
</tr>
<tr>
<td>Weinreich 2021 (1200)</td>
<td>6</td>
<td>736</td>
<td>23</td>
<td>748</td>
<td>31.3%</td>
<td>0.27 [0.11, 0.65]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td>2091</td>
<td>59</td>
<td>1341</td>
<td>100.0%</td>
<td>0.22 [0.14, 0.36]</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>23</td>
<td>59</td>
<td></td>
<td>59</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi\(^2\) = 0.22, df = 1 (P = 0.64); I\(^2\) = 0%
Test for overall effect: Z = 6.07 (P < 0.00001)

Reference

Table 21. GRADE evidence profile, Recommendation 19

**Question:** Sotrovimab compared to no sotrovimab for ambulatory persons with mild to moderate COVID-19 at high risk for progression to severe disease

*Last updated 6/16/2021; last reviewed 9/19/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>№ of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td><strong>Mortality (follow up: 29 days)</strong></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td><strong>Hospitalization (&gt;24 hours for any cause) (follow up: 29 days)</strong></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td><strong>Progression to severe or critical disease (follow up: 29 days)</strong></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td><strong>Serious adverse events (follow up: 29 days)</strong></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.
Risk of bias: Study limitations
Inconsistency: Unexplained heterogeneity across study findings
Indirectness: Applicability or generalizability to the research question
Imprecision: The confidence in the estimate of an effect to support a particular decision
Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.
CI: Confidence interval; RR: Risk ratio

Explanations
a. Small number of events; fragility present
b. RR estimated by using continuity correction of 0.5.
c. As the RR 95% CI is wide due to sparse data, absolute risk difference recalculated independently and not based on RR.
d. COVID-19 related hospitalizations is a surrogate for ICU admission, mechanical ventilation and death. Not rated down for indirectness.

Disclaimer: Provisional evidence rating based on preliminary evidence from non-peer reviewed publication.

Reference
Table 22. GRADE evidence profile

**Question:** Bamlanivimab compared to no bamlanivimab for non-hospitalized persons with COVID-19

**Last updated 1/29/2021; last reviewed 9/19/2021**

<table>
<thead>
<tr>
<th></th>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>№ of patients</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Hospitalization (including ED visits) with COVID-19 (follow up: 29 days)</td>
<td></td>
<td>5/309 (1.6%)</td>
<td>9/143 (6.3%)</td>
<td>RR 0.26 (0.09 to 0.75)</td>
<td>47 fewer per 1,000 (from 57 fewer to 16 fewer)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>309</td>
<td>143</td>
<td>-</td>
<td>MD 0.49 lower (0.87 lower to 0.11 lower)</td>
</tr>
<tr>
<td>Viral clearance (follow up: 3 days; assessed with: change from baseline in SARS-CoV-2 viral load)</td>
<td></td>
<td>309</td>
<td>143</td>
<td>-</td>
<td>MD 0.22 lower (0.6 lower to 0.15 higher)</td>
</tr>
<tr>
<td>Viral clearance (follow up: 11 days; assessed with: change from baseline in SARS-CoV-2 viral load)</td>
<td></td>
<td>309</td>
<td>143</td>
<td>-</td>
<td>RR 0.15 (0.01 to 3.78)</td>
</tr>
<tr>
<td>Serious adverse events (upper abdominal pain)</td>
<td></td>
<td>0/309 (0.0%)</td>
<td>1/143 (0.7%)</td>
<td>RR 1.15 (0.01 to 10.67)</td>
<td>6 more per 1,000 (from 5 more to 11 more)</td>
</tr>
<tr>
<td>Infusion-related adverse events</td>
<td></td>
<td>7/309 (2.3%)</td>
<td>2/143 (1.4%)</td>
<td>RR 1.62 (0.34 to 7.70)</td>
<td>9 more per 1,000 (from 9 fewer to 94 more)</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.
Risk of bias: Study limitations
Inconsistency: Unexplained heterogeneity across study findings
Indirectness: Applicability or generalizability to the research question
Imprecision: The confidence in the estimate of an effect to support a particular decision
Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; RR: Risk ratio; MD: Mean difference

Explanations
a. Uncertain that the treatment was provided in enough participants at risk of developing severe disease to be representative of the general population.
b. The 95% CI may not include a meaningful difference. Few events reported suggests fragility of the estimate.
c. Measure of viral clearance is a surrogate outcome for hospital admission, need for intensive care, intubation and death.
d. The 95% CI includes values that suggest either an increase or decrease in harm. Few events reported suggests fragility of the estimate.

Reference
Table 23. GRADE evidence profile, Recommendation 20

**Question:** Bamlanivimab monotherapy compared to no bamlanivimab monotherapy for patients hospitalized for COVID-19

Last updated 1/29/2021; last reviewed 9/19/2021

<table>
<thead>
<tr>
<th>Nr of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious a</td>
<td>none</td>
<td></td>
</tr>
</tbody>
</table>

### Mortality

<table>
<thead>
<tr>
<th>Nr of patients</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>bamlanivimab</td>
<td>9/163 (5.5%)</td>
<td>5/151 (3.3%)</td>
<td>HR 2.00 (0.67 to 5.99)</td>
</tr>
<tr>
<td>no bamlanivimab</td>
<td></td>
<td></td>
<td>32 more per 1,000 (from 11 fewer to 150 more)</td>
</tr>
</tbody>
</table>

Certainty: MODERATE

Importance: CRITICAL

### Clinical improvement at day 5 (assessed with: pulmonary ordinal outcome [scale 1-7; 1 = least severe])

<table>
<thead>
<tr>
<th>Nr of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>161</td>
<td>OR 0.85 (0.56 to 1.29)</td>
<td>MODERATE</td>
<td>CRITICAL</td>
</tr>
</tbody>
</table>

### Serious adverse events (follow up: 5 days)

<table>
<thead>
<tr>
<th>Nr of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/163 (2.5%)</td>
<td>RR 1.85 (0.34 to 9.97)</td>
<td>MODERATE</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>2/151 (1.3%)</td>
<td>11 more per 1,000 (from 9 fewer to 119 more)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Serious adverse events (follow up: 28 days)

<table>
<thead>
<tr>
<th>Nr of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>5/163 (3.1%)</td>
<td>RR 0.93 (0.27 to 3.14)</td>
<td>MODERATE</td>
<td>IMPORTANT</td>
</tr>
<tr>
<td>5/151 (3.3%)</td>
<td>2 fewer per 1,000 (from 24 fewer to 71 more)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Infusion-related adverse events

<table>
<thead>
<tr>
<th>Nr of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>23/163 (14.1%)</td>
<td>OR 1.64 (0.79 to 3.44)</td>
<td>MODERATE</td>
<td>IMPORTANT</td>
</tr>
<tr>
<td>21/151 (13.9%)</td>
<td>70 more per 1,000 (from 26 fewer to 218 more)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

Last updated February 3, 2022 and posted online at www.idsociety.org/COVID19guidelines.
Please check website for most updated version of these guidelines.
Risk of bias: Study limitations
Inconsistency: Unexplained heterogeneity across study findings
Indirectness: Applicability or generalizability to the research question
Imprecision: The confidence in the estimate of an effect to support a particular decision
Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.
CI: Confidence interval; HR: Hazard Ratio; OR: Odds ratio; RR: Risk ratio

Explanations
a. The 95% CI includes the potential for both appreciable benefit as well as the potential for harm. Few events reported do not meet the optimal information size and suggest fragility of the estimate
b. Study-provided odds ratio adjusted for baseline ordinal category and trial pharmacy.
c. Study-provided odds ratio adjusted for the trial pharmacy.

Reference
Janus Kinase Inhibitors

Baricitinib

Section last reviewed and updated 10/11/2021

Last literature search conducted 9/30/2021

Recommendation 21: Among hospitalized adults with severe* COVID-19 having elevated inflammatory markers, the IDSA panel suggests baricitinib rather than no baricitinib.
(Conditional recommendation, Moderate certainty of evidence)

Remarks:

- Baricitinib 4 mg per day (or appropriate renal dosing) up to 14 days or until discharge from hospital.
- Baricitinib appears to demonstrate the most benefit in those with severe COVID-19 on high-flow oxygen/non-invasive ventilation at baseline.
- Limited additional data suggest a mortality reduction even among patients requiring mechanical ventilation.
- Patients who receive baricitinib for treatment of COVID-19 should not receive tocilizumab or other IL-6 inhibitors.

Recommendation 22: Among hospitalized patients with severe* COVID-19 who cannot receive a corticosteroid (which is standard of care) because of a contraindication, the IDSA guideline panel suggests use of baricitinib with remdesivir rather than remdesivir alone.
(Conditional recommendation, Low certainty of evidence)

• Remark: Baricitinib 4 mg daily dose for 14 days or until hospital discharge. The benefits of baricitinib plus remdesivir for persons on mechanical ventilation are uncertain.

*Severe illness is defined as patients with SpO2 ≤94% on room air, including patients on supplemental oxygen, oxygen through a high-flow device, or non-invasive ventilation.
Why is baricitinib considered for treatment?

Baricitinib, a selective Janus kinase 1 and 2 (JAK1 and JAK2, respectively) inhibitor currently FDA-approved for the treatment of RA, is being investigated in multiple studies for treatment of COVID-19. The proposed benefits of baricitinib in the management of COVID-19 may be two-fold as it has both anti-inflammatory and potential antiviral activity [170]. Janus kinase (JAK) mediates cytokine signaling, which contributes to inflammation; JAK inhibitors, therefore, may decrease cytokine-mediated inflammation. Baricitinib inhibits host intracellular membrane proteins AP2-associated protein kinase 1 (AAK1) and also binds cyclin G-associated kinase (GAK), both thought to play a role in receptor mediated endocytosis of many viruses including Ebola, dengue, hepatitis C, and SARS-CoV-2 [171-173]. Baricitinib has been evaluated in people with COVID-19 in both randomized and non-randomized studies [174-178].

Based on experience in clinical trials for RA, baricitinib has been associated with an increased risk of adverse effects including infections (especially upper respiratory tract infections), thrombosis, lymphopenia, anemia, increases in lipids, elevations in liver enzymes, and elevations in creatinine phosphokinase [170]. In clinical trials for RA, baricitinib was associated with a numerically higher risk of upper respiratory tract infections and herpes simplex and herpes zoster infections compared with placebo [179]. Opportunistic infections such as herpes simplex, herpes zoster, and tuberculosis [180, 181] have been reported in patients taking baricitinib. Many of these side effects appear to be dose related, with increased incidence in patients taking baricitinib 4 mg compared with 2 mg. Patients enrolled in Adaptive COVID-19 Treatment Trial (ACTT-2) and COV-BARRIER received baricitinib 4 mg daily for two weeks or until discharge, a shorter duration than those taking the drug for RA.

Patients with COVID-19 have been found to have abnormalities in coagulation parameters and might have an elevated risk of thrombosis [182]. Baricitinib receipt was associated with an increased incidence of thrombosis when compared with placebo receipt in clinical trials for its FDA approval for RA, especially at a higher dose of 4 mg daily [170]. During the 16-week treatment period in RA trials, venous thromboembolism (VTE) occurred in five patients treated with baricitinib 4 mg daily, compared with zero in the 2 mg daily and placebo groups. Arterial thrombosis occurred in two patients treated with baricitinib 4 mg, two patients...
treated with baricitinib 2 mg, and one patient on placebo. In ACTT-2, the percentage of patients reported to have VTE was numerically higher in the combination group (21 patients [4.1%] vs. 16 patients [3.1%]) although it was similar overall (absolute difference 1%, 95% CI -1.3 to 3.3) [183]. Of note, all patients in the trial were recommended to receive VTE prophylaxis if they had no contraindication. We do not have long-term data, especially on safety, development of the aforementioned adverse effects, and opportunistic infections from these two trials.

**Summary of the evidence**

**Baricitinib**

Our literature search identified one RCT that compared the use of baricitinib (4 mg daily dose up to 14 days) to placebo in hospitalized adults with severe COVID (NIAID OS: 4 – hospitalized, not requiring supplemental oxygen; 5 – hospitalized, requiring supplemental oxygen; or 6 – hospitalized, receiving non-invasive ventilation or high-flow oxygen devices) [178, 184]. In the COV-BARRIER trial, randomization was stratified by disease severity, age, region, and use of corticosteroids. Participants in both arms had ≥1 elevated inflammatory marker (CRP, d-dimer, LDH [lactate dehydrogenase], ferritin) and also received standard of care, which included corticosteroids in 79% and/or antivirals (e.g., remdesivir in 18.9%).

An additional presentation of baricitinib treatment for critically ill (OS-7) patients with COVID-19 pneumonia requiring invasive mechanical ventilation was identified that reported on the outcomes of mortality, need for invasive mechanical ventilation, days of hospitalization, and serious adverse events [185].

**Baricitinib without corticosteroids, with remdesivir**

Our literature search identified one RCT that reported on the use of baricitinib (4 mg daily dose) plus remdesivir in hospitalized patients with moderate and severe COVID-19 ([183]. This trial was conducted as the second stage of the ACTT-2, where subjects were randomized to receive combination therapy with baricitinib and remdesivir or remdesivir alone [183] (Table 26). Randomization was stratified by disease severity classified by an OS of clinical status (4+5 vs 6+7 [7 –patients with an ordinal scale of 6 (high-flow oxygen and non-invasive ventilation) or
7 (mechanical ventilation or ECMO). Mild to moderate disease was defined as patients with an ordinal scale of 4 (hospitalized, but not requiring supplemental oxygen) or 5 (requiring supplemental oxygen). The trial was initiated before corticosteroids were commonly used for severe COVID-19.

**Benefits**

**Baricitinib**

Treatment of hospitalized patients with severe COVID-19 with baricitinib rather than no baricitinib reduced 60-day mortality (HR: 0.62; 95% CI: 0.47 to 0.83; moderate CoE). The odds of COVID-19 disease progression trends toward a reduction in persons receiving treatment with baricitinib (OR: 0.85; 95% CI: 0.67, 1.08; moderate CoE).

Treatment of critically ill hospitalized patients with baricitinib rather than no baricitinib reduced 60-day mortality (HR 0.56; 95% CI: 0.33 to 0.97; low CoE). However, the sample size for this sub-study was only 101 participants.

**Baricitinib without corticosteroids, with remdesivir**

In ACTT-2, the combination of baricitinib and remdesivir showed a trend towards lower mortality (4.7% vs. 7.1%; rate ratio: 0.65; 95% CI 0.39, 1.09; moderate CoE). In patients stratified within the severe COVID-19 pneumonia group, defined as 6 or 7 on the ordinal scale, subjects who received baricitinib and remdesivir were more likely to experience clinical recovery (defined as a value of <4 on the ordinal scale) at day 28 (69.3% vs. 59.7%; rate ratio 1.29; 95% CI 1.00, 1.66; moderate CoE). The original stratification was altered as 40 subjects were misclassified at baseline; however, re-analysis of the original stratified data produced a similar result. Patients in the baricitinib arm were less likely to require initiation of mechanical ventilation or ECMO through day 29 (10% vs. 15.2%; RR: 0.66; 95% CI 0.46, 0.93; low CoE). In summary, it appeared that patients requiring supplemental oxygen or non-invasive ventilation at baseline benefitted most from baricitinib; the benefit was less clear in patients already on mechanical ventilation.

**Harms**
The risk of serious adverse events in hospitalized patients with severe or critical COVID-19 receiving baricitinib was not greater than those not receiving baricitinib (RR: 0.82; 95% CI: 0.65, 1.03; moderate CoE and RR 0.70; 95% CI: 0.50 to 0.97, moderate CoE, respectively).

In ACTT-2, patients receiving baricitinib and remdesivir had a lower risk of developing any serious adverse events through day 28 (16% vs. 21%; RR 0.76; 95% CI 0.59, 0.99; moderate CoE) whether or not thought to be related to the study drug. In this trial, the overall rate of new infections was lower in the baricitinib plus remdesivir group compared with remdesivir alone (30 patients [5.9%] versus 57 patients [11.2%]) [183]. However, patients who received concomitant glucocorticoids had a higher incidence of serious or non-serious infections as compared with those who did not: 25.1% and 5.5%, respectively. It was not specified what proportion of these patients in the study were in the baricitinib combination group versus the control group.

**Other considerations**

**Baricitinib**

The panel agreed on the overall certainty of evidence as moderate due to concerns with imprecision, as some outcomes have concerns with fragility. The guideline panel recognized the resource implications based on the dose and duration reported in the trial (4 mg daily up to 14 days). Additional data from a small study of hospitalized patients with critical COVID-19 suggest consistent benefits; however, shares concerns with imprecision based on a small sample. Based on that the panel broadened the population in the recommendation to hospitalized adults with severe COVID-19 having elevated inflammatory markers, including those on mechanical ventilation.

**Baricitinib without corticosteroids**

The panel agreed that the overall certainty of evidence was low due to concerns with risk of bias, driven by the use of data from post hoc analyses and imprecision, which recognized the limited events and concerns with fragility in the group who likely benefited most (those requiring supplemental oxygen or non-invasive ventilation). The guideline panel noted the
importance of suggesting baricitinib plus remdesivir as an option for persons unable to receive corticosteroids.

Conclusions and research needs for this recommendation

The guideline panel suggests baricitinib in addition to standard of care for patients hospitalized with severe COVID-19. The guideline panel suggests baricitinib with remdesivir for persons for whom corticosteroids are indicated but who cannot receive them due to a contraindication. Baricitinib plus remdesivir should be reserved for patients who cannot take corticosteroids because dexamethasone has been proven to reduce mortality in patients hospitalized with COVID-19 who require supplemental oxygen or mechanical ventilation and, for this reason, dexamethasone is recommended by the panel for this group. It is uncertain whether baricitinib plus remdesivir will have the same benefit as dexamethasone. As of the time of this narrative, there are no head-to-head trials evaluating either the combination of baricitinib plus tocilizumab or evaluating baricitinib compared to tocilizumab. Patients who received JAK inhibitors should not receive tocilizumab or other immunomodulators as no adequate evidence is available for its combined use.
Table 24. GRADE evidence profile, Recommendation 24

**Question:** Baricitinib compared to no baricitinib for hospitalized patients receiving standard of care for severe COVID-19

Last reviewed and updated 10/11/2021

### Certainty assessment

<table>
<thead>
<tr>
<th>Nº of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Nº of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>baricitinib</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>no baricitinib</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality (follow up: 60 days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious a</td>
<td>none</td>
<td>79/764 (10.3%)</td>
<td>116/761 (15.2%)</td>
<td>HR 0.62 (0.47 to 0.83)</td>
<td>55 fewer per 1,000 (from 78 fewer to 24 fewer)</td>
</tr>
<tr>
<td>Disease progression (follow up: 28 days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious b</td>
<td>none</td>
<td>212/764 (27.7%)</td>
<td>232/761 (30.5%)</td>
<td>OR 0.85 (0.67 to 1.08) c</td>
<td>33 fewer per 1,000 (from 78 fewer to 17 more)</td>
</tr>
<tr>
<td>Serious adverse events (follow up: 28 days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious a,d</td>
<td>none</td>
<td>110/750 (14.7%)</td>
<td>135/752 (18.0%)</td>
<td>RR 0.82 (0.65 to 1.03)</td>
<td>32 fewer per 1,000 (from 63 fewer to 5 more)</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

### Risk of bias:

- **Study limitations**
- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision
- **Publication bias:** Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; HR: Hazard Ratio; OR: Odds ratio; RR: Risk ratio

**Explanations**

- Few events suggest fragility of the estimate.
b. 95% CI cannot exclude no benefit.
c. Multiple imputation includes N=756 for placebo and N=762 for baricitinib.
d. 95% CI cannot exclude no harm.

References
Table 25. GRADE evidence profile, Recommendation 21

Question: Baricitinib compared to no baricitinib for critically ill (OS-7) patients with COVID-19 pneumonia requiring invasive mechanical ventilation

New evidence profile developed 10/11/2021

<table>
<thead>
<tr>
<th>Mortality (follow up: 60 days)</th>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>№ of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Invasive mechanical ventilation-free days (follow up: 60 days)</th>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>----------------------------------------------------------------</td>
<td></td>
<td>№ of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td>----------------------------------------------------------------</td>
<td></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Days of hospitalization (follow up: 60 days)</th>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>№ of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Serious adverse events (follow up: 28 days)</th>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>№ of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>

GRADE Working Group grades of evidence

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Risk of bias: Study limitations

- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision

Publication bias: Selective publication of studies
NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; HR: Hazard Ratio; MD: Mean difference; RR: Risk ratio

Explanations
a. Few number of events, does not meet optimal information size
b. Pooled mortality event data RR: 0.73 (95% CI: 0.50, 1.06) cannot exclude no meaningful benefit and therefore suggests fragility when compared with the HR.
c. 95% CI includes both the possibility of benefit and risk of harm
d. Adjusted for age (<65, >65) and region (U.S., rest of the world)
e. 95% CI cannot exclude no benefit

Reference
Table 26. GRADE evidence profile, Recommendation 22

**Question**: Baricitinib with remdesivir compared to remdesivir for hospitalized patients with COVID-19

*Last updated 5/16/2021; last reviewed 10/11/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>№ of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
<td>Indirectness</td>
</tr>
<tr>
<td>Mortality (follow up: 28 days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 ¹</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>

**Clinical recovery - hospitalized requiring supplemental O₂/receiving noninvasive ventilation or high-flow O₂ (ordinal 5+6) (assessed with: Ordinal scale <4)**

| 1 ¹ | randomized trials | serious b | not serious | not serious | serious c | none | 344/391 (88.0%) | 316/389 (81.2%) | RR 1.08 (1.02 to 1.15) | 65 more per 1,000 (from 16 more to 122 more) | ⚫⚫ | CRITICAL |

**Clinical recovery - receiving noninvasive ventilation or high-flow O₂, invasive mechanical ventilation or ECMO (ordinal 6+7; stratified) (assessed with: Ordinal scale <4)**

| 1 ¹ | randomized trials | not serious | not serious | not serious | serious e | none | 122/176 (69.3%) | 114/191 (59.7%) | HR 1.29 (1.00 to 1.66) | 93 more per 1,000 (from 0 fewer to 182 more) | ⚫⚫ | CRITICAL |

**New use of mechanical ventilation or ECMO (follow up: 29 days)**

| 1 ¹ | randomized trials | serious f | not serious | not serious | serious g | none | 46/461 (10.0%) | 70/461 (15.2%) | RR 0.66 (0.46 to 0.93) | 52 fewer per 1,000 (from 82 fewer to 11 fewer) | ⚫⚫ | CRITICAL |

**Serious adverse events (follow up: 28 days)**
<table>
<thead>
<tr>
<th>Nº of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Nº of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious ²</td>
<td>none</td>
<td>81/507 (16.0%)</td>
<td>RR 0.76 (0.59 to 0.99)</td>
<td>MODERATE</td>
<td>CRITICAL</td>
</tr>
</tbody>
</table>

GRADE Working Group grades of evidence

- **High certainty**: We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty**: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty**: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty**: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.

**Risk of bias:** Study limitations

- Inconsistency: Unexplained heterogeneity across study findings
- Indirectness: Applicability or generalizability to the research question
- Imprecision: The confidence in the estimate of an effect to support a particular decision
- Publication bias: Selective publication of studies

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; RR: Risk ratio; HR: Hazard Ratio; OR: Odds ratio; RDV: Remdesivir

**Explanations**

- a. 95% CI includes substantial benefits as well as substantial harms
- b. Non-stratified subgroup post hoc analysis.
- c. Lower boundary of the 95% CI crosses our threshold for a meaningful difference.
- d. Data from table S6. Although described as "analysis as randomized" in this stratum of severe COVID-19 patients, the analysis included moving patients from a baseline of "moderate" to "severe" post hoc (19 in the baricitinib group vs 21 in the placebo group), thus altering the original stratification. However, re-analysis using original strata data (ordinal scale 6 and 7 from table 2) and 28-day cutoff (as a binary, non-time to event analysis) produce a similar result (RR 1.2, 95% CI 1.005 to 1.43). Not rated down for post hoc analysis concerns.
- e. 95% CI includes substantial benefits as well as no effect
- g. Less than 300 events; concern for fragility
- h. SAEs in 5 or more participants in any preferred term by treatment group. 6/507 were thought related to study drug in the baricitinib group; 5/509 were thought to be related to the study drug in the placebo group.

**Reference**

Tofacitinib

Section last reviewed and updated 8/21/2021

Last literature search conducted 7/31/2021

Recommendation 23: Among hospitalized adults with severe* COVID-19, but not on non-invasive or invasive mechanical ventilation, the IDSA panel suggests tofacitinib rather than no tofacitinib. (Conditional recommendation, Low certainty of evidence)

Remarks:

- Tofacitinib appears to demonstrate the most benefit in those with severe COVID-19 on supplemental or high-flow oxygen.
- Patients treated with tofacitinib should be on at least prophylactic dose anticoagulant.
- Patients who receive tofacitinib should not receive tocilizumab or other IL-6 inhibitor for treatment of COVID-19.
- The STOP-COVID Trial did not include immunocompromised patients.

*Severe illness is defined as patients with SpO2 ≤94% on room air, including patients on supplemental oxygen or oxygen through a high-flow device.

Why is tofacitinib considered for treatment?

Tofacitinib is a JAK inhibitor that preferentially inhibits JAK-1 and JAK-3 though it is active on all other JAK isoforms. It is FDA-approved for moderate to severe RA, active psoriatic arthritis, and moderate to severe ulcerative colitis. Like baricitinib, it is expected that JAK inhibition leads to downstream suppression of cytokine production, thereby modulating the inflammatory cascade that results in systemic inflammation in patients with severe COVID-19. See baricitinib section (above) for additional rationale on considerations for treatment.
Summary of the evidence

Our literature search identified one RCT that compared the use of tofacitinib 10 mg every 12 hours for up to 14 days or placebo [186]. Patients included were those who had laboratory-confirmed SARS-CoV-2 infection and evidence of COVID-19 pneumonia on imaging and who were hospitalized for less than 72 hours. Patients in this study could not be receiving non-invasive ventilation, mechanical ventilation, or ECMO at baseline. Additionally, patients with a history of or current thrombosis, personal or first-degree family history of blood clotting disorders, immunosuppression, any active cancer, or those with certain cytopenias were excluded from this trial. Patients who received other potent immunosuppressants, or other biologic agents were excluded, while the use of glucocorticoids for the management of COVID-19 was permitted. A composite outcome of death at day 28 or respiratory failure (defined as progression to NIAID ordinal scale 6, 7, or 8) was the primary outcome.

Benefits

Treatment of hospitalized patients with COVID-19 pneumonia with tofacitinib resulted in a lower risk of the composite outcome of death or respiratory failure compared to no tofacitinib (RR: 0.63; 95% CI: 0.41, 0.97; low CoE). However, results failed to show or to exclude a beneficial or detrimental effect on mortality alone (RR: 0.49; 95% CI: 0.15, 1.63; low CoE) or progression to mechanical ventilation or ECMO by day 28 (RR: 0.25; 95% CI: 0.03, 2.20; low CoE).

Harms

Patients who received tofacitinib experienced more serious adverse events; however, this may not be meaningfully different from those that received placebo (RR: 1.18; 95%CI: 0.64, 2.15; low CoE). Use of tofacitinib for other indications has shown an increase in thrombotic events which prompted a black box warning by the FDA [187, 188]. As COVID-19 infection itself increases the risk for VTE events; it is important to note that the patients studied were either on prophylactic or full dose anticoagulation during treatment with tofacitinib.
Tofacitinib carries four black boxed warnings for its labeled indications including a warning for 1) serious infections including tuberculosis, invasive fungal infections, bacterial, viral and other opportunistic pathogens; 2) mortality; 3) thrombosis; and 4) lymphoma and other malignancies, including an increased rate of EBV-mediated post-transplant lymphoproliferative disorder [187-190].

Other considerations

The panel agreed that the overall certainty of evidence was low due to concerns of imprecision, which recognized the limited number of events and concerns about fragility of the results in the group who likely would benefit the most (those requiring supplemental oxygen or oxygen through a high-flow device).

Conclusions and research needs for this recommendation

The guideline panel suggests tofacitinib in addition to standard of care for patient hospitalized for severe COVID-19. Due to the increased risk of VTE with treatment with tofacitinib, patients should receive at least prophylactic doses of anticoagulants during their hospital stay. Patients who received JAK inhibitors should not receive tocilizumab or other immunomodulators as no adequate evidence is available for its combined use.
Table 27. GRADE evidence profile, Recommendation 23

**Question:** Tofacitinib compared to no tofacitinib for hospitalized patients with COVID-19

*New evidence profile developed 8/21/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td>Death or respiratory failure (follow-up: 28 days)</td>
<td>1 (^1) randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Mortality (follow-up: 28 days)</td>
<td>1 (^1) randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Progression to mechanical ventilation or ECMO (follow-up: 28 days)</td>
<td>1 (^1) randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Serious adverse events (follow-up: 28 days)</td>
<td>1 (^1) randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>

GRADE Working Group grades of evidence

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

Risk of bias: Study limitations

- Inconsistency: Unexplained heterogeneity across study findings
- Indirectness: Applicability or generalizability to the research question
- Imprecision: The confidence in the estimate of an effect to support a particular decision
- Publication bias: Selective publication of studies
NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; ECMO: Extracorporeal mechanical oxygenation; RR: Risk ratio

Explanations
a. Small number of events; fragility present.
   b. Upper boundary of the 95% CI crosses a threshold of meaningful effect.
   c. 95% CI cannot exclude no harm.
   d. One DVT was observed in the tofacitinib group vs zero in the placebo group.

Reference
Ivermectin

Section last reviewed and updated 8/10/2021

Last literature search conducted 7/31/2021

Recommendation 24: In hospitalized patients with COVID-19, the IDSA panel suggests against ivermectin outside of the context of a clinical trial. (Conditional recommendation, very low certainty of evidence)

Recommendation 25: In ambulatory persons with COVID-19, the IDSA panel suggests against ivermectin outside of the context of a clinical trial. (Conditional recommendation, very low certainty of evidence)

Why is ivermectin considered for treatment?

Ivermectin is an anti-parasitic agent that is FDA-approved for onchocerciasis and strongyloidiasis and is used off-label for the treatment of many parasitic infections. Although it has in vitro activity against some viruses, including SARS-CoV-2, it has no proven therapeutic utility. In vitro activity against SARS-CoV-2 [191] requires concentrations considerably higher than those achieved in human plasma and lung tissue to reach the in vitro IC50 [192]. Ivermectin has been shown to have anti-inflammatory effects in in vitro and in vivo studies hence hypothesized to have a mechanism beyond its anti-viral effects in the treatment of COVID-19 [193, 194].

Since ivermectin is generally well tolerated, it was empirically evaluated in uncontrolled studies for COVID-19, alone and in combination with other off-label medications.

Summary of the evidence

Our search identified 15 studies in patients with COVID-19 with ages ranging between 8 and 86 years that reported on the outcomes of mortality, symptom resolution, viral clearance, and adverse events, and informed the evidence review for inpatient and outpatient therapy.
Eligible studies compared treatment with ivermectin against a placebo or standard of care. Studies comparing ivermectin to a non-placebo, active comparison (i.e., a different agent considered a possible treatment for COVID-19 infection by clinicians) or that did not provide a comparison arm were not included in these analyses. Several studies did not meet eligibility for inclusion in this review. Four trials compared ivermectin to hydroxychloroquine (comparison to treatment with evidence of harm) [213-215]; two trials examined ivermectin as prophylactic treatment [216, 217]; and three trials did not provide study data in a peer-reviewed, published or pre-print manuscript [215, 218, 219].

The studies that informed the recommendations for hospitalized patients included 10 RCTs [195-197, 199, 200, 205-209] and two non-randomized studies [198, 201]. Eight RCTs [197, 199, 202-204, 210-212] informed the recommendation for ambulatory persons. Each of them compared an active treatment arm of ivermectin to an inactive comparison (e.g., standard of care with or without placebo).

The evidence informing the recommendations for treating hospitalized and ambulatory persons with ivermectin reported on the use of a range of doses (100 mcg/kg/day to 400 mcg/kg/day) and durations (one day up to seven days). Among studies reporting on hospitalized patients, substantial heterogeneity was observed, introduced by one study (Supplementary Figure s9c) [195]. Ahmed 2021 treated patients with ivermectin for a duration of five days, rather than one day as used by the remaining studies. This may explain the heterogeneity between studies; however, excluding Ahmed 2021, any meaningful reduction in viral clearance was still not demonstrated by the summary estimate (Supplementary Figure s9d). Heterogeneity was not observed for other outcomes reported for hospitalized or ambulatory persons.

Among the RCTs, the risk of bias was high in two trials because of unsuccessful randomization into treatment and control groups. Hashim et al (2020) [199] inadequately randomized participants by allocating them to respective treatment arms on odd and even days, as well as assigning all critically ill patients to the ivermectin arm, and Podder et al (2020) [200] allocated participants based on odd or even registration numbers. In addition, across many RCTs, there were concerns due to lack of blinding of study personnel, which may lead to
over- or under-estimates of treatment effects, particularly for subjective outcomes (e.g., symptom resolution, adverse events).

**Benefits**

**Inpatients**

The evidence from RCTs failed to show a reduction or increase in mortality among persons with COVID-19 (RR: 0.66; 95% CI: 0.31, 1.42; low CoE). In addition, the evidence from non-randomized studies cannot exclude no meaningful reduction in mortality among persons treated with ivermectin with COVID-19 (RR: 0.60; 95% CI: 0.37, 0.97, very low CoE). Persons receiving treatment with ivermectin rather than no ivermectin failed to demonstrate a beneficial or detrimental effect on symptom resolution or viral clearance at day seven (RR: 1.07; 95% CI: 0.69, 1.65; very low CoE and RR: 1.25; 95% CI: 0.72, 2.15; very low CoE, respectively).

**Outpatients**

The evidence is very uncertain, but ivermectin may reduce the time to recovery among outpatients with COVID-19 (mean difference: 3.46 days fewer; 95% CI: 5.40 to 1.52 days fewer; very low CoE). However, treatment with ivermectin failed to demonstrate a beneficial or detrimental effect on mortality, avoidance of progression to severe disease, or viral clearance at day seven (RR: 0.48; 95% CI: 0.13, 1.76; very low CoE, RR: 0.64; 95% CI: 0.26, 1.54; very low CoE, and RR: 1.13; 95% CI: 0.79, 1.62; very low CoE, respectively).

**Harms**

In doses typically used for the treatment of parasitic infections, ivermectin is well tolerated. We are unable to exclude the potential for adverse events in hospitalized and serious adverse events in non-hospitalized persons with COVID-19 treated with ivermectin rather than no ivermectin, (RR: 0.80; 95% CI: 0.39, 1.64; low CoE and RR: 0.99; 95% CI: 0.14, 6.96; low CoE, respectively).

**Other considerations**
The panel determined the certainty of evidence of treatment of ivermectin for hospitalized and non-hospitalized patients to be very low due to concerns with risk of bias (i.e., study limitations) and imprecision. In addition, there were concerns about publication bias, as the available evidence consisted mostly of positive trials of smaller size. The guideline panel made a conditional recommendation against treatment of COVID-19 with ivermectin outside of the context of a clinical trial for both patients with COVID-19 hospitalized or in the outpatient setting.

Conclusions and research needs for this recommendation

The guideline panel suggests against ivermectin for the treatment of hospitalized patients with COVID-19, unless in the context of a clinical trial. The guideline panel suggests against ivermectin for the treatment of outpatients with COVID-19, unless in the context of a clinical trial. Well-designed, adequately powered, and well-executed clinical trials are needed to inform decisions on treating COVID-19 with ivermectin (Supplementary Table s2).
Table 28. GRADE evidence profile, Recommendation 24
Question: Ivermectin compared to no ivermectin for patients hospitalized with COVID-19

Last reviewed and updated 8/10/2021

<table>
<thead>
<tr>
<th>№ of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
</table>

Mortality (RCTs)

| 7 | randomized trials | not serious | not serious | very serious a | none | 10/337 (3.0%) | 16/265 (6.0%) | RR 0.66 (0.31 to 1.42) | 21 fewer per 1,000 (from 42 fewer to 25 more) | ⬤⬤◯◯ | CRITICAL |

Mortality (NRS)

| 2 | observational studies | serious b | not serious | not serious | serious a | none | 26/189 (13.8%) | 29/178 (16.3%) | RR 0.60 (0.37 to 0.97) | 65 fewer per 1,000 (from 103 fewer to 5 fewer) | ⬤◯◯◯ | CRITICAL |

Symptom resolution (follow-up: 7 days)

| 1 | randomized trials | serious c | not serious | not serious | very serious a | none | 16/25 (64.0%) | 15/25 (60.0%) | RR 1.07 (0.69 to 1.65) | 42 more per 1,000 (from 186 fewer to 390 more) | ⬤◯◯◯ | CRITICAL |

Viral clearance at day 7 (RCTs) (follow-up: range 7 days to 29 days)

| 5 | randomized trials | serious d | serious e | serious f | very serious a | none | 75/161 (46.6%) | 40/104 (38.5%) | RR 1.25 (0.72 to 2.15) | 96 more per 1,000 (from 108 fewer to 442 more) | ⬤◯◯◯ | IMPORTANT |

Adverse events (follow-up: 28 days)

| 3 | randomized trials | not serious | not serious | not serious | very serious a | none | 13/69 (18.8%) | 7/31 (22.6%) | RR 0.80 (0.39 to 1.64) | 45 fewer per 1,000 (from 138 fewer to 145 more) | ⬤◯◯◯ | IMPORTANT |

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
**Risk of bias:** Study limitations  
**Inconsistency:** Unexplained heterogeneity across study findings  
**Indirectness:** Applicability or generalizability to the research question  
**Imprecision:** The confidence in the estimate of an effect to support a particular decision  
**Publication bias:** Selective publication of studies  

**NB:** Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

**CI:** Confidence interval; **RR:** Risk ratio

**Explanations**

a. The 95% CI includes the potential for both appreciable benefit as well as the potential for harm. Few events reported do not meet the optimal information size and suggest fragility of the estimate.

b. Concerns with unmeasured and residual confounding. Gorial 2020 single arm with historical control. Hashim 2020 used even vs. odd days to place subjects into treatment groups with critical patients not included in the placebo group. In Rajter, corticosteroids were used in 19.6% of usual care patients vs. 39.8% of ivermectin patients.

c. Open-label trial may lead to bias with measurement of subjective outcomes.

d. Podder 2020 assigns participants based on odd or even registration numbers, also, 20 patients were excluded following randomization without sensitivity analysis to explore imbalance across treatment arms.

e. Substantial heterogeneity observed ($I^2=72\%$). Possibly explained by the longer duration of treatment (5 days compared to 1 day) in Ahmed 2021.

f. Viral clearance is a surrogate for clinical improvement, which is an important endpoint for the management of COVID-19.

**References**


5. Mohan A, Tiwari P, Suri T, Mittal S, Patel AA, Jain A. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial. Research Square 2021: Available at: [https://doi.org/10.21203/rs.3.rs-191648/v1](https://doi.org/10.21203/rs.3.rs-191648/v1) [Preprint 2 February 2021].


Table 29. GRADE evidence profile, Recommendation 25

**Question:** Ivermectin compared to no ivermectin for ambulatory persons for management of COVID-19

**Last reviewed and updated 8/10/2021**

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ivermectin</td>
<td>no ivermectin</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
</tr>
</tbody>
</table>

**Mortality**

<table>
<thead>
<tr>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>randomized trials</td>
<td>serious a</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious b</td>
<td>none</td>
<td>4/815 (0.5%)</td>
<td>11/816 (1.3%)</td>
<td>RR 0.48 (0.13 to 1.76)</td>
<td>7 fewer per 1,000 (from 12 fewer to 10 more)</td>
<td>VERY LOW</td>
</tr>
</tbody>
</table>

**Progression to severe disease (assessed with: need for invasive ventilation)**

<table>
<thead>
<tr>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>randomized trials</td>
<td>serious c</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious b</td>
<td>none</td>
<td>9/565(1.6%)</td>
<td>15/566 (2.7%)</td>
<td>RR 0.64 (0.26 to 1.54)</td>
<td>10 fewer per 1,000 (from 20 fewer to 14 more)</td>
<td>VERY LOW</td>
</tr>
</tbody>
</table>

**Viral clearance at day 7 (RCTs) (follow-up: range 6 days to 29 days)**

<table>
<thead>
<tr>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>randomized trials</td>
<td>serious c</td>
<td>not serious</td>
<td>serious d,e</td>
<td>very serious b</td>
<td>none</td>
<td>72/164 (43.9%)</td>
<td>61/161 (37.9%)</td>
<td>RR 1.13 (0.79 to 1.62)</td>
<td>49 more per 1,000 (from 80 fewer to 235 more)</td>
<td>VERY LOW</td>
</tr>
</tbody>
</table>

**Time to recovery (assessed with: days)**

<table>
<thead>
<tr>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>randomized trials</td>
<td>serious c</td>
<td>serious f</td>
<td>not serious</td>
<td>serious h</td>
<td>none</td>
<td>448</td>
<td>446</td>
<td>-</td>
<td>MD 3.46 days fewer (5.4 fewer to 1.52 fewer)</td>
<td>VERY LOW</td>
</tr>
</tbody>
</table>

**Serious adverse events (respiratory failure, sepsis, multiorgan failure, etc.)**

<table>
<thead>
<tr>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Relative (95% CI)</th>
<th>Absolute (95% CI)</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious i</td>
<td>none</td>
<td>2/200 (1.0%)</td>
<td>2/198 (1.0%)</td>
<td>RR 0.99 (0.14 to 6.96)</td>
<td>0 fewer per 1,000 (from 9 fewer to 60 more)</td>
<td>LOW</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
**Risk of bias:** Study limitations

**Inconsistency:** Unexplained heterogeneity across study findings

**Indirectness:** Applicability or generalizability to the research question

**Imprecision:** The confidence in the estimate of an effect to support a particular decision

**Publication bias:** Selective publication of studies

*NB:* Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

**CI:** Confidence interval; **RR:** Risk ratio; **MD:** Mean difference

**Explanations**

a. Concerns with unmeasured and residual confounding. Gorial 2020 single arm with historical control. Hashim 2020 used even vs. odd days to place subjects into treatment groups with critical patients not included in the placebo group. In Rajtal, corticosteroids were used in 19.6% of usual care patients vs. 39.8% of ivermectin patients.

b. The 95% CI includes the potential for both appreciable benefit as well as the potential for harm. Few events reported do not meet the optimal information size and suggest fragility of the estimate.

c. Open-label trial may lead to bias with measurement of subjective outcomes.

d. Viral clearance is a surrogate for clinical improvement, such as hospitalization, need for ICU care and mechanical ventilation.

e. Ravikirti 2021 reported viral clearance at day 6.

f. High heterogeneity I²=96

g. Ivermectin was combined with doxycycline.

h. Number of events is less than the optimal information size, which may suggest fragility in the estimate of effect.

i. The 95% CI cannot exclude the potential of increased SAEs in the treatment arm. Few events suggest fragility in the estimate.

**References**


Fluvoxamine

Section last reviewed and updated 11/8/2021

Last literature search conducted 10/31/2021

Recommendation 26: Among ambulatory patients with COVID-19, the IDSA guideline panel recommends fluvoxamine only in the context of a clinical trial. (Knowledge gap)

Why is fluvoxamine considered for treatment?

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which is currently FDA-approved for the treatment of obsessive-compulsive disorder. SSRIs have been shown to have affinity for Sigma-1 receptors, which have been demonstrated to modulate cytokine levels in animal models of septic shock [220]. Additionally, pharmacologic agents that act at Sigma-1 receptors have demonstrated in vitro activity against SARS-CoV-2 [221]. Amongst the SSRIs, fluvoxamine has been shown to have the high affinity for these receptors making it a potential repurposed drug option for the management of COVID-19 [222]. SSRIs like fluvoxamine may decrease uptake of serotonin from platelets during thrombosis, resulting in decreased neutrophil recruitment and platelet aggregation, which may be helpful in the early stages of COVID-19 [223, 224].

Summary of the evidence

Our search identified two RCTs that reported on ambulatory patients with SARS-CoV-2 infection [225, 226]. Patients in these studies were randomized to fluvoxamine or placebo/usual care. Both trials included symptomatic outpatients who tested positive for SARS-CoV-2 infection within seven days. Reis included patients who were at high risk for severe infection and utilized a composite primary outcome of hospitalization or emergency room visit lasting greater than six hours [226]. Additional outcomes reported in the two trials included mortality, hospitalization, emergency room visit lasting >6 hours, progression to oxygen saturation <92%, viral clearance, and serious adverse events.
Benefits

Outpatients

Among symptomatic ambulatory patients with COVID-19, fluvoxamine failed to demonstrate or to exclude a beneficial effect on mortality at 28 days compared to no fluvoxamine (RR: 0.69; 95% CI: 0.38, 1.27; low CoE). Fluvoxamine showed a reduction of the composite outcome of hospitalizations, emergency room visits lasting >6 hours, or oxygen saturation <92% (RR: 0.64; 0.50, 0.84; low CoE). When evaluating the effect on hospitalizations only, there was a trend toward less hospitalizations in fluvoxamine treated patients compared to those not receiving fluvoxamine (RR: 0.75; 95% CI: 0.57, 0.99; low CoE). Treatment with fluvoxamine failed to show a benefit in viral clearance at day seven (RR: 0.74; 0.52, 1.05; very low CoE).

Harms

The risk of serious adverse events in patients receiving fluvoxamine was not greater than those not receiving fluvoxamine (RR: 0.81; 95% CI: 0.59, 1.12; low CoE).

Other considerations

The panel agreed on the overall low certainty of evidence given the sparseness in mortality data and because upper boundary of the 95% confidence interval failed to exclude the risk of possible harms. The panel also had concerns about the generalizability/indirectness in the results surrounding hospitalization and emergency room visit >6 hours as one study [226] was partially conducted in patients with extended stays in emergency settings (mobile hospitals) to inform the primary endpoint, and it is unclear if resource constraints (possible contingency setting) may have affected the total number of events (i.e., emergency room stays and rates of hospitalization).

Conclusions and research needs for this recommendation
The guideline panel recommends fluvoxamine only in the context of a clinical trial to better delineate the effects of fluvoxamine on disease progression, such as need for hospital admission, ICU care, and ultimately, mortality.
## Table 30. GRADE evidence profile, Recommendation 26
**Question:** Fluvoxamine compared to no fluvoxamine for ambulatory patients with COVID-19

*New evidence profile developed 10/22/2021; last updated 11/8/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mortality (follow up: 28 days)</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2&lt;sup&gt;1,2&lt;/sup&gt; randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Hospitalization, emergency room visits (&gt;6 hours), or oxygen saturation &lt;92% (follow up: 28 days)</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2&lt;sup&gt;1,2&lt;/sup&gt; randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>serious&lt;sup&gt;c&lt;/sup&gt;</td>
<td>serious&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Hospitalization for COVID-19 (follow up: 28 days)</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2&lt;sup&gt;1,2&lt;/sup&gt; randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Viral clearance (follow up: 7 days)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1&lt;sup&gt;2&lt;/sup&gt; randomized trials</td>
<td>serious&lt;sup&gt;d&lt;/sup&gt;</td>
<td>not serious</td>
<td>serious&lt;sup&gt;e&lt;/sup&gt;</td>
<td>very serious&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2&lt;sup&gt;1,2&lt;/sup&gt; randomized trials</td>
<td>not serious</td>
<td>not serious</td>
<td>not serious</td>
<td>very serious&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

### GRADE Working Group grades of evidence
- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

---

<sup>a</sup> Last updated February 3, 2022 and posted online at www.idsociety.org/COVID19guidelines.
Please check website for most updated version of these guidelines.
Risk of bias: Study limitations
Inconsistency: Unexplained heterogeneity across study findings
Indirectness: Applicability or generalizability to the research question
Imprecision: The confidence in the estimate of an effect to support a particular decision
Publication bias: Selective publication of studies

NB: Certainty ratings may be derived from evidence that includes pre-print articles, which have not been peer reviewed or published.

CI: Confidence interval; RR: Risk ratio; MD: Mean difference

Explanations
a. Lenze et al had a 15-day follow-up period; Reis et al had a 28 day follow up period; Serious adverse events for Reis et al included only the non-mortal grade 4 and grade 3 treatment emergent adverse events.
b. 95% CI includes both the potential for benefit and the risk of harms; few events suggest fragility of the estimate.
c. Hospitalization, emergency room visits are surrogate marker for clinical deterioration leading to ICU care, ventilation and mortality. In addition, best supportive care may have been substantially different in Brazil at that time compared to the U.S. health system.
d. Data available for approximately 1/3 of study population per treatment group.
e. Viral clearance is a surrogate for clinical improvement, such as hospitalization, need for ICU care, and mechanical ventilation.
f. 95% CI cannot exclude the possibility of meaningful harm.

References
Nirmatrelvir/Ritonavir

**Section last reviewed and updated 12/29/2021**

**Last literature search conducted 12/28/2021**

**Resources:**
- University of Liverpool: COVID-19 drug interaction checker
- University of Liverpool: HIV drug interaction checker

**Recommendation 27 (NEW):** In ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests nirmatrelvir/ritonavir initiated within five days of symptom onset rather than no nirmatrelvir/ritonavir. (Conditional recommendation, Low certainty of evidence)

**Remarks:**
- Patients’ medications need to be screened for serious drug interactions (i.e., medication reconciliation). Patients on ritonavir- or cobicistat-containing HIV or HCV regimens should continue their treatment as indicated.
- Dosing based on renal function:
  - Estimated glomerular filtration rate (eGFR) > 60 ml/min: 300 mg nirmatrelvir/100 mg ritonavir every 12 hours for five days
  - eGFR ≤60 and ≥30 mL/min: 150 mg nirmatrelvir/100 mg ritonavir every 12 hours for five days
  - eGFR <30 mL/min: not recommended
- Patients with mild to moderate COVID-19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID-19 may also receive nirmatrelvir/ritonavir
- Options for treatment and management of ambulatory patients include nirmatrelvir/ritonavir, three-day treatment with remdesivir, molnupiravir, and neutralizing monoclonal antibodies. Patient-specific factors (e.g., symptom duration, renal function,
drug interactions) as well as product availability should drive decision-making regarding choice of agent. Data for combination treatment do not exist in this setting.

**Figure 7.** FDA EUA criteria for the use of nirmatrelvir/ritonavir co-packaged as Paxlovid™

| Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. |

**Reference**


**Why is nirmatrelvir/ritonavir considered for treatment?**

Nirmatrelvir is an inhibitor to the main protease (Mpro) of SARS-CoV-2; inhibition of this enzyme blocks viral replication. Nirmatrelvir is a substrate of the cytochrome P450 3A4 isoenzyme system and is co-packaged with an HIV-1 protease inhibitor, ritonavir, a potent inhibitor of cytochrome P450 3A4. Coadministration results in higher concentrations and a longer half-life of nirmatrelvir, allowing for every 12-hour dosing. The U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to nirmatrelvir/ritonavir on December 22, 2021, for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progression to severe COVID-19, including hospitalization or death [227].

**Summary of the evidence**

Our search identified one RCT reporting on treatment of mild to moderate COVID-19 in patients at high risk for progression to severe disease [227]. Data have not yet been published, but data to prepare this recommendation was extracted from the FDA EUA document.
**Benefits**

**Nirmatrelvir/ritonavir**

All-cause mortality through day 28 may be lower in patients receiving nirmatrelvir/ritonavir compared to no nirmatrelvir/ritonavir (RR: 0.04; 95% CI: 0.00, 0.69; low CoE). Patients treated with nirmatrelvir/ritonavir rather than no nirmatrelvir/ritonavir may have fewer COVID-19-related hospitalizations (RR: 0.12; 95% CI: 0.06, 0.26; low CoE). The composite endpoint of COVID-19-related hospitalizations or mortality was lower in patients receiving nirmatrelvir/ritonavir compared to no nirmatrelvir/ritonavir (RR: 0.12; 95% CI: 0.06, 0.25; low CoE).

**Harms**

**Nirmatrelvir/ritonavir**

Serious treatment-emergent adverse events were not reported in the FDA EUA.

Given co-formulation with ritonavir as a pharmacokinetic booster, there is potential for significant drug interactions. Contraindications exist between agents that can have their levels increased or decreased by nirmatrelvir and/or ritonavir and agents that can speed up the metabolism of the components of nirmatrelvir and/or ritonavir resulting in a loss of virologic response and possible resistance. These drug interactions can result in treatment failure or serious adverse events, which may lead to severe, life-threatening, or fatal events from greater exposures (i.e., higher levels) of concomitant medications. See [Figures 8 and 9](#).
Figure 8. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions ¹

- Alpha1-adrenoreceptor antagonist: alfuzosin
- Analgesics: pethidine, piroxicam, propoxyphene
- Antianginal: ranolazine
- Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine
- Anti-gout: colchicine
- Antipsychotics: lurasidone, pimozide, clozapine
- Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine
- HMG-CoA reductase inhibitors: lovastatin, simvastatin
- PDE5 inhibitor: sildenafil (Revatio®) when used for pulmonary arterial hypertension (PAH)
- Sedative/hypnotics: triazolam, oral midazolam

Reference

Figure 9. Nirmatrelvir/ritonavir is contraindicated with drugs that are potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance ¹

- Anticancer drugs: apalutamide
- Anticonvulsant: carbamazepine, phenobarbital, phenytoin
- Antimycobacterials: rifampin
- Herbal products: St. John’s Wort (Hypericum perforatum)

Reference
Less severe but clinically meaningful drug interactions may also occur when nirmatrelvir/ritonavir is co-administered with other agents. Levels of immunosuppressive agents such as tacrolimus, cyclosporine, or sirolimus can be increased when administered with nirmatrelvir/ritonavir. Hormonal contraceptives containing ethinyl estradiol may possibly have reduced effectiveness due to lowered ethinyl estradiol levels when administered with nirmatrelvir/ritonavir. Women of childbearing potential should be counseled to use a back-up, non-hormonal method of contraception.

Patients with moderate renal impairment (eGFR <60 and ≥30 mL/min) will need to be counseled that they will only take one 150 mg nirmatrelvir tablet (oval shape, pink) with one 100 mg of ritonavir twice daily, instead of the regular dose of two 150 mg nirmatrelvir (300 mg) tablets with one 100 mg of ritonavir twice daily. When dispensing the product for patients with moderate renal impairment, pharmacists are instructed to alter the blister cards to ensure that patients receive the correct dose. Pharmacists need to adhere to the specific instructions when dispensing the product according to instructions provided in the EUA [228]. Given the lack of renal function/eGFR data at the point of dispensing providers must specify the numeric dosage of each agent on the prescription to ensure the correct dose is provided to the patient at the point of dispensing. There are no data in patients with severe renal disease (eGFR ≤ 30 mL/min) and this medication is currently not recommended in patients with severe renal disease until more data on dosing in this population are available.

There are no dose adjustments needed for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment, however data are lacking in patients with Child-Pugh C and is therefore not recommended in this population.

According to the EUA, nirmatrelvir/ritonavir use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.

Other considerations

Nirmatrelvir/ritonavir

The panel agreed that the overall certainty of the evidence for the treatment of ambulatory patients was low; there are concerns with the inability to exclude potential risks to bias because of
limited availability of study details within the EUA, and there is imprecision due to a low number of events reported. The EUA did not report safety data (e.g., adverse events or severe adverse events) from the trial. The panel agreed that the benefits are likely to outweigh any potential harms in patients with COVID-19 who are at high risk of severe disease; however, recognized concerns with drug interactions must be considered.

The evidence confirms that using nirmatrelvir/ritonavir early in the disease process when viral loads are high confers maximum benefit. It is critical to make a rapid diagnosis and treat ambulatory patients with COVID-19 early in the disease course.

**Conclusions and research needs for this recommendation**

**Nirmatrelvir/ritonavir**

The guideline panel suggests the use of nirmatrelvir/ritonavir for ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease who are within five days of symptom onset. More data are needed on the potential adverse effects of this medication.
Table 31. GRADE evidence profile, Recommendation 27

Question: Nirmatrelvir/ritonavir compared to no nirmatrelvir/ritonavir for ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease

New evidence profile developed 12/23/2021; last updated 2/3/2022

<table>
<thead>
<tr>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>No nirmatrelvir/ritonavir</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
<td></td>
</tr>
<tr>
<td>nirmatrelvir/ritonavir</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All-cause mortality (follow-up: 28 days)

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>randomized trials</td>
<td>serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>0/1039 (0.0%)</td>
<td>12/1046 (1.1%)</td>
<td>RR 0.04 (0.00 to 0.68)</td>
<td>11 fewer per 1,000 (from 18 fewer to 5 fewer)</td>
</tr>
</tbody>
</table>

COVID-19-related hospitalizations (follow-up: 28 days)

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>randomized trials</td>
<td>serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>8/1039 (0.8%)</td>
<td>65/1046 (6.2%)</td>
<td>RR 0.12 (0.06 to 0.26)</td>
<td>55 fewer per 1,000 (from 58 fewer to 46 fewer)</td>
</tr>
</tbody>
</table>

COVID-19-related hospitalization or all-cause death (follow-up: 28 days)

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>randomized trials</td>
<td>serious</td>
<td>not serious</td>
<td>not serious</td>
<td>serious</td>
<td>none</td>
<td>8/1039 (0.8%)</td>
<td>66/1046 (6.3%)</td>
<td>RR 0.12 (0.06 to 0.25)</td>
<td>56 fewer per 1,000 (from 59 fewer to 47 fewer)</td>
</tr>
</tbody>
</table>

Serious adverse events - not reported

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
</table>

GRADE Working Group grades of evidence

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect

Risk of bias:

- **Study limitations**
- **Inconsistency:** Unexplained heterogeneity across study findings
- **Indirectness:** Applicability or generalizability to the research question
- **Imprecision:** The confidence in the estimate of an effect to support a particular decision

Publication bias:

- **Selective publication of studies**

NB: Certainty ratings are derived from evidence that has not been peer reviewed or published.

CI: Confidence interval; RR: Risk ratio
Explanations

a. Evidence profile based on information reported in FDA EUA and due to limited available study details, unable to exclude potential risks of bias. Concerns about selective outcome reporting as hospitalization or death from any cause and all-cause mortality are reported out of 10 outcome measures identified in the trial protocol, including SAEs and adverse events.

b. The primary SARS-CoV-2 variant across both treatment arms was Delta (98%), including clades 21J, 21A, and 21I.

c. Small number of events; fragility present

d. Recalculated due to zero events in the intervention arm.

e. COVID-19 related hospitalizations is a surrogate for ICU admission, mechanical ventilation and death. Not rated down.

Reference

Molnupiravir

Section last reviewed and updated 12/28/2021

Last literature search conducted 12/28/2021

Recommendation 28 (NEW): In ambulatory patients (≥18 years) with mild to moderate COVID-19 at high risk for progression to severe disease who have no other treatment options*, the IDSA guideline panel suggests molnupiravir initiated within five days of symptom onset rather than no molnupiravir. (Conditional recommendation, Low certainty of evidence)

Remarks:

- Patients who put a higher value on the putative mutagenesis, adverse events or reproductive concerns, and a lower value on the uncertain benefits, would reasonably decline molnupiravir.
- Molnupiravir 800 mg for five days.
- Patients with mild to moderate COVID-19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID-19 may also receive molnupiravir.
- Molnupiravir is not authorized under the FDA EUA for use in patients <18 years, because it may affect bone and cartilage growth.
- Molnupiravir is not recommended under the FDA EUA for use during pregnancy.
- Molnupiravir is not authorized under the FDA EUA for pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19, because benefit of treatment has not been observed in individuals when treatment is started after hospitalization due to COVID-19.

*Other options for treatment and management of ambulatory patients include nirmatrelvir/ritonavir, three-day treatment with remdesivir, and neutralizing monoclonal antibodies. Patient-specific factors (e.g., symptom duration, renal function, drug interactions) as well as product availability should drive decision-making regarding choice of agent. Data for combination treatment do not exist in this setting.
Figure 10. FDA EUA criteria for the use of molnupiravir 1

Molnupiravir may only be used for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high-risk for progression to severe COVID, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate.

Reference

Why is molnupiravir considered for treatment?

Molnupiravir is an oral antiviral that targets the genetic machinery that is responsible for SARS COV-2 replication. Molnupiravir is an oral pro-drug that is converted to β-D-N4-hydroxycytidine (NHC) which acts as a substrate for RNA-dependent RNA polymerase. After it is incorporated into the viral RNA, serial mutations develop, resulting in a virus that is less fit for ongoing viral replication. One phase I RCT evaluated the safety and tolerability of molnupiravir in healthy adults without COVID-19 [229]. The study reported molnupiravir to be well tolerated, with no increased reports of serious adverse events among persons in the molnupiravir arm compared to those receiving placebo. The FDA granted EUA to molnupiravir on December 23, 2021, for the treatment of mild to moderate COVID-19 in adults (≥18 years) who are at high risk for progression to severe COVID-19, including hospitalization or death.

Summary of the evidence

Two RCTs reported on treatment of unvaccinated patients with COVID-19 with either 800 mg of molnupiravir or placebo for five days [230, 231]. In one phase III trial (MOVe-OUT trial) reporting on the outcomes of death, hospitalization and serious adverse events, patients with mild to moderate COVID-19 received either molnupiravir or placebo within five days after the onset of symptoms. In the phase IIa trial reporting on the outcomes of death and serious adverse events in patients with symptom duration <7 days received molnupiravir or placebo.

Benefits
COVID-19-related mortality may be lower in patients receiving molnupiravir rather than placebo (RR: 0.11; 95% CI: 0.01, 0.86; low CoE). Similarly, COVID-19-related hospitalizations and the composite of all-cause hospitalization or death may trend towards a reduction among patients receiving molnupiravir rather than no molnupiravir (RR: 0.68; 95% CI: 0.48, 1.00; low CoE and HR: 0.69; 95% CI: 0.48, 1.01; low CoE, respectively).

**Harms**

Patients treated with molnupiravir may not experience greater serious adverse events than those receiving placebo (RR: 0.43; 95% CI: 0.17, 1.11; low CoE).

Based on findings from animal reproduction studies, molnupiravir may cause fetal harm when administered to pregnant individuals [232]. Other concerns with molnupiravir include the possibility of viral mutagenesis in persons with compromised immune systems who are unable to clear the virus. Females of childbearing potential should be counseled to use a reliable method of contraception during treatment and for four days after the last dose. Men of reproductive potential who are sexually active with females of childbearing potential should be counseled to use a reliable method of contraception during treatment and for at least three months after the last dose of molnupiravir. It is also not recommended in children <18 years of age for the concern of bone growth.

Molnupiravir does not require renal or hepatic dose adjustment.

**Other considerations**

The panel agreed that the overall certainty of evidence for treatment of ambulatory patients was low, given concerns with imprecision, driven by few reported events and a relatively small effect.

The use of molnupiravir presents additional considerations and potential concerns regarding viral mutagenesis in immunocompromised persons and safety in persons of reproductive age, for which more data are needed to quantify such effects. The panel recognized that alternative treatment options exist with the possibility of greater benefit with a smaller known safety profile. The FDA required the manufacturers to conduct additional animal studies on the impact of the drug on spermatogenesis and to establish a pregnancy registry if the drug was inadvertently administered during pregnancy.
The evidence confirms that using molnupiravir early in the disease process when viral loads are high confers maximum benefit. It is critical to make a rapid diagnosis and treat ambulatory patients with COVID-19 early in the disease course.

**Conclusions**

The guideline panel suggests the use of molnupiravir for ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease who are within five days of symptom onset and have no other treatment options. More data are needed on the potential adverse effects of this medication. The evidence supporting this recommendation will be reassessed with the release of updated published information from the MOVe-OUT study and other trials.
Table 32. GRADE evidence profile, Recommendation 28

**Question:** Molnupiravir compared to no molnupiravir for ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease

*New evidence profile developed 12/30/2021*

<table>
<thead>
<tr>
<th>Certainty assessment</th>
<th>№ of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
<td>Indirectness</td>
</tr>
<tr>
<td>COVID-19-related mortality (follow-up: range 28 days to 29 days)</td>
<td></td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>COVID-19-related hospitalizations (follow-up: 29 days)</td>
<td></td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Hospitalization or death (all-cause) (follow-up: 29 days)</td>
<td></td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
<tr>
<td>Serious adverse events (follow-up: range 28 days to 29 days)</td>
<td></td>
<td>randomized trials</td>
<td>not serious</td>
<td>not serious</td>
</tr>
</tbody>
</table>

GRADE Working Group grades of evidence

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect
Risk of bias: Study limitations
Inconsistency: Unexplained heterogeneity across study findings
Indirectness: Applicability or generalizability to the research question
Imprecision: The confidence in the estimate of an effect to support a particular decision
Publication bias: Selective publication of studies

NB: Certainty ratings are derived from evidence that has not been peer reviewed or published.

CI: Confidence interval; HR: Hazard ratio; RR: Risk ratio

Explanations
a. In Bernal 2021, after day 29, one additional death resulting from adverse events occurred in the molnupiravir group and three additional deaths occurred in the placebo group. In Fischer 2021, at day 31, one additional death resulting from hypoxia occurred in the placebo group.
b. Small number of events; fragility present.
c. 95% CI cannot exclude no meaningful benefit.
d. COVID-19 related hospitalizations is a surrogate for ICU admission, mechanical ventilation and death. Not rated down.
e. All 10 patients reported as died at day 29 had been hospitalized.
f. Small number of events.
g. 95% CI cannot exclude the possibility of harms.

References
Narrative summaries of treatments undergoing evaluation

In addition to the clinical questions addressed above, the panel identified several treatments currently undergoing evaluation for which additional data are needed to rate recommendations. Narrative summaries for these treatments are provided below.

HIV antivirals

Last reviewed 4/11/2020; no updates made since 4/11/2020

In vitro antiviral activity of darunavir against SARS-CoV-2 showed no activity at clinically relevant concentrations. Three randomized, open-label clinical trials are currently listed on evaluating darunavir/cobicistat as a potential therapeutic option for COVID-19. Janssen, the manufacturer of darunavir/cobicistat has reported that one of these trials [233] has concluded that darunavir/cobicistat plus conventional treatments was not effective in achieving viral clearance at day seven post randomization, compared to conventional treatments alone. Clinical outcomes of this trial including rate of critical illness and mortality 14 days after randomization, have not been reported to date.

Lopinavir-ritonavir combined with interferon beta or other antivirals

Last reviewed and updated 9/4/2020

Lopinavir-ritonavir is a combination of protease inhibitors for the treatment of HIV infection. Lopinavir-ritonavir has been shown to have in vitro antiviral activity against beta-coronaviruses such as SARS-CoV, and MERS-CoV [62, 64, 65, 234]. Since lopinavir-ritonavir is not specifically designed for treatment of coronavirus, lopinavir-ritonavir alone may not demonstrate a difference from placebo in reducing viral load when treatment was initiated at a median of 13 days after symptoms onset [65]. In an open-label treatment trial, lopinavir-ritonavir with ribavirin reduced the mortality and requirement of intensive care support of hospitalized SARS patients compared with historical control [65]. Many interferons, especially interferon beta have been shown to have modest in-vitro antiviral activity against SARS-CoV
and MERS-CoV [62, 234]. Lopinavir-ritonavir or interferon beta-1b has been shown to reduce viral load of MERS-CoV and improve lung pathology in a nonhuman primate model of common marmoset [64].

An RCT on the triple combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b, compared with single agent lopinavir-ritonavir for 14 days was conducted in the treatment of 127 adult patients admitted to hospital with COVID-19 [68]. Patients who had NEWS2 of at least one, and with symptom duration of 14 days or less were recruited and randomly assigned to either triple combination or control group in a ratio of 2:1. Treatment with triple combination was well tolerated and had a significantly shorter median time to suppress the viral load in nasopharyngeal specimen, and a significantly shorter time to alleviate symptoms, and resulted in shorter hospital stay. Since the median number of days from symptom onset to the start of study treatment was five days, only one patient in the control group received ventilator support and no patient died during the study. It is not possible to generalize the effectiveness of triple therapy in critically ill patients.

Lopinavir-ritonavir was further investigated in two retrospective cohort studies using HCQ [235] and arbidol [236], an indole-derivative licensed for decades in Russia and China against influenza, for comparison. Lopinavir-ritonavir was associated with more rapid viral clearance (median, 21 days vs. 28 days) than HCQ in 65 mild to moderate COVID-19 patients in South Korea, but there was no difference in time to clinical improvement [235]. Lopinavir-ritonavir was found to be inferior to arbidol in terms of viral clearance on day 14 after admission. But the number of patients was small (n=50) and all patients received atomized inhalation of recombinant human interferon-α2b injection. The efficacy of arbidol monotherapy remains uncertain [236].

Subcutaneous injection of interferon β-1a was used for the treatment of 42 severe COVID-19 adult patients in an open-label randomized clinical trial in Iran. Although there was no significant improvement in time to clinical response in the interferon-treated group, the overall mortality at 28 days was reduced in the interferon-treated then the control group (19% vs. 43.6%, p= 0.015) [237].
COVID-19 convalescent plasma for prophylaxis

*Last reviewed and updated 9/4/2020*

Studies of convalescent plasma for treatment of hospitalized patients with COVID-19 were discussed in a previous section. Use of convalescent plasma as prophylaxis in individuals with high-risk exposure to SARS-CoV-2 is under study, with at least five clinical trials in clinicaltrials.gov as of August 6, 2020 that include arms in which individuals exposed to SARS-CoV-2 but without disease may receive convalescent plasma [238-242]. Issues associated with regulatory concerns, safety, workflow, and trial design were recently reviewed [243]. Distinct from the polyclonal antibodies present in convalescent plasma, monoclonal antibodies specific for respiratory viruses have also been used in certain populations for protection against disease in specific high-risk populations [244, 245], and animal models have suggested utility in prophylaxis against SARS coronavirus infection [246]. There are multiple trials listed in clinicaltrials.gov of different SARS-CoV-2 monoclonal antibodies for treatment or prophylaxis, with other potential monoclonal antibodies in earlier stages of development. No data on safety or efficacy are yet reported.

Ribavirin

*Last reviewed 4/11/2020; no updates made since 4/11/2020*

There are only *in vitro* data available on the activity of ribavirin on SARS-CoV-2 currently. The EC$_{50}$ (half maximal effective concentrations) was significantly higher than for chloroquine and remdesivir, so it appears less potent *in vitro* compared to these agents [16]. There are limited clinical studies in SARS-CoV-1 and MERS-CoV infections. In a systematic review of ribavirin treatment in patients infected with SARS-CoV-1, 26 studies were classified as inconclusive, and four showed possible harm [247]. In a retrospective observational study in patients with MERS-CoV infection, the combination of ribavirin and interferon, compared to no antiviral treatment, was not associated with improvement in the 90-day mortality or more rapid MERS-CoV RNA clearance [248].
Oseltamivir

_Oseltamivir is a neuraminidase inhibitor used for prophylaxis and treatment of influenza. Given its specificity for an enzyme not found on coronaviruses, it is unclear what the mechanism of action would be against COVID-19. However, this has been used in combinations of antiviral therapy in Wuhan [249] and continues to be explored as a therapeutic option as part of combination regimens. Two trials evaluating combination regimens are underway in Wuhan [250, 251] as well as a trial in Thailand proposing different combinations [252]. None of the trials or case reports have examined oseltamivir as monotherapy._

Intravenous immunoglobulin

_Intravenous immunoglobulin (IVIg) has been used as an adjuvant to treat a variety of pathogens either as a pooled product or in a concentrated more pathogen focused (hyperimmune) form. As the community from which a given batch of IVIg is derived from includes increasing numbers of individuals who have recovered from SARS-CoV-2, the possibility of protective antibodies being present in the pooled product is increased. However, the potential utility of IVIg for the treatment of SARS-CoV-2 is unknown at this time. Its use has been reported in a few patients with COVID-19 [253], but studies are needed to determine if there may be a role for IVIg in the treatment of SARS-CoV-2._

One open-label trial randomized patients with COVID-19 (SpO₂ ≤96% on ≥4 liters O₂ by nasal cannula but not on mechanical ventilation) to either three days of IVIg (n=16) or no IVIg (n=17) [254]. During the study period (30 days or hospital discharge), two patients in the IVIg arm and seven in the standard of care arm required mechanical ventilation, one patient in the IVIg arm and three patients in the standard of care arm died. No adverse events were reported in the IVIg arm. Co-treatments with remdesivir, convalescent plasma, and corticosteroids were balanced across arms at baseline; however, methylprednisolone was provided with each IVIg dose in the treatment arm, and co-interventions provided during the treatment period were
unbalanced. One retrospective cohort reported on 58 patients who received IVIg; however, the study did not identify a standard of care group and multiple co-treatments were provided [255]. Two case series reported on eight patients [253, 256] with severe COVID-19 who received IVIg for five consecutive days. All patients were discharged from the hospital.

Should NSAIDS be stopped in patients with COVID-19?

*Last reviewed and updated 9/4/2020*

The role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of SARS-CoV-2 was debated widely in the first few months of the COVID-19 pandemic. The discussion was prompted by warnings from European health officials regarding the possibility of increased risk of infection or severity of disease in those taking NSAIDS. These concerns were based on early unconfirmed reports in four patients and supported by theoretical mechanistic concerns about the role NSAIDs play in SARS-CoV-2 pathogenesis. Human coronaviruses, including SARS-CoV-2, use ACE2 to bind to human targets and gain entry into target cells [257]. It has been theorized that NSAIDs, due to upregulation in ACE2 in human target cells, may lead to an increased risk of infection or a more severe course of COVID-19 in those taking NSAIDs. In addition, there are well known risks of non-steroidal anti-inflammatory agents including cardiovascular, gastrointestinal and renal adverse events [258, 259]. In the setting of bacterial pneumonia, NSAIDs may impair recruitment of polymorphonuclear cells, resulting in a delayed inflammatory response and resolution of infection, however a causal relationship has not been established [260, 261].

A case-control study from Italy published in May 2020 did not demonstrate an increased risk of SARS-CoV-2 infection in those taking NSAIDs chronically (adjusted OR: 1.06; 95% CI 0.98, 1.15) [262]. In April 2020, the WHO produced a scientific brief detailing a systematic review that included 73 studies in patients with acute respiratory infections. While no direct studies for patients with MERS, SARS, or SARS-CoV-2 were available for analysis, there was no evidence of adverse events [263]. In a large registry trial that included data from five hospitals in Massachusetts, there was a lower risk of hospitalization in those with SARS-CoV-2 prescribed naproxen or ibuprofen, however it is difficult to determine if these patients were actively taking
these medications at the time of COVID-19 diagnosis [264]. Randomized controlled trials are currently underway to better understand the safety of NSAIDs in the management of patients with COVID-19 [265, 266].

Should ACE inhibitors and ARBs for hypertension be stopped in patients with COVID-19?

*Last reviewed and updated 9/4/2020*

Angiotensin converting enzyme 2 (ACE2) is the entry receptor for SARS-CoV-2 on human cells. Animal experiments have shown mixed findings on the effect of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) on ACE2 levels and activity, leading to two contrasting hypotheses in COVID-19 [267-269]. The harmful hypothesis is that ACEIs and ARBs may increase the risk of infection and severity of COVID-19 via increased ACE2 expression. On the contrary, infection with other coronaviruses have been shown to decrease ACE2 levels *in vitro* [270], which may lead to increased angiotensin II activity resulting in pulmonary, cardiovascular and other end organ damage in patients with COVID-19 [267, 271]. This has led to speculation about a beneficial hypothesis that ACEI and ARBs may have a therapeutic role in COVID-19, by inhibiting the renin-angiotensin-aldosterone axis.

There have been several recent observational studies on the effects of ACEIs and ARBs in patients tested for and diagnosed with COVID-19. A multi-center retrospective study [272] evaluated 1,128 patents admitted to nine hospitals in Hubei province, China with COVID-19 including 188 (17%), who were on an ACEI or ARB. The risk of 28-day all-cause mortality was lower in ACEI/ARB group vs. non-ACEI/ARB group (IRD: -0.24; 95% CI: -0.43, -0.05). After adjusting the all-cause mortality was still lower in the ACEI/ARB group compared to the non-ACEI/ARB group (HR: 0.42; 95% CI 0.15, 0.89). Another single center retrospective study [273] among 1178 hospitalized patients with COVID-19, had 362 patients with hypertension and 115 were on ACEI/ARBs. There was no difference between those with severe vs. non-severe illness in use of ACEIs (9.2% vs. 10.1%; *P* = .80), and ARBs (24.9% vs. 21.2%; *P* = 0.40). There was also
no difference between non-survivors and survivors in use of ACEIs (9.1% vs. 9.8%; \( P = 0.85 \)) and ARBs (19.5% vs. 23.9%; \( P = 0.42 \)).

Another study [274] among 1200 COVID-19 patients hospitalized in two hospitals in London, UK observed that chronic ACEI/ARB use was not associated with an increase in severity of COVID-19. Within their cohort of 1200 patients, 399 (33.3%) were on an ACEI/ARB and while unadjusted odds of critical care admission or death within 21 days were not significantly different between patients on ACEI/ARB vs. not (OR 0.83; 95% CI 0.64, 1.07), adjustment for age, sex and co-morbidities presented an OR of 0.63 (95% CI 0.47, 0.84, \( p<0.01 \)) for the composite outcomes in patients on ACEI/ARB. An observational study from Italy [275] evaluated multiple predictors of in-hospital mortality in 311 patients with hypertension and COVID-19. The patients in this study were significantly older, with a higher BMI, comorbidities, and severity of disease. In a multivariate Cox regression analysis chronic use of ACEI and ARBs (aHR, 0.97; 95% CI: 0.68, 1.39; \( P = .88 \)) were not associated with an increase in in-hospital mortality. A population-based case-control study [262] from Lombardy, Italy compared 6272 COVID-19 patients with 30,759 controls matched on sex, age, and municipality of residence. In a logistic-regression multivariate analysis, use of ARBs or ACEI did not show an association with COVID-19 among cases (aOR, 0.95, 95% CI 0.86 to 1.05 for ARBs and 0.96, 95% CI, 0.87 to 1.07 for ACEI). It also did not show an association with severe or fatal disease (for ARBs, aOR 0.83; 95% CI 0.63, 1.10; for ACEI, aOR 0.91; 95% CI 0.69, 1.21). Reynolds et al [276] analyzed data available for patients tested for COVID-19, available in the electronic medical records for New York University Langone Health system. In the study, 12,594 patients were tested, 5,894 (46.8%) were positive and 1,002 of these patients (17.0%) had severe illness. They performed propensity score matching and a Bayesian analysis to assess the relationship between various classes of antihypertensives including ACEI and ARBs and the likelihood of a positive COVID-19 test and severe disease. The study did not show a positive association for ACEI and ARBs with having a positive test for SARS-CoV-2 or developing severe infection. A retrospective cohort study using data from Danish national administrative registries, had an unadjusted 30-day mortality of 18.1% in the group with ACEI/ARB use compared to the 7.3% in the nonuser group, but the association was not significant after adjustment for age, sex and medical history (aHR
0.83; 95% CI: 0.67, 1.03). In that study, ACEI/ARB use compared with other antihypertensive agents was not significantly associated with higher incidence of COVID-19 (a HR 1.05 95% CI 0.80–1.36) [277]. One retrospective cohort study done in severe COVID-19 patient’s showed ACEI/ARB use, after adjusting for other variables, to be independently associated with elevated creatinine >10.1 mg/L (OR 3.22; 95% CI: 2.28, 4.54). Consistent ACEI/ARB use was independently associated with AKI stage ≥1 (ALT ratio 3.28; 95% CI: 2.17, 4.94) [278].

Data from these observational studies suggest that ACEI and ARBs do not increase the risk of acquiring COVID-19, developing severe disease or death. One study showed possible increase risk of renal dysfunction in severe COVID-19. There are limitations though inherent to retrospective observational studies, especially differences in unmeasured prognostic factors between the compared groups that might be responsible for the difference in outcomes and not treatment with ACEI or ARBs. Most professional scientific and medical societies have recommended that ACEI or ARBs be continued in people who have an indication for these medications [279-281].

Antibacterials and antifungals

Last reviewed and updated 9/4/2020

Patients with COVID-19 often present to hospitals with viral pneumonia with accompanying febrile illness and respiratory symptoms. Differential diagnoses may include bacterial pneumonia, for which antibiotics are prescribed. Concerns for bacterial superinfections also exist. Studies performed early in the COVID-19 pandemic reported high percentages of antibiotic use in China (58-95%) [1, 249, 282], Spain (74%) [283], and New York (65%) [284]. These studies are not granular and do not report if they describe co-infection at presentation or the development of superinfection, limiting the ability to ascertain the reasons for antibiotic use.

Data reporting co-infection in patients presenting with COVID-19 for care is sparse. Rawson and colleagues reviewed 18 studies of human coronavirus infections reporting co-infections, of which nine were COVID-19 [285]. These cumulatively reported a bacterial and
fungal co-infection rate of 8% (62/806). The studies evaluated were heterogeneous. One brief report of 393 patients in New York reported a bacteremia rate of 5.6%, which varied significantly between patients receiving invasive mechanical ventilation (15/126 [11.9%]) and those who were not (4/222 [1.8%]) [286]. Another study looked at 88,201 blood cultures performed during March 2020 in New York, comparing order volume, positivity, and etiologies between patients with COVID-19 and others during the time period [287]. The study found a significantly lower rate of bacteremia in COVID-19 patients (3.8%) than either COVID-19 negative (8%) or untested (7.1%) (p<0.001). When commensal skin organisms were excluded, the positivity rate in COVID-19 patients was 1.6% [287]. A study in Texas reviewed the use of antibiotics and incidence of coinfections in 147 PCR-positive COVID-19 patients [288]. Eighty-seven (59%) patients received empiric antibiotics, though none of the 47 (32%) patients with respiratory cultures had positive results. 112 patients (76%) had blood cultures collected also, and while nine were positive, eight of those were considered contaminants [288].

The apparent discordance between bacterial and fungal co-infection in patients with COVID-19 at presentation and the use of antibacterial therapy has potential negative effects, namely in antimicrobial resistance. Publications report on patients with severe and critical COVID-19 patients treated with immunomodulatory therapies, including corticosteroids, IL-6 antagonists, IL-1 antagonists, and others [289]. In one preprint examining outcomes of in a cohort of 154 patients receiving invasive mechanically ventilation, mortality was reduced in patients treated with tocilizumab (IPTW-adjusted model, HR 0.55; 95% CI 0.33, 0.90); however, superinfections were more commonly reported (54% vs. 26%, p<0.001), primarily due to ventilator-associated pneumonia [111]. Initiating and continuing empiric antibiotics at the time of admission may lead to superinfections that are antibiotic resistant [290].

Favipiravir

Last reviewed and updated 9/4/2020

Favipiravir is a purine analog that inhibits the RNA dependent RNA polymerase of influenza and other RNA viruses [291]. The drug is approved in Japan for treatment of influenza.
However, because of its teratogenicity risk, favipiravir should not be given during pregnancy and there are substantial concerns about its use in women in child-bearing potential.

In terms of its potential role in COVID-19, favipiravir has *in vitro* activity against SARS-CoV-2 [16]. However, it is uncertain whether adequate drug levels can be achieved in vivo to inhibit SARS-CoV-2. There have been small clinical trials with this drug in people with COVID-19. In a non-randomized, open-label study in China [292], oral favipiravir was associated with shorter time to viral clearance and greater improvement in chest imaging than lopinavir/ritonavir (in both groups, the oral antiviral was given with aerosolized alpha-interferon). However, because the study was small and not randomized, it was not possible to conclude that favipiravir is effective in treating COVID-19. A randomized, open-label trial compared favipiravir to umifenovir, an antiviral approved in Russia and China, in people with COVID-19 [293]. The clinical recovery rate at day seven was not significantly different between the two groups. There appeared to be an impact of favipiravir in the sub-group of people who did not have critical illness, but more data are needed. An exploratory clinical trial, also conducted in China, randomized 30 hospitalized adults with COVID-19 into a baloxavir marboxil, favipiravir or control group. There was no apparent effect of favipiravir (or baloxivir) on viral clearance [294]. There are ongoing clinical trials assessing favipiravir for treatment of COVID-19.

**Immunomodulatory agents**

*Last reviewed and updated 9/4/2020*

Some patients with COVID-19 develop a hyperinflammatory state that may incorporate elements of cytokine release syndrome seen in conditions such as secondary hemophagocytic lymphohistiocytosis. The etiology is unclear, but patients who develop significantly elevated CRP, ferritin, and D-dimer levels with the syndrome have an increased risk of mortality, associated with respiratory failure, multiorgan dysfunction, and hypercoagulability. Numerous immunomodulatory agents are under investigation to address this immunologic complication.

**IL-1 inhibitors:** Anakinra is an FDA approved IL-1-beta inhibitor that is currently FDA-approved for rheumatoid arthritis and Neonatal-Onset Multisystem Inflammatory Disease. High- and low-
dose anakinra was investigated in a recent retrospective cohort study in Italian patients with COVID-19, moderate to severe ARDS, and hyperinflammation. Patients receiving anakinra were compared to a historical control group with COVID-19 who fulfilled eligibility criteria for anakinra. The low-dose anakinra group was stopped early due to lack of effect. In the high-dose anakinra group, 3/29 (10%) patients died versus 7/16 (44%) in the historical control group, however there was no difference in the rates of mechanical ventilation-free survival [295]. Anakinra is being investigated in numerous trials including this randomized placebo-controlled trial [296]. Canakinumab is another IL-1-beta antagonist with limited human data for COVID-19 that is being studied in a phase III clinical trial [297, 298].

**Janus kinase inhibitors:** Baricitinib, a JAK inhibitor currently FDA-approved for the treatment of rheumatoid arthritis, is being investigated in multiple studies for COVID-19. The proposed benefits of baricitinib in the management of COVID-19 are two-fold as it has both anti-inflammatory and likely antiviral activity. Janus kinase mediates cytokine signaling which contributes to inflammation, which may reduce risk of the associated hyperinflammatory syndrome and ARDS. Baricitinib inhibits AAK1 and also binds GAK, both thought to play a role in receptor mediated endocytosis of many viruses including SARS-CoV-2 [173]. In an open-label non-randomized study from Italy, baricitinib with lopinavir/ritonavir (n=12) were compared to lopinavir/ritonavir (n=12) alone at one institution over two consecutive time periods. After two weeks in the baricitinib group, no patients required ICU transfer and 7/12 (58%) were discharged. In the lopinavir/ritonavir group, 4/12 (33%) required ICU transfer and only 1/12 patients were discharged by day 14. No serious adverse events or infections occurred in the baricitinib group [174]. In the ACTT-2 trial, baricitinib is being compared to remdesivir and numerous other RCTs are currently underway to better understand the role of baricitinib in the management of COVID-19 [299-303].

**GM-CSF inhibitors:** Monoclonal antibodies that bind to GM-CSF are under investigation for the treatment of hyperinflammation associated with COVID-19. GM-CSF inhibitors are postulated to disrupt the downstream signaling of pro-inflammatory cytokines. One agent, mavrilimumumab was studied in a single center non-randomized cohort study in non-ventilated patients in Italy.
Trial participants had SARS-CoV-2 infection with a PaO2: FiO2 ratio <300 mm Hg, pulmonary infiltrates, and evidence of hyperinflammation (CRP >100 mg/L or ferritin >900 µg/L and any increase in LDH). Patients in the treatment group received a single dose of mavrilimumab 6 mg/kg (n=13). A similar cohort managed by the same medical team received no mavrilimumab due to lack of consent and lack of access to mavrilimumab (n=26). Mortality rates were 0/13 in the mavrilimumab group and 7/26 (27%) died in the control group. Median days to clinical improvement (defined as a reduction of two or more points on the seven-point ordinal scale) was 8 (IQR: 5-11) versus 19 (IQR: 11 >28), in the mavrilimumab versus control groups, respectively. Mavrilimumab was well tolerated in all patients [304]. Randomized controlled trials are underway to investigate the role of GM-CSF inhibitors in the management of COVID-19 [305-307].

**Complement inhibitors:** In mouse models of both SARS-CoV and MERS-CoV, complement activation has been shown to play a role in the pathogenesis of ARDS. Eculizumab, a complement inhibitor that is already approved by the FDA for other conditions including myasthenia gravis and paroxysmal nocturnal hemoglobinuria, is currently being studied for the treatment of COVID-19 [308]. Ravulizumab, another complement inhibitor, is also being investigated in randomized trials for COVID-19 [300].

SARS-CoV-2 in children and treatment of multisystem inflammatory syndrome in children (MIS-C)

*Last reviewed and updated 9/4/2020*

**Treatment**

Compared with adults, children generally have milder illness from SARS-CoV-2 infection [309, 310]. However, severe illness does occur in children, even those with no predisposing factors [310, 311]. Among children admitted to the hospital for COVID-19, one-third are admitted to intensive care [310]. Despite this, clinical trials of therapeutic interventions for COVID-19 have almost exclusively focused on adult patients. For example, in the first of two recent studies of the antiviral remdesivir [312, 313], patients younger than 18 years were
excluded [314], and the number of children between 12 and 18 years included in the analysis for the second paper was not reported [145]. These studies led to FDA EUA of remdesivir for both adults and children [315], with no published data available on either safety or efficacy in children under 12 years. A phase II/III open-label study in this population has started (the “CARAVAN” trial [147]). Future studies of both therapeutics and vaccines will need to include children to assure their safety and efficacy in this population.

**Multisystem inflammatory syndrome in children**

Multisystem inflammatory syndrome in children (MIS-C) or Pediatric Multisystem Inflammatory Syndrome is a rare acute inflammatory syndrome with some similarities to Kawasaki disease that has recently been reported in children. Reports from Europe and the United States generally describe critically ill children with fever, rash, conjunctivitis, abdominal complaints, shock, and significant cardiac dysfunction [316-328]. Case definitions have been developed to better characterize these patients (Table 33) [329, 330].

Patients with Kawasaki disease also present with fever and symptoms including rash, conjunctivitis, peripheral extremity changes, lymphadenopathy, and oral mucosal changes such as red, cracked lips and “strawberry tongue.” However, while Kawasaki disease and MIS-C share some similarities, there are also key differences [331]. Both are hyperinflammatory syndromes, both have findings of medium vessel vasculitis and both can present with the signs/symptoms described for Kawasaki disease. MIS-C is more likely to affect older children (average age 8-11 years versus younger than five years in Kawasaki disease), cause more severe disease (more patients presenting with shock), present frequently with gastrointestinal symptoms, includes some neurologic involvement, and more commonly causes cardiac myocarditis and ventricular dysfunction leading to hypotension or arrhythmias. In contrast, Kawasaki disease more commonly causes coronary artery dilatation. A small study of cytokine profiles in children distinguished MIS-C from severe COVID-19 based on a higher level of the combination of TNF-α and IL-10 in MIS-C patients [332].

Empiric treatment of MIS-C has generally involved immunomodulatory agents such as high-dose IV immunoglobulin (2 g/kg), corticosteroids, aspirin and rarely more targeted anti-
inflammatory medications such as anakinra [316-319, 325, 326, 328]. Most of the children with MIS-C have had a history of prior SARS-CoV-2 infection several weeks earlier confirmed by viral detection of antibody testing or have had documented prior exposure to COVID-19, suggesting that this condition is a post-infectious immunologic phenomenon.

Future research should focus on how and why the immune system responds to SARS-CoV-2 causing a spectrum of illness in children, identifying genetic or environmental risk factors for MIS-C, and discovering optimum treatment for children with MIS-C. Multidisciplinary, collaborative approaches to data registries and clinical trials that promote evidence-based care for these children are needed.
Table 33. Case definitions for Multisystem Inflammatory Syndrome in Children (MIS-C) and Paediatric multisystem inflammatory syndrome (PMIS)

<table>
<thead>
<tr>
<th>MIS-C (CDC 2020)¹</th>
<th>PMIS (Royal College of Paediatrics and Child Health 2020)²</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Includes</strong></td>
<td><strong>Includes</strong></td>
</tr>
<tr>
<td>Age &lt;21 years presenting with:</td>
<td>A child presenting with:</td>
</tr>
<tr>
<td>• Fever (&gt;38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours)</td>
<td>• Persistent fever &gt;38.5°C</td>
</tr>
<tr>
<td>• Laboratory evidence of inflammation (including, but not limited to, one or more of the following: an elevated C-reactive protein, erythrocyte sedimentation rate, fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase, or interleukin 6, elevated neutrophils, reduced lymphocytes and low albumin),</td>
<td>• Laboratory evidence of inflammation (neutrophilia, elevated CRP and lymphopenia)</td>
</tr>
<tr>
<td>• Evidence of clinically severe illness requiring hospitalization, with multisystem (&gt;2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological)</td>
<td>• Evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features (listed in Appendix of reference)</td>
</tr>
<tr>
<td><strong>Excludes</strong></td>
<td><strong>Excludes</strong></td>
</tr>
<tr>
<td>Patients with alternative plausible diagnoses</td>
<td>Patients with any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus</td>
</tr>
<tr>
<td><strong>Other criteria</strong></td>
<td><strong>Other criteria</strong></td>
</tr>
<tr>
<td>Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; OR COVID-19 exposure within the 4 weeks prior to the onset of symptoms</td>
<td>SARS-CoV-2 PCR testing may be positive or negative</td>
</tr>
</tbody>
</table>

References
Discussion

During epidemics like the current COVID-19 pandemic, when there are no clinically proven treatments, the tendency is to use drugs based on *in vitro* antiviral activity, or on anti-inflammatory effects or based on limited observational studies. It is commendable that observational studies are done during an epidemic, but often they do not have concurrent controls, have a significant risk of bias, and use surrogate outcomes like viral clearance rather than patient-important outcomes. Medications that were thought to be effective based on *in vitro* studies and observational studies for other diseases were later proven to be ineffective in clinical trials [333].

Due to the understandable urgency in producing, synthesizing and disseminating data during the current pandemic, there has been a noticeable increase in fast track publication of studies. In addition to well-established concerns that may decrease our certainty in the available evidence, there may be additional issues that will ultimately influence the trustworthiness of that evidence, including: 1) Circumvention of usual research steps (delay of IRB approval [334], inclusion of same patients in several studies); 2) Limited peer-review process (the usual due diligence from editors and reviewers is side-stepped, potentially leading to unnoticed errors in data and calculations, incomplete reporting of methods and results, as well as underestimation of study limitations); 3) Increased potential for publication bias (in the interest of showing promising data and in the race to achieve recognition, there may be added inclination to publish positive results and disregard negative ones). The extent and impact of these considerations remain currently uncertain but were acknowledged in the development of this guideline.

Despite these limitations, the recommendations in this guideline are based on evidence from the best available clinical studies with patient-important endpoints. The panel determined that when an explicit trade-off between the highly uncertain benefits (e.g., the panel was unable to confirm that HCQ increases viral cure or reduces mortality) and the known putative harms (QT prolongation and drug-drug interactions) were considered, a net positive benefit was not reached and could possibly be negative (risk of excess harm). The safety of drugs used
for the treatment of COVID-19, especially in patients with cardiovascular disease, immunosuppressive conditions, or those who are critically ill with multi-organ failure has also not been studied. Drugs like AZ and HCQ can cause QT prolongation and potentially life-threatening arrhythmias. Steroids and IL-6 inhibitors can be immunosuppressive and potentially increase risk of secondary infections. Steroids may produce long term side effect such as osteonecrosis [335]. In instances where the panel could not make a determination whether the benefits outweigh harms, it is be ethical and prudent to enroll patients with COVID-19 in clinical trials, rather than use clinically unproven therapies [336]. There are multiple ongoing trials, some with adaptive designs, which potentially can quickly answer pressing questions on efficacy and safety of drugs in the treatment of patients with COVID-19.

We acknowledge that enrolling patients in RCTs might not be feasible for many frontline providers due to limited access and infrastructure. Should lack of access to clinical trials exist, we encourage setting up local or collaborative registries to systematically evaluate the efficacy and safety of drugs to contribute to the knowledge base. Without such evaluations we often attribute success to drugs and failure to disease (COVID-19) [333]. During such a pandemic, barriers to conducting studies and enrolling patients in trials for already overburdened frontline providers should be minimized while ensuring the rights and safety of patients [337].

For clinical trials and observational studies, it is critical to determine a priori standardized and practical definitions of patient populations, clinical syndromes, disease severity and outcomes. Observational and non-experimental studies can sometimes answer questions not addressed by trials, but there is still a need for standardized definitions. For clinical syndromes clearly distinguishing between asymptomatic carrier state, upper respiratory tract infection and lower respiratory tract infection is important. Illness severity should be reasonably defined using readily available clinical criteria of end organ failure, like the degree of respiratory failure using SpO2 (percentage of oxyhemoglobin saturation) or PaO2:FiO2 ratios (partial pressure of oxygen in arterial blood: fractional percentage of inspired oxygen) for lower respiratory tract infection, as opposed to location-based severity determinations such as ICU admission, which can lead to bias based on resource limitations (i.e., bed availability) or regional/institutional practice patterns [338]. For outcomes of prophylaxis trials, the primary
endpoint should be prevention of infection and for therapeutic trials patient centered outcomes like reduction of mortality (both short term and long term) [339]. Trials should also study treatments in high-risk populations or special populations like immunosuppressed patients, people with HIV, patients with cardiovascular comorbidities and pregnant women. The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19.

This is a living guideline that will be frequently updated as new data emerges. Updates and changes to the guideline will be posted to the IDSA website.
Acknowledgement: The expert panel thanks the Infectious Diseases Society of America for supporting guideline development, and specifically Cindy Sears, Dana Wollins, Genet Demisashi, and Rebecca Goldwater for their continued support throughout the guideline process. The panel would also like to acknowledge Haya Waseem, Kapeena Sivakumaran, and Nicholas J. Newman for supporting the evidence base for this guideline.

Financial Support: This project was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC) (grant number 6 NU50CK000477-04-01). The CDC is an agency within the Department of Health and Human Services (HHS). The contents of this guideline do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.

COI Summary: The following list is a reflection of what has been reported to IDSA. To provide thorough transparency, IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest is determined by a review process which includes assessment by the Board of Directors liaison to the Standards and Practice Guideline Committee and, if necessary, the Conflicts of Interest and Ethics Committee. The assessment of disclosed relationships for possible COI is based on the relative weight of the financial relationship (i.e., monetary amount) and the relevance of the relationship (i.e., the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. L.B. receives research funding from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, and Wellcome Trust, and serves as chair of the Antimicrobial Drug Advisory Committee of the Food and Drug Administration. V.C. receives research funding from the Health and Medical Research Fund. K. E. serves as a scientific advisor for Merck, Bionet, IBM, Sanofi, X4 Pharmaceuticals, Inc., Seqirus, Inc., Moderna, Inc. and Pfizer, and receives research funding from the Centers for Disease Control and Prevention and the National Institutes of Health. R. G. has served on a scientific advisory
board for Gilead Sciences, Inc., serves on a scientific advisory board for Merck, and receives research funding from the NIH. J.G. serves in an advisory role for Qpex and Shionogi; receives research funding from Merck; previously served in an advisory role for Acceletrate, Achaogen, Astellas, Melinta, Nabriva, Paratek, scPharmaceutic, Spero and Tetraphase; and previously served on the speakers bureau for Astellas, Melinta, Merck and Shiongi. M.H.M receives research funding from the Agency for Healthcare Research and Quality, the Endocrine Society, the Society for Vascular Surgery and The American Society of Hematology and is a Board member for the Evidence Foundation. W.J.M. serves in an advisory role for Seqirus, Inc. and receives research funding from Ansun Biopharma, Astellas Pharma, AstraZeneca, Abbott Laboratories, Enanta Pharmaceuticals, Gilead Sciences, Janssen Pharmaceuticals, Karius, Merck, Melinta Therapeutics, Nabriva Therapeutics, Roche and Tetraphase Pharmaceuticals. S.S. serves as an advisory board member for Amplyx Pharmaceuticals, Inc.; as an advisor/consultant to ReViral Ltd.; receives research funding from Ansun BioPharma, F2G, Shire (now Takeda), University of Nebraska, Cidara Therapeutics; and has served as an advisor for Janssen Pharmaceutica and Acidophil. A.H.S. receives research funding from the U.S. Department of Veterans Affairs. Y.F.Y. receives honoraria for evidence reviews and teaching from the Evidence Foundation, honoraria for evidence reviews for the American Gastroenterological Association, and serves as a Director for the Evidence Foundation and for the U.S. GRADE Network. All other authors: no disclosures reported. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
References


12. GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available at: https://gradepro.org/.


43. Molina JM, Delaquerre C, Goff J, et al. No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in


154. U.S. Food and Drug Administration. FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR EVUSHELD™ (tixagevimab co-packaged with


250. Ning Q, Han M. A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia. Available at: https://clinicaltrials.gov/ct2/show/NCT04255017.

251. Ning Q, Han M. A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia. Available at: https://clinicaltrials.gov/ct2/show/NCT04261270.


313. Gilead Sciences, Inc. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19). Available at: https://clinicaltrials.gov/ct2/show/NCT04292899.


